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Introduction 
Stem cells 
Stem cells hold the highest position in the cellular hierarchy as they generate the 
downstream cells that eventually differentiate into specialized cells. Stem cell is a general 
term that includes cells able to generate the entire organisms as well as maintain tissue 
homeostasis (Meshorer and Misteli 2006). Stem cells, differently from specialized cells, are 
able to self-renew and differentiate, and have potentially unlimited proliferative capacity. 
Stem cells can be classified in three main groups: embryonic stem cells (ESCs), which are 
pluripotent and can thereby generate the entire organism, and tissue-specific embryonic and 
adult stem cells, which generate specific tissues in the embryo and in the adult, respectively. 
Embryonic Stem cells 
  Fertilization of an egg forms the zygote, which is a totipotent cell. Proliferated 
totipotent cells then differentiate into pluripotent ESCs and extra-embryonic cell types 
(Fujimaki, Machida et al. 2013). Pluripotent ESCs have the potential to differentiate into the 
entire organism and are derived from the blastocyst during embryogenesis, but do not 
generate extra-embryonic structures (Thomson, Itskovitz-Eldor et al. 1998). One of the 
earliest specifications during embryogenesis is the formation of trophectoderm. 
Trophectoderm is an extra embryonic ectoderm that provides protection of the inner cell mass 
(ICM) of blastocysts and also originates from trophoblasts. Trophoblasts contribute to 
formation of the ectoplacental cone in maternal endometrium for the nutrient exchange with 
maternal blood, the precise mechanisms of which is not clearly understood yet (Fig. 1) 
(Roberts, Ezashi et al. 2018).   
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Figure 1. Scheme of stem cells status in embryogenesis until blastocyst. From zygote until the 
morula stage multiple cell divisions of totipotent cells occur, which are followed by a first 
differentiation into ESCs that in turn generate the first cell lineage specification (into endoderm, 
mesoderm, and ectoderm). Upon cell differentiation the blastocyst starts to form. The initial blastocyst 
consists of pluripotent embryonic stem cells (ES cells) which make the inner cell mass (ICM) and 
trophectoderm originated from trophoblasts. 
After successful proliferative stages of the ICM, the ESC population starts to lose 
pluripotency by forming three distinct layers, which are multipotent and can give rise to 
multiple types of cells, but are limited to a specific lineage (Berdasco and Esteller 2011): the 
endoderm (inner layer), which gives rise to the inner system of organs such as liver and 
digestive system; the mesoderm (middle layer), which gives rise to muscle, heart, bone and 
circulatory systems, and the ectoderm (outer layer), which gives rise to skin, nervous system, 
and brain (Thomson, Itskovitz-Eldor et al. 1998, Pijuan-Sala, Guibentif et al. 2018).  These 
layers then keep self-renew, proliferate, and differentiate into specialized cells, ultimately 
forming the corresponding tissues and organs of the body. The specific properties (self-
renewal, pluripotency, and unlimited proliferation) of ESCs are controlled by chromatin 
conformation (Meshorer and Misteli 2006) and regulation of the expression of transcription 
factors such as Nanog2, Oct3/4, Sox2 (Boyer, Lee et al. 2005).  
After 32-cells stage of the embryonic development, the embryo starts undergoing 
morphological changes regulated by heterogeneous transcription factors like, for instance, 
Nanog and Gata6, that induce the expressions of genes such as Fgf4, Gata4 and SRY-box 17, 
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respectively (Pijuan-Sala, Guibentif et al. 2018). Along with morphological changes, further 
differentiation and specification of the ICM into three layers allows to initiate the 
development of the organs, as mentioned above (Pijuan-Sala, Guibentif et al. 2018). For 
example, muscle development requires the induction of expression of muscle specific 
transcription factors in the mesodermal layer.  
Although the origin of the all muscles is the mesodermal cell lineage, development of 
muscle in different parts of the body depends on different transcription factors, such as Pitx2 
for extra-ocular muscles, Tbx1 and Pitx2 for branchial arch muscles, and Pax3 for limb 
muscles (Comai and Tajbakhsh 2014). This heterogeneity of transcription factors allows the 
development of different muscles: smooth, striated, skeletal muscles, in different regions of 
the body (Gopalakrishnan, Comai et al. 2015). Along with differentiation and tissue 
development, embryonic stem cells that are responsible for tissue development will also self-
renew. The tissue-specific ESCs that self-renew constitute the future tissue-specific stem cell 
reservoir in the adult. For instance, during mid-embryogenesis, after initial muscle 
development, some self-renewing muscle stem cells express Pax7, which, after birth will 
constitute muscle stem cells, called satellite cells, located between the basal lamina and the 
plasma membrane of the myofiber (Tajbakhsh 2009) (Comai and Tajbakhsh 2014).  
Nowadays, some transcription factors known to regulate the ESCs (Oct4, Sox2) are 
used in combination with other factors (Klf4 ± cMyc) to transform specialised, tissue-specific 
cells into induced Pluripotent Stem Cells (iPSCs), which constitute a fourth group stem cells, 
which are able to generate an entire organism or differentiate into specific cell types 
(Takahashi, Tanabe et al. 2007, Ramakrishna, Kim et al. 2014). 
Adult (somatic) stem cells 
Adult stem cells (ASCs), also called as somatic stem cells, are present in the adult and 
are derived from existing stem cells by self-renewal mechanisms. However, since they are 
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tissue-specific are not pluripotent, but multipotent or unipotent (Rossi, Jamieson et al. 2008, 
Fujimaki, Machida et al. 2013). Adult stem cells are essential for tissue homeostasis and 
tissue regeneration after injury. They can generate one or a few cell types (such as unipotent 
satellite cells or multipotent hematopoietic stem cells (HSCs)) (Fujimaki, Machida et al. 
2013). Adult stem cells may undergo self-renewal by asymmetric mitotic division that 
generates a stem cell and a cell that will later differentiate into specialized cells (Berika, 
Elgayyar et al. 2014). However, stem cells can also undergo symmetric cell division, ending 
in either two self-renewing daughter cells or two cells commited to differentiate. Different 
types of stem cells have been shown to undergo one or the other type of cell division, such as 
intestinal stem cells that undergo symmetric division (Lopez-Garcia, Klein et al. 2010). 
However, along with the development of more powerful techniques, the situation appears 
more complex, and it seems that both types of events may occur, with stem cells self-
renewing by both asymmetric and symmetric division, as it is the case for intestinal, 
hematopoietic, and neural stem cells (Obernier, Cebrian-Silla et al. 2018) (Srinivasan, Than et 
al. 2016) (Zhao, Chen et al. 2017) (Noctor, Martinez-Cerdeno et al. 2004). For example 
satellite cells have been shown to undergo both symmetric and asymmetric division (Cossu 
and Tajbakhsh 2007). 
The self-renewal activity makes stem cells always available in the organism. Most 
adult stem cells are quiescent and, upon activation, undergo either symmetric or asymmetric 
division to generate their progeny or self-renew (thereby restoring the stem cell pool), 
respectively (Ito and Suda 2014). Other stem cells keep renewing and being activated (for 
instance intestinal stem cells (Qi and Chen 2015)). ASCs are divided into sub-groups 
depending on the tissue they differentiate in, for instance hematopoietic stem cells (HSCs), 
skeletal muscle stem (satellite) cells, neural stem cells, etc. Most tissues have specific ASCs 
that play a role in the maintenance of the tissue. Most adult stem cells generate progenitor 
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cells, which have lower self-renewal potential but remain highly proliferative and more 
committed to differentiate into specialized cells (Akashi, Traver et al. 2000). 
Different types of adult stem cells 
Hematopoietic stem cells 
Hematopoietic stem cells (HSC) are derived from the bone marrow of the adult, and 
originate from the mesodermal layer of the embryo (Fujimaki, Machida et al. 2013). HSCs are 
responsible for homeostasis and maintenance of all specialized cells in the circulatory and 
immune systems. HSCs can self-renew to maintain the stem cell pool and multipotency. The 
HSPCs (hematopoietic stem and progenitor cells) can be classified into 3 groups: LT-HSCs 
(long-term HSCs) which are mostly quiescent and self-renew to maintain the stem cell pool in 
the long-term, ST-HSCs (short-term HSCs) that are activated HSCs with reduced capacity of 
self-renewal and are committed to differentiate (Vannini, Girotra et al. 2016), and MPP 
(multipotent progenitor) cells that have proliferation and differentiation potential but lost their 
self-renewal capacity (Bryder, Rossi et al. 2006).  
MPP cells can differentiate into two different sub-classes: common myeloid 
progenitors or common lymphoid progenitors. Common myeloid progenitors give rise to 
monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes, dendritic cells, 
and platelets whereas lymphoid cells: B and T cells, natural killer cells are derived from 
common lymphoid progenitors (Fig. 2) (Chao, Seita et al. 2008). 
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Figure 2. Scheme for hematopoiesis. In the group of HSPCs, Long-Term HSCs (LT-HSCs) are a 
generally quiescent and self-renewing class of HSCs, which may also change class into activated 
short-term HSCs (ST-HSCs). ST-HCs have lower self-renewal capacity than LT-HSCs and can commit 
into the class of multipotent progenitor cells (MMPs) for differentiation. MMPs have high 
proliferation capacity and can differentiate into two sub-groups of progenitors, common myeloid 
progenitors (CMPs) or common lymphoid progenitors (CLPs). CMPs give rise to differentiated 
erythrocytes, platelets, macrophages, neutrophils, eosinophils and basophils, In the other class, CLPs 
can give rise to B and T cells and natural killer cells. 
Mesenchymal stem cells 
In addition to HSCs, mesenchymal stem cells (MSCs) are also derived from the bone 
marrow. MSCs originate from the mesodermal layer of embryonic cells (Marquez-Curtis, 
Janowska-Wieczorek et al. 2015). Even though the major source of MSCs is the bone 
marrow, MSCs can also be derived from many other tissues such as tendons, muscle, adipose 
tissue and micro-vessels of connective tissues, and in this case they are referred as pericytes 
(Caplan and Bruder 2001, Wong, Rowley et al. 2015). MSCs are indeed one of the types of 
ASCs with the widest range of multipotency, and can differentiate and generate multiple types 
of tissue-specific cells in addition to maintain their high self-renewing capacity (Marquez-
Curtis, Janowska-Wieczorek et al. 2015) (Lindner, Kramer et al. 2010). MSCs mainly 
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differentiate into mesodermal-originated lineages such as cartilage, adipose tissue, and bones 
by chondrogenesis, adipogenesis, and osteogenesis, respectively (Caplan and Bruder 2001).  
 
Figure 3. Scheme of multiple fates of mesenchymal stem cells (MSCs). MSC differentiation towards 
multiple mesodermal lineages is shown by osteogenesis, chondrogenesis, and adipogenesis. MSC 
differentiation into non-mesodermal lineages is represented by hepatogenesis and neurogenesis that 
gives endodermal and ectodermal lineages, respectively. Self-renewal is indicated with a curved 
arrow. MSCs are also referred as stromal cells in the bone marrow. 
Additionally it has been suggested that MSCs generate non-mesodermal lineages such 
as neural cells or hepatocytes in the liver, which are normally derived from ectodermal and 
endodermal lineages, respectively (Fig. 3). This suggests that MSCs are more prone to be 
pluripotent than lineage-specific multipotent cells are (da Silva Meirelles, Chagastelles et al. 
2006). MSCs derived from different tissues have similar characteristics but specific culturing 
methods can induce their differentiation into specific lineages. This fact underscores the 
importance of the cellular niche and environmental effects on the stem cell fate (Caplan and 
Bruder 2001, da Silva Meirelles, Chagastelles et al. 2006). Importantly, it is still debated 
whether MSCs cells are really pluripotent, since chemical treatments and different culture 
conditions may not recapitulate the in vivo condition and may rather artificially induce fate 
change. Additional ambiguity resides in the fact that the surface markers used for 
identification of MSCs are shared in other connective tissues, potentially resulting in 
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overestimation of the presence of MSCs in several tissues, or of their ability to generate these 
cells (Bianco, Cao et al. 2013).    
Endothelial stem cells  
Endothelial stem cells are responsible for the generation and maintenance of blood 
vessels through angiogenesis. The origin of endothelial stem cells is still an open question. It 
is also unclear whether these cells are HSPC-derived circulating endothelial-like cells, or 
vascular resident endothelial cells, or mesenchymal cells (Basile and Yoder 2014). 
Epithelial Stem Cells 
Epithelial stem cells are responsible for constitution of the surface or lining of organs 
such as the epidermis of skin and lining of intestines (Blanpain, Horsley et al. 2007). Different 
populations of epithelial stem cells have diverse characteristics and different functions 
depending on the tissue they constitute, such as epidermal stem cells, intestinal stem cells, and 
mammary stem cells. 
1- Epidermal stem cells 
Epidermal stem and progenitor cells, which consist of different population of stem 
cells, are responsible for the maintenance and repair of the skin epidermis (Schepeler, Page et 
al. 2014). Epidermis consists of multiple layers: interfollicular epidermis, hair follicle and 
sebaceaous gland (SbG), and sweat glands (SwG). Distinct stem cells play a role in the 
homeostasis and regeneration of these different layers. These stem cells can be distinguished 
by their different characteristics such as cell cycle entry or frequency of the cell cycle 
(Sotiropoulou and Blanpain 2012).    
The best characterized epidermal stem cells are i) bulge stem cells, which reside in the 
bulge of hair follicles, and are more quiescent than other epidermal cells and are responsible 
for regeneration of the hair follicle (Sotiropoulou and Blanpain 2012), and ii) hair germ cells 
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that are responsible for generation of hairs. During each cycle of hair growth, hair germ cells 
are activated. Upon hair germ cells activation, bulge stem cells are also activated to generate a 
population that will return to quiescence or contribute to maintenance of the hair follicle. 
Epidermal stem cells also include actively cycling stem cells that are responsible for the 
maintenance of upper hair follicles, SbGs, SwGs, and interfollicular epidermis (Kretzschmar 
and Watt 2014). 
2- Intestinal stem cells 
 One of the most rapidly self-renewing epithelial tissues is the intestinal lining, which 
is composed of projections, called villi, and invaginations referred as crypts of Lieberkühn 
that host multipotent intestinal stem cells (Tan and Barker 2014). Intestinal stem cells reside 
at the base of the crypt and along with proliferation they move apically towards the villi, 
losing the proliferation capacity along the way, and finally they terminally differentiate. There 
are two types of stem cells in the intestine, which can be distinguished by their localization 
and specific marker: LGR5+ or BMI+. LGR5+ stem cells, also known as CBC (crypt base 
columnar cells), are highly proliferative and self-renewing stem cells that are at the base of 
the intestinal invagination whereas BMI+ cells are referred as +4 stem cells due to their 
positioning at the base of the crypt. BMI+ stem cells are mostly quiescent, and it is generally 
believed that they play a role in regeneration upon injury, whereas CBC cells are responsible 
for daily maintenance (Qi and Chen 2015). The symmetrically dividing CBC cells either 
move apically toward the villi in the form of trans-amplifying cells, which finally 
differentiates and maintain the tissue, or self-renew and maintain the stem cell pool (Lopez-
Garcia, Klein et al. 2010).  
3- Mammary stem cells 
 Mammary stem cells (MaSCs) are bipotent cells responsible for the development and 
regeneration of the mammary epithelium. MaSCs are an heterogenous population among 
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themselves, with slow-cycling cells, long-term and short-term repopulating cells (Visvader 
and Stingl 2014). During normal homeostasis, similarly to ISCs, MaSCs undergo successive 
cycles of regeneration to compensate for the loss of tissue (Blanpain, Horsley et al. 2007). 
Mammary glands display morphological changes during puberty as well as during pregnancy. 
MaSCs give rise to 2 types of progenitor cells: tubular and alveolar cells that generate tubular 
myoepithelial cells and luminal tubulars cells, and alveolar myoepithelial cells and luminal 
alveolar cells, respectively (Rios, Fu et al. 2014). During pregnancy, alveolar cells undergo a 
large expansion generating milk producing alveoli, whereas during normal homeostasis the 
tubular myoepithelial sub-group of progenitors is prevalent (Rios, Fu et al. 2014, Visvader 
and Stingl 2014). 
Neural stem cells 
 Neural stem cells (NSCs) are responsible for homeostasis and regeneration of the 
central nervous system (CNS). During embryogenesis, NSCs and their progenitors can be 
found in two regions of the embryonic neural tissue: the ventricular zone, where NSCs self-
renew and proliferate to generate progenitor cells, and the subventricular zone, where NSCs 
progenitors are recruited from the ventricular zone. NSCs in the subventricular zone lose their 
self-renewing capacity but can proliferate and differentiate into specialized cells of the 
nervous system (Zhang and Jiao 2015).  
Similar to embryonic stages, NSCs include heterogenous populations. NSCs located in 
the subventricular zone of lateral ventricles give rise to the neurons of the olfactory bulb, 
whereas NSCs that give rise to granule cells are located in the subgranular zone of the 
hippocampus (Silva-Vargas, Crouch et al. 2013, Fuentealba, Rompani et al. 2015). Mostly 
quiescent NSCs that periodically self-renew as well as amplify and generate neuroblasts 
(downstream progenitors), are referred as type B1 cells (Silva-Vargas, Crouch et al. 2013). It 
is also suggested that B1 cells are originated from embryonic stages, where during mid-
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embryonic development a population of NSCs become quiescent and get activated early at 
post-natal stages to generate the progeny. B1 cells can also be activated in the adult to 
maintain homeostasis and provide tissue regeneration (Fuentealba, Rompani et al. 2015, 
Furutachi, Miya et al. 2015). 
Adult skeletal muscle stem cells 
Skeletal muscle cells originate from myogenic muscle stem cells during myogenesis in 
the adult. Skeletal muscle stem cells are also called satellite cells (SCs) because of their 
position in the muscle fiber, where they are located between the basal lamina and the plasma 
membrane (Tajbakhsh 2009). During embryonic and postnatal development muscle stem cells 
actively proliferate into myoblasts and then differentiate into multi-nucleated myotubes that 
later constitute the myofibers. Muscle stem cells are responsible for the growth and expansion 
of the skeletal muscle tissue in the developing organism (Zammit, Heslop et al. 2002). In the 
adult, satellite cells are quiescent, unless activated by muscle damage or to ensure muscle 
homeostasis. Upon activation, satellite cells become highly proliferative (myoblasts), and 
later commit to differentiate, following the same cellular lineage as in embryonic and 
postnatal development (Fig. 4) (Zammit, Heslop et al. 2002).  
The transcription factor paired box 7 (Pax7) has a crucial role in the maintenance as 
well as activation of SCs (von Maltzahn, Jones et al. 2013). Pax7 and Pax3 are expressed both 
in quiescent and active SCs (myoblasts), although after SC activation the expression of these 
regulatory factors diminishes (Relaix, Montarras et al. 2006). 
In adult myogenesis Pax3 is only expressed in specific muscles (such as the 
diaphragm), whereas Pax7 is a common regulatory factor. In SCs, Pax7 expression represses 
differentiation and allows self-renewal, unless other myogenic regulatory factors (MRFs) are 
expressed (Gayraud-Morel, Chretien et al. 2007). MRFs are the determinants of the SC fate 
upon activation (Zammit, Relaix et al. 2006). Following SCs activation and expression of 
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Myf5, myoblasts commit to differentiate and later, by successive expression of downstream 
MRFs MyoD, Mrf 4, and Myogenin, keep differentiating and eventually form myofibers (Fig. 
4) (Zammit, Relaix et al. 2006). 
  
Figure 4. Scheme of tibialis anterior (TA) muscle composition and cell origin. The TA muscle 
embodies hundreds of myofibers (labeled with green boundaries). Multi-nucleated myofibers contain 
satellite cells (SCs, or MuSCs, muscle stem cells) embedded at the periphery. Upon injury, quiescent 
SCs activate and start expressing MyoD. Activated SCs will exponentially proliferate and are then 
called myoblasts. Myogenin expression will induce differentiation of SC-derived cells, and fusion into 
multi-nucleated myotubes that are marked by the expression of the structural protein myosin heavy 
chain (MHC). 
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Regulation of myogenesis 
 The well-studied paired-box (Pax3 or Pax7) and myogenic transcription factors 
(MyoD, Myf5, Myogenin) are prior regulators of the fate of skeletal muscle stem cells and 
their progeny. In the adult, Pax7 is the key gene that gives the myogenic characteristics and 
stemness to the satellite cells  (some cells may also express Pax3, see above) (Seale, Sabourin 
et al. 2000, von Maltzahn, Jones et al. 2013). Upon activation, satellite cells will start 
expressing the myogenic factor MyoD, and as Pax7+ MyoD+ cells will then perform 
symmetric or asymmetric cell division. Mostly SCs undergo symmetric cell division (90% of 
total cell divisions) generating two identical either stem or differentiation-committed cells 
(Cossu and Tajbakhsh 2007). Upon asymmetric division, SCs either return back to quiescence 
by self-renewing as Pax7+ MyoD- cells, or commit to differentiate as MyoD+ cells 
(Bentzinger, Wang et al. 2012).  
The MRFs Myf5 and MyoD are suggested to play a distinctive role in the fate of 
activated SCs in the adult (Gayraud-Morel, Chretien et al. 2007). Myf5 has also been shown 
to play a role in satellite cell decision: in the absence of Myf5 activated SCs undergo self-
renewal and in the presence of this factor they are more prone for myogenic differentiation 
(Gayraud-Morel, Chretien et al. 2012) MyoD, which stands for myoblast determination 
protein, plays a role in myoblasts proliferation and commitment to differentiation, by leading 
exit from the cell cycle. It indeed promotes the expression of the cell cycle arrest protein p21 
that inhibits cyclin-dependent kinases (CDK) that in turn inhibit MyoD (Guo, Wang et al. 
1995).  
MyoD also represses cell renewal. MyoD starts to be expressed at low levels upon SC 
activation, and its expression is upregulated from commitment to early differentiation. 
Transcriptional activation of MyoD is strongly dependent on chromatin modification. LSD1 
(Lysine specific demethylase 1) recruitment facilitates the removal of H3K9 methylation, then 
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induces the expression of noncoding enhancer RNA (eRNA), which resides upstream of the 
MyoD gene and is required for MyoD expression (Scionti, Hayashi et al. 2017). MyoD is 
upregulated via a coupled function of self-enhancing activity and through the transcription 
factor Six1 that binds to the Core Enhancer Region of MyoD, likely through chromatin 
structure modifications (Liu, Chakroun et al. 2013). Finally, upregulation of MyoD and other 
transcription factors like MEF2 (myocte enchancer factor 2), along with histone acetyl 
transferases p300 and PCAF (p300/CBP (CREB-binding protein)-associated factor), 
SWI/SNF (switch/sucrose non-fermentable) chromatin remodeling complex (Rudnicki, Le 
Grand et al. 2008), will induce differentiation, characterized by expression of Myogenin, 
followed by expression of myosin heavy chain (MHC), and cell fusion (Robinson and 
Dilworth 2018). 
 As mentioned earlier, satellite cells are quiescent throughout life and are activated 
upon injury, implying that the niche in which the SCs reside and neighbouring cell-to-cell 
contacts play a key role in the regulation and fate of these cells. Along with myogenic 
transcription factors, a network of kinases and several pathways, such as PI3K 
(phosphoinositide 3-kinase)/Akt, Notch signaling, and Wnt/bcatenin signaling pathways, 
explained in more detail below, are stimulated by external signals during myogenesis.  
Regulation of myogenesis through the Akt pathway 
One of the key pathways activated during myogenesis is the PI3K/Akt kinase 
pathway. It has been shown that the PI3K p110a-subunit has a significant role in the 
activation of SCs upon injury by inducing quiescence exit (Wang, Zhu et al. 2018). PI3Ks are 
a family of lipid kinases. Upon activation through extracellular signaling, they induce 
intracellular signals to regulate physiological functions (Thorpe, Yuzugullu et al. 2015). PI3K 
activation leads to direct or PDK (Phosphoinositide-3 dependent kinase)-dependent 
phosphorylation of Akt (step 1 in Fig. 5), a serine/threonine kinase that is thus recruited to the 
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cellular membrane, and in turn mediates downstream responses by phosphorylating several of 
intracellular proteins.  
Among the key targets of activated Akt is the mTORC1 pathway, that controls protein 
synthesis by sensing the nutrient and energetic status of cells (Wang, Zhu et al. 2018) (Knight 
and Kothary 2011). Activation of mTORC1 through the PI3K/Akt pathway induces 
expression of transcription factors responsible for cell cycle entry, for instance c-jun (Wang, 
Zhu et al. 2018), and the PI3K/Akt/mTORC is thus implicated in cell quiescence and 
proliferation. Additionally to cell cycle entry, PI3K-Akt-dependent phosphorylation of the 
transcription factor FOXO3a (forkhead box protein 3a) blocks the nuclear entry of this factor 
and induces its cytoplasmic arrest. Cytoplasmic arrest of the FOXO3 factor will inhibit 
transcription of FOXO3–target genes that prevalently play a role in cell cycle arrest or 
apoptosis (Sandri, Sandri et al. 2004, Wang, Zhu et al. 2018). Altogether this process has 
inhibitory effects on muscle regeneration.   
 As mentioned above PI3K/Akt kinases play a key role in SCs activation and myoblasts 
proliferation, but Akt kinases are also implicated in myogenic differentiation. Although most 
studies on Akt kinases refer to Akt1, there are actually three Akt kinases: Akt1, Akt2, and 
Akt3 that share high homology in the catalytic and regulatory domains but differ in the linker 
domain (Clark and Toker 2014). Akt1 and Akt2 are prominently expressed in all tissue types 
examined so far whereas Akt3 seems to be mostly expressed in neural and testicular tissues 
(Heron-Milhavet, Franckhauser et al. 2006).  
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Figure 5. Distinct roles of Akt1 and Akt2 in myogenesis. Myogenesis is split into 3 steps in this 
scheme. Step 1: Upon injury, SCs exit quiescence by PI3K-110a activation. PI3K phosphorylates Akt1 
directly or via PDK1. Phosphorylated Akt1 inhibits the activity of p21 (cell cycle inhibitor) by 
phosphorylation of this factor in the cytoplasm. Step 2: After proliferation of SC-derived myoblasts, 
MyoD is upregulated and high levels are maintained by self-regulation, which in turn results in 
upregulation of Akt2. It is speculated, but not clearly demonstrated yet, that MyoD upregulates Akt2. 
Akt2 blocks the phosphorylation of p21 by direct interaction with this protein. p21 in interaction with 
Akt2 is recruited to or remains in nucleus and induces cell cycle arrest. Step 3: Phospho-Akt2 
phosphorylates p300 (histone acetyl transferase) and induces formation of the MyoD-p300 complex 
that includes additional transcription factors. Thereafter, myogenic differentiation factors such as 
Myogenin will be expressed and cells will commit to differentiate and later fuse into myotubes. Since 
the regulator of Akt2 is not clearly known yet, activation of Akt 2 by potential factors is indicated with 
dotted red arrows). Encircled P indicates phosphorylation of the protein. 
 Akt1 and Akt2 have distinct roles at different stages of myogenesis (Knight and 
Kothary 2011). Akt1 is responsible for proliferation of myogenic cells and their maintainance 
in the cell cycle. Activated phospho-Akt1 phosphorylates and thereby inhibits p21 (or cyclin-
dependent kinase inhibitor 1), a potent inhibitor of the cell cycle, (step 1 in Figure 5).  
Phosphorylated p21 cannot induce cell cycle arrest. Akt2, which is upregulated during early 
differentiation (Vandromme, Rochat et al. 2001), directly interacts with p21 and so protects 
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this factor from phosphorylation by Akt1, and as a consequence induces cell cycle arrest (step 
2 in Figure 5) (Heron-Milhavet, Franckhauser et al. 2006) (Heron-Milhavet, Franckhauser et 
al. 2013).  
Another regulator of proliferation in myogenic cells is the Pitx2-HuR (pituitary 
homeobox 2- mRNA binding protein) complex. Pitx2-HuR complex protects cyclin D1 
(Ccnd1) transcripts from degradation. Activated Akt2 phosphorylates Pitx2 that dissociates 
from the Pitx2-HuR complex, and in turn decreases the stability of cyclin D1 transcripts and 
finally affects the proliferation potential of myogenic cells (Gherzi, Trabucchi et al. 2010). 
Along with induction of cell cycle arrest, activated Akt2 also phosphorylates the p300 histone 
acetyl transferase that will be recruited to form the p300-MyoD complex and induce 
myogenic differentiation by activating the MyoD-target gene expression (Chen, Wang et al. 
2015).  
Even though globally Akt kinases are activated by PI3K, regulation and activation of 
Akt2 has not been clearly elucidated during myogenesis. However, there are indications that 
mTORC2, a regulator of cellular metabolism and cytoskeleton, or directly Akt kinases, 
instead of being activated by PI3K are activated by PI3K-related kinases (a group of kinases 
related to PI3K, that include kinases implicated in the repair of DNA damage ATM, ATR, 
DNA-PK-cs) (Halaby, Hibma et al. 2008, Zheng, Mao et al. 2016, Toulany, Maier et al. 
2017), mTORC2 would then phosphorylate Akt2 during myogenesis, promoting cell 
differentiation (step 3 in Figure 5) (Shu and Houghton 2009). 
Regulation of myogenesis through other pathways 
In addition to PI3K and Akt pathways, p38 (a mitogen-activated protein kinase, or 
MAPK) plays a role during myogenesis. P38 helps the transition of proliferating myoblasts 
into cell cycle arrest and commitment to differentiate. TNFa (tumor necrosis factor a), 
inflammatory cytokines and TGFb growth factors have been implicated in the activation of 
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p38 MAPK during the transition of proliferating myogenic cells into differentiating state 
(Knight and Kothary 2011). It has been suggested that p38 has a suppressing effect on 
proliferation, by inducing the JNK (c-Jun N-terminal) pathway, and thereby inducing 
differentiation. Differentiation is induced through chromatin modification, phosphorylation of 
transcription factors, and also by inducing the formation of transcription factor complexes 
(MyoD, E47, MEF2, p300) that regulate the expression of genes involved in differentiation 
(Segales, Perdiguero et al. 2016). 
 The Notch signaling plays a crucial role in quiescence and activation of satellite cells 
as well as their fate choice to self-renew or return to quiescence (Kitamoto and Hanaoka 
2010) (Mourikis and Tajbakhsh 2014). Three isoforms of Notch receptors have been 
described: Notch1, Notch2 and Notch3. Interaction of ligands (such as Delta-like1, Delta-
like4, Jagged1 and Jagged 2) with the Notch receptor induces cleavage of the Notch 
intracellular active domain (NICD). NICD interaction with RBPJ (recombining binding 
protein), a coactivator, induces expression of proteins that repress transcription Hes1, Hey1, 
HeyL (Baghdadi and Tajbakhsh 2018). It has been demonstrated that Notch1 and Notch 2 
signaling strongly sustains SCs quiescence in the niche (Mourikis, Sambasivan et al. 2012, 
Fujimaki, Seko et al. 2018), but once the niche is disrupted, this signaling is downregulated 
driving the cells in the activated state, and promoting proliferation (Mourikis and Tajbakhsh 
2014).  
Additionally, it was suggested that proliferating cells undergo a phase of increased 
Notch signaling, which potentially drives into cell cycle exit, and promotes differentiation or 
self-renewal (Mourikis and Tajbakhsh 2014). Moreover, Notch3 signaling has been 
specifically implicated in the regulation of SCs proliferation, since in the absence of Notch3 
SCs become highly proliferative in culture. Notch3 absence also results in a higher number of 
quiescent SCs in vivo after injury. It has also been reported that constitutive active form of 
Notch3 (N3ICD) upregulates Nrarp (Notch-regulated ankyrin repeat-containing protein), a 
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negative feedback regulator of Notch1. These findings suggest that Notch3 may have a 
potential inhibitory effect on Notch1 signaling, since Notch1 is essential to maintain cell 
quiescence (Kitamoto and Hanaoka 2010).  
The Wnt/B-catenin signaling pathway also plays a role in the regulation of myogenic 
cell fate (Suzuki, Pelikan et al. 2015) (Murphy, Keefe et al. 2014), although there are 
contradictory results on whether this pathway is indispensible for myogenic cells. Indeed, 
according to in vitro studies, Wnt/B-catenin is implicated in the regulation of cell proliferation 
by stimulation of cyclin gene expression, thereby intervening in the cell cycle as well as in 
fusion and maturation of differentiated myotubes (Suzuki, Pelikan et al. 2015). Conversely, in 
vivo studies have shown that Wnt/B-catenin signaling is not indispensible, and injured muscle 
can be regenerated even in the absence of this pathway (Murphy, Keefe et al. 2014). 
DNA damage and DNA damage response 
 Different types of DNA damages can occur in cells throughout the life of the 
organism. These damages are caused by endogenous or exogenous genotoxic stresses such as 
reactive oxygen species (ROS) and replication fork mismanagement for the former, and 
ionising radiations (IR), chemicals, anti-tumour drugs, and UV light for the latter (Blanpain, 
Mohrin et al. 2011). Cells have developed specific mechanisms to overcome the DNA 
damage, which are globally referred as DNA damage response (DDR) (Insinga, Cicalese et al. 
2014). If necessary, DDR blocks the cell cycle until the damage is processed, and activates 
specific repair pathways depending on the type of DNA damage.  
Major DNA damage repair pathways are: mismatch repair (MMR) that processes 
mismatches in the double helix, base-excision repair (BER) that repairs small or non-bulky 
DNA adducts, and nucleotide excision repair (NER) that repairs DNA bulky adducts (Fig. 6) 
(Iyama and Wilson 2013). In some circumstances such as upon oxidative stress, simple DNA 
lesions such as base lesions, DNA cross-links, etc., as well as stalled repair of DNA lesions 
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listed in Figure 6 could lead to formation of DNA single-strand breaks (SSBs) (Abbotts and 
Wilson 2017). Thereafter SSBs are repaired by single-strand break repair (SSBR), which 
could be counted as a sub-BER pathway as most of the proteins processing SSBs also play a 
role in BER. When both DNA strands are broken (DSBs) then the prevalent repair mechanism 
is either non-homologous end-joining (NHEJ) or homologous recombination (HR) (Fig. 6) 
(Iyama and Wilson 2013). 
HR is almost exclusive or prevalent in prokaryotic organisms, but is also relevant in 
eukaryotes, including mammals, whereas NHEJ is prevalent in higher eukaryotes, less 
frequent in yeast, rare in bacteria like Mycobacterium smegmatis, Mycobacterium 
tuberculosis, Bacillus subtilis, and occasional in bacteria as Escherchia coli (Gong, 
Bongiorno et al. 2005, Chayot, Danckaert et al. 2010). The complexity and the number of 
NHEJ factors increase from bacteria to mammals. Several variants of these major DSB repair 
mechanism have been described (Currall, Chiang et al. 2013).  
Below is a survey of the characteristics of DSB repair mechanisms, with the exclusion 
of the prevalent NHEJ and HR that will be discussed in a further section. 
The choice of the repair pathway depends on the phase of the cell cycle (or on being 
non-cycling) as well as the DNA sequences at the damage site, that may allow full or partial 
pairing, or require DNA resection for homology search (see below). NHEJ can take place 
during all phases of the cell cycle or in G0, since it is not an homology-directed repair (that 
requires an homologous sequence) (Currall, Chiang et al. 2013). NHEJ can be classical (c-
NHEJ), the prevalent form that ligates the DNA broken ends in a DNA-PKcs dependent 
manner (see below in the non-homologous end-joining section) or alternative (alt-NHEJ), 
which is normally less frequent and is better detected when c-NHEJ is impaired.  
Alt-NHEJ requires 1-5 complementary nucleotide annealing to bring the DNA broken 
ends together. In the absence of short sequence annealing, single-stranded DNA resection of 
the broken ends is activated to generate sequences that can be paired (5-25 base pairs) with 
 30 
other end. This mechanism, that will necessarily generate deletion of the sequences around 
the DSB, is referred as micro-homology mediated end-joining (MMEJ) (McVey and Lee 
2008). Usually resection activity in MMEJ is short, unless homology search fails, which 
promotes further resection, and so until successful complementary sequence annealing occurs 
(or DNA is so extensively degraded that is no longer compatible with cell survival) (Sinha, Li 
et al. 2017) (Zhang and Jasin 2011). Because of this resection activity alt-NHEJ is more error-
prone than c-NHEJ and necessarily induces deletions at the junction site (Betermier, Bertrand 
et al. 2014).  
 
Figure 6. Scheme of different DNA damaging agents, DNA damages, and prevalent DNA repair 
mechanisms (adapted from Blanpain et al. 2011 (Blanpain, Mohrin et al. 2011)). 
Although HR is globally reported as an error-free DSB repair, this is not always the 
case, since homology search and initiation of HR depend on the nature of the DSBs as well as 
the nature of the homologous sequence (Guirouilh-Barbat, Lambert et al. 2014). Indeed, HR 
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may generate loss of heterozygosity if it takes place on two different alleles, or translocations 
if the template region is not located on sister chromatid/homologous chromosome. Moreover, 
variants of this repair mechanism are intrinsically associated with sequence alterations. For 
example, in addition to classical HR, DNA damage can be repaired by single-strand annealing 
(SSA), which is to some extent similar to MMEJ in the initial phase, and is more prone in 
DSBs located in regions carrying repeated sequences (such as tandem repeats, interspersed 
repetitive DNA, etc.) (Currall, Chiang et al. 2013). SSA causes deletions due to resection 
activity until complementary strands are found to allow anneal, forming a synapse of the 
DNA ends. The flanking sites will be resected by endonuclease activity, followed by ligation 
and DNA synthesis by a DNA polymerase to fill the gap (Bhargava, Onyango et al. 2016).  
Break-induced replication (BIR) is another form of HR-related mechanism that also 
induces mutations and affects genomic stability. As other HR pathways, BIR initiates with 
end-resection however only one (single-stranded) broken-end is engaged in invading the 
template sequence that, instead of forming the Holliday junction, will form a migrating D-
loop (replication bubble). Then, DNA synthesis on the leading strand will extend the ssDNA. 
The lagging strand is synthesized through Okazaki fragments, as during DNA replication, 
although here via an asynchronous mechanism that leads to potential genomic instabilities.  
This is the case for either for mismatches on the newly synthesized strands, or for invasion 
(and copy) of on an homologous region located elsewhere in the genome (Kramara, Osia et al. 
2018).  
Similar to BIR, but engaging both broken ends, a mechanism called synthesis-
dependent strand annealing (SDSA), consists in 3′ ssDNA tail annealing with the template, 
followed by extension through DNA synthesis as in HR. The newly formed DNA will ligate 
back to the other broken end, thereby without formation of the Holliday junction (Sung and 
Klein 2006).  
The rest of this dissertation will be concentrated on DSBs and NHEJ.  
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Initial steps in the response to DSBs 
Upon DSB formation, the ataxia telangiectasia mutated (ATM) protein kinase is 
activated by auto-phosphorylation of serine 1981. Auto-phosphorylation of the Ser1981 unit 
will trigger separation of the inactive ATM dimer into activated phosphorylated ATM 
monomer (Lee and Paull 2007) that is recruited to the DNA damage site. Activated ATM 
phosphorylates the histone H2AX as well as the tumor suppressor protein p53, CHK2 
(checkpoint protein 2), BRCA1 (breast cancer type 1 susceptibility protein 1), NBS1 (nibrin), 
SMC1 (structural maintenance of chromosomes protein 1), and MDC1 mediator of DNA 
damage checkpoint protein 1 (see below), as well as other ATM substrates that act as 
effectors of cellular processes in response to the damage to trigger cell cycle arrest and 
activate repair pathways (Kurz and Lees-Miller 2004).  
Indeed, an initial step upon DNA damage is cell cycle arrest induced by checkpoint 
kinases such as CHK2 that is activated by ATM, or CHK1 that is activated by ATR, another 
transducer of the DNA damage signal that is activated by a large spectrum of DNA damages 
in addition to DSBs. Activated CHK2 phosphorylates cell cycle regulators such as CDC25 
(cell division cycle 25) and additionally activates the tumor suppressor protein p53 that will 
promote activation of the CDKs (cyclin dependent kinase) inhibitor p21, a cell cycle inhibitor 
(Zannini, Delia et al. 2014). On rare occasions where ATM function is impaired, DSBs can 
also activate the ataxia telangiectasia and Rad3-related (ATR) protein kinase (Tomimatsu, 
Mukherjee et al. 2009).  
The other essential DNA damage sensor factor is the multi-functional MRN complex 
that consists of Mre11 (meiotic recombination 11 homolog 1), Rad50 (ATP-binding cassette-
ATPase), and NBS1. Due to its binding sites, NBS1 acts like an anchor, keeping the DDR 
proteins on the DNA damage site. NBS1 contains multiple domains: a BRCT domains, a 
phospho-protein binding domain that detects the DNA damage signal for instance through 
phosphorylated histones, and also binding sites for multiple proteins such as ATM, Mre11, 
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(CtIP) C-terminal binding protein (CtBP)-interacting protein, that plays a role in HR, as 
explained below (Syed and Tainer 2018). BRCA1, an E3 ubiquitin ligase, has also a BRCT 
domain that allows recruitment and formation of a complex with RAP80 at DNA damage 
sites.  BRCA1 plays a mediator role in the choice of the DSB repair pathways. In competition 
with 53BP1 (p53 binding protein 1), it facilitates MRE11/CtIP resection activity and induces 
HR (Fig. 7). BRCA1 in interaction with BARD1 has a role in mediating the recruitment of 
RAD51 and BRCA2 during HR (Zhao, Steinfeld et al. 2017).  
Following activation of ATM, the histone H2AX is phosphorylated on Ser139 (and is 
then called gH2AX) for several kilobases around the DSB, and is used as a DSB marker 
(Burma, Chen et al. 2001). Although H2AX is mainly phosphorylated by ATM, DNA-PKcs 
and ATR (other PI3K-related kinases) can also do it. Phosphorylation of H2AX represents the 
major initial step of chromatin modification, which is necessary to allow the recruitment of 
downstream repair proteins (Paull, Rogakou et al. 2000, Goodarzi and Jeggo 2013). Once 
H2AX is phosphorylated, methylated MDC1 will detect gH2AX and will be recruited to DNA 
damage site (Watanabe, Iimori et al. 2018). MDC1 accumulated at the DNA damage site is 
then phosphorylated and mediates the recruitment of the MRN complex (Spycher, Miller et 
al. 2008), as well as RNF8 (Fig.7a), and RNF168 ubiquitin ligases. Ubiquitylated chromatin 
will be occupied by 53BP1 (Fig.7a) (Bohgaki, Bohgaki et al. 2013) and BRCA1 
(Nepomuceno, Fernandes et al. 2017). 53BP1 interacts with the BRCT domain of 
phosphorylated MDC1, which is crucial for initiation of DDR (Eliezer, Argaman et al. 2009). 
Additionally, 53BP1 can be directly recruited to DSBs through interaction of its Tudor 
domain with the dimethylated form of histone H4 (H4K20me2) (Botuyan, Lee et al. 2006). 
53BP1 recruitment maintains the modified chromatin structure initiated by MDC1 and 
RNF8/RNF168 to recruit downstream DDR proteins. 53BP1 plays a role in mediating 
chromatin modification for DSB repair in heterochromatin (Noon, Shibata et al. 2010) and is 
also implicated in the choice of repair pathway. In this context, 53BP1 recruitment at DSBs 
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blocks the resection activity of the MRN complex thereby counteracting with initiation of HR 
as well as class-switch recombination in T and B cells (Ward, Reina-San-Martin et al. 2004) 
(Bunting, Callen et al. 2010). Furthermore, ATM-dependent interaction of 53BP1 with BLM 
blocks the resection activity of MRN/CtIP and thereby the induction of alternative NHEJ in 
the G1 phase (Grabarz, Guirouilh-Barbat et al. 2013). Additionally, by facilitating the 
formation of DSB synapses, 53BP1 promotes long-range DNA end-joining during V(D)J 
recombination (Difilippantonio, Gapud et al. 2008). In conclusion, although 53BP1 is 
dispensible for NHEJ, it is essential to suppress alternative NHEJ and for holding DSB 
synapses together thereby limiting large DNA deletions or translocations in lymphocytes 
derived from ATM deficient mice (Rybanska-Spaeder, Reynolds et al. 2013).  
Homologous recombination (HR) 
The HR repair pathway mainly operates in cells with DSBs occurring at late S/G2 
phase of cell cycle, including those generated by stalled replication forks. It also acts in 
meiotic divisions to repair DSBs that generate crossing overs of genomic regions (Liu, Srihari 
et al. 2014). This pathway is based on DNA synthesis to replace the damaged locus, whose 
DNA ends have been previously resected and present now a single-strand tail. Then, an 
homologous intact DNA region, normally the sister chromatid, is invaded by the broken end 
and used as template for DNA synthesis (Jeggo, Geuting et al. 2011) (Wright, Shah et al. 
2018). On rare occasions HR occurs in the G1 phase of the cell cycle, when the sister 
chromatid is not present and in this case the homologous chromosome or sequences is used as 
template (Orthwein, Noordermeer et al. 2015). This event may lead to loss of heterozygosity 
if the broken and the template alleles are different, potentially generating duplication of an 
impaired or oncogenic allele, with consequences for diseases and cancerogenesis (Liu, Srihari 
et al. 2014).   
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Figure 7. DNA damage response (DDR) stimulation upon MRN recruitment, ATM activation and 
choice of the DSB repair pathway. a) Chromatin modification by ATM-dependent phosphorylation of 
histone H2AX and recruitment of 53BP1, MDC1, and RNF8. b) Homologous recombination pathway 
initiated by the MRN complex, and MRE11/CTIP resection activity. c) Non-homologous end-joining 
repair pathway initiated by 53BP1 that has inhibitory effect on resection of DNA broken-ends, a 
process that would lead to the alternative repair mechanism, homologous recombination. d) 
Alternative non-homologous end-joining repair pathway relies on key player of other repair pathways. 
(Adapted from (Goodarzi and Jeggo 2009) and (Mladenov and Iliakis 2011)). 
HR repair is considered almost error-free, although HR-dependent altered DNA 
synthesis has been reported (Malkova and Haber 2012). In addition, HR may generate 
translocations if pairing and exchange of DNA sequences occurs on different chromosomes, 
potentially generating more severe genomic alterations than NHEJ (Liu, Srihari et al. 2014). 
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HR is based on the MRN (Mre11, Rad50, Nbs1) complex that resects DNA (through Mre11) 
and recruits downstream proteins as CtIP, EXO1, DNA2 helicase/endonuclease, to continue 
resection and processing the DNA broken ends.  
The DNA end processing will form 3’ single-stranded DNA (ssDNA) overhangs. 
Proteins Rad51, Rad52, BRCA1/2, XRCC2/3, Rad54, BLM, WRN are then recruited to 
single-stranded 3’ overhangs to invade the intact homologous strand, which is then copied by 
several DNA polymerases, mainly Pol δ (delta) and to a minor extent Pol ζ (zeta), and perhaps 
also Pol η (eta), Pol a (alpha), and Pol ε (epsilon), although the participation of these last three 
DNA polymerases in HR it is not clear or fully supported (McVey, Khodaverdian et al. 2016). 
The DNA is ligated by ligase 1 and possible DNA structures formed during the process, 
including the Holliday junction, are resolved by the GEN1 resolvase or some helicase and 
nuclease activities such as those of BLM, topoisomerase IIIa, and MUS81-EME1 (Fig. 7b) 
(Goodarzi and Jeggo 2013, Liu, Srihari et al. 2014). 
Non-Homologous End-Joining (NHEJ) 
Unlike HR, NHEJ repairs DSBs both in dividing cells (including in G1 when the sister 
chromatid is not present) and non-dividing cells (G0 phase), taking into account that NHEJ 
does not need a homologous DNA template to process the damage. NHEJ is the prevalent 
repair pathway processing DSBs in non-dividing cells in mammals (Liu, Srihari et al. 2014). 
In addition to accidental DSBs, NHEJ is also required for the repair of programmed DSBs in 
V(D)J recombination and Class Switch Recombination in B and T cells (Manis, Dudley et al. 
2002) (Kienker, Shin et al. 2000). Two types of NHEJ pathways have been identified each 
involving different sets of proteins. The commonly activated and less error-prone NHEJ is 
called canonical or classical NHEJ (c-NHEJ, or simply NHEJ) whereas the other end-joining 
pathway is defined alternative NHEJ (alt-NHEJ). Generally, alt-NHEJ is activated when the 
c-NHEJ pathway is impaired, and is more error prone than c-NHEJ, due to the more extensive 
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DSB end processing (Fig. 7d) (Sinha, Li et al. 2017) (Zhang and Jasin 2011) (Soni, Siemann 
et al. 2014). Nevertheless, in human cells, rather c-NHEJ is held responsible for translocations 
whereas alt-NHEJ primarily induces deletion due to resection activity for homology search, as 
explained above (Ghezraoui, Piganeau et al. 2014).   
After detection of DSB and the occurrence of chromatin modification leading to 
chromatin relaxation, repair proteins of either HR or NHEJ are recruited to the broken site. 
53BP1, which has a role in chromatin modification, as mentioned earlier, (Noon, Shibata et 
al. 2010), also promotes NHEJ and blocks HR. 53BP1 interacts with the MRN complex (Lee, 
Goodarzi et al. 2010), inhibits the nuclease activity of Mre11, thus limiting the formation of 
the ssDNA overhang and thereby inhibiting BRCA1 interaction with the damaged site, which 
would lead to HR (Fig. 7 a, b). As a consequence, through 53BP1, NHEJ proteins will be 
recruited to the damage site (Fig. 7a, c) (Liu, Srihari et al. 2014, Liu and Huang 2014). The 
initial step of c-NHEJ repair consists in Ku70-Ku80 heterodimer binding to the DSB ends. 
Ring formation of the Ku70/80 dimer around double-stranded (ds) DNA protects the 
broken ends from nuclease activity and allows the recruitment of the DNA-dependent protein 
kinase catalytic subunit (DNA-PKcs) (Gottlieb and Jackson 1993). Following DNA-PKcs 
binding to DNA ends, the protein kinase auto-transphosphorylates and becomes active by 
forming the DNA-PKcs/Ku70/80 complex called DNAPK. Activated DNAPK plays a crucial 
role in tethering broken DNA ends (Blackford and Jackson 2017). DNA-PKcs can also 
phosphorylate the histone H2AX, Akt kinases, and the Werner helicase (WRN), as well as 
Artemis, polynucleotide kinase/phosphatase (PNKP), and p53. It also mediates the 
recruitment of these factors to the repair site (Araki, Fujimori et al. 1997, Mladenov and 
Iliakis 2011) (Burma, Chen et al. 2006).  
If DNA ends are not immediately ligatable, after activation of DNA-PKcs, DNA end 
processing enzymes are recruited at the broken site, as Artemis that has nuclease activity 
(mainly active in V(D)J recombination) (van der Burg, Verkaik et al. 2007) (Moscariello, 
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Wieloch et al. 2015), polynucleotide kinase 3`phosphatase (PNK) that generates 3’-P and 5’-
OH DNA ends (Chappell, Hanakahi et al. 2002), and polymerases Pol m (mu) and Pol l 
(lambda) that synthesize DNA to complete the double-stranded DNA (Chayot, Montagne et 
al. 2012) (Chang, Watanabe et al. 2016) (Bertocci, De Smet et al. 2006, Sastre-Moreno, Pryor 
et al. 2017) (Pryor, Waters et al. 2015). DNA end processing is finalized by ligation of broken 
ends by ligase IV activity in interaction with XRCC4 and stimulation by XLF/Cernunnos 
(Fig. 7c) (Ahnesorg, Smith et al. 2006). Additionally, PAXX protein interacts with Ku 
proteins and stabilizes the DNA damage repair proteins at the DSB site during the repair 
process. PAXX is suggested to be an accessory protein, as in the absence of PAXX DSB 
repair is not strongly ablated unless XLF/ Cernunnos is missing (Tadi, Tellier-Lebegue et al. 
2016) (Liu, Shao et al. 2017).  
Although less efficient, also alt-NHEJ may operate on DSBs. Alt-NHEJ is initiated by 
poly (ADP-ribose) polymerase (PARP) activity and by the MRN complex (Rass, Grabarz et 
al. 2009), followed by recruitment of the WRN helicase, DNA polymerase beta (Pol b) (Ray, 
Breuer et al. 2018), polymerase theta (Pol θ) (Mateos-Gomez, Kent et al. 2017), and the 
nuclease CtIP, followed by the scaffold protein XRCC1 and ligase 1 or ligase 3 (Soni, 
Siemann et al. 2014) (Goodarzi and Jeggo 2013). Interestingly, the repair proteins involved in 
alt-NHEJ are key players in other pathways, for instance HR (CtIP, WRN) and BER and NER 
(XRCC1, ligase 3) (Fig. 7d) (McVey and Lee 2008). Generally in alt-NHEJ, micro-homology 
between DNA ends is required for ligation. As described in a previous section, micro-
homology may not be immediately available, and extensive DNA resection may occur before 
critical resected regions have the possibility to pair; this results in generally larger DNA end 
processing than in c-NHEJ. More in general, alt-NHEJ is potentially more error prone than c-
NHEJ and HR (Taty-Taty, Chailleux et al. 2016) (Betermier, Bertrand et al. 2014).  
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Role of poly (ADP-rybose) polymerases in the selection of the DSB repair pathway 
The poly (ADP-rybose) polymerase 1 (PARP1) plays multiple roles in DNA damage 
repair, namely in base excision repair (BER) and nucleotide excision repair (NER), which 
targets non-helix distorting and bulky single-stranded breaks, respectively. It is also involved 
in radiation-induced DSBs through activation of ATM (Aguilar-Quesada, Munoz-Gamez et 
al. 2007). Moreover, PARP1 plays a complex role in the selection of the DSB repair pathway: 
it indeed recruits key HR proteins like BRCA1, thereby promoting HR (Li and Yu 2013), but 
also downregulates BRCA1 activity by stabilizing the BRCA1-RAP80 complex, and thereby 
restricting excessive HR activity which may lead to chromosomal rearrangements (Hu, Petit 
et al. 2014). PARP1 also promotes NHEJ by stimulating the kinase activity of DNA-PKcs, 
and through chromatin remodeling, as well as facilitating fast recruitment of c-NHEJ proteins 
such as Ku70/80 proteins, and ligase 4 to the DNA damage site (Wei and Yu 2016).  
Despite the PARylation-dependent recruitment of c-NHEJ proteins, the PARylated 
form of Ku proteins cannot bind to DNA. In agreement with this notion, it has been recently 
shown that PARP1 and Ku70/80 proteins are recruited to the DNA damage site relatively 
early, suggesting that these proteins compete with each other as DSB sensors. It has been also 
shown that PARylation of Ku70/80 removes this complex from the DNA mainly on the S and 
G2 phases of the cell cycle (Yang, Liu et al. 2018).  
PARP1 has also a function in alternative NHEJ repair, through recruitment of the 
MRN complex, promoting end-resection necessary to this DSB repair mechanism (Audebert, 
Salles et al. 2004). The highly homologous PARP2 protein, is also implicated in BER, favours 
HR by stabilizing HR proteins at the replication forks. Moreover, by limiting the binding of 
53BP1 to DSBs it promotes DNA end-resection, favoring HR or alt-NHEJ over classic NHEJ 
(Fouquin, Guirouilh-Barbat et al. 2017). It is considered that PARP1 and PARP2 have 
overlapping functions. Consequently, PARP inhibition (for instance by anti-cancer drugs) 
may favour one DSB repair mechanisms over the other.   
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Double-strand breaks in adult stem cells 
 The consequences of unrepaired DSBs are particularly critical in adult stem cells as 
unrepaired damage may block proliferation, or conversely promote premature differentiation, 
as it is the case for hair follicle melanocytes (Blanpain, Mohrin et al. 2011). Moreover, 
mutations resulting from inaccurate repair could be passed on to the progeny. In all these 
cases the tissue integrity and tissue function can be impaired. Additionally, accumulation of 
DNA damage could lead to diminished stem cell pool, thereby affecting self-renewal and 
ultimately altering tissue homeostasis, which promotes aging (Blanpain, Mohrin et al. 2011). 
Therefore the accuracy and efficiency of DNA damage repair play a crucial role in 
maintaining the integrity of stem cells as well as their progeny (Insinga, Cicalese et al. 2014). 
In the few cases analysed to date, adult stem cells appear to respond to DSBs in diverse 
manner, although generally quite efficiently, and repair DSBs with different mechanisms 
(Blanpain, Mohrin et al. 2011). 
 For instance human HSCs, which are one of the most radiosensitive (and best studied) 
type of stem cells (Milyavsky, Gan et al. 2010) showed less efficient and delayed repair than 
their derived progenitors upon irradiation and displayed high rate of apoptosis, implicating a 
certain extent of inaccurately repaired or unrepaired DSBs (Milyavsky, Gan et al. 2010). 
Conversely, rodent quiescent HSCs dominantly repair radiation (IR)-induced DSBs by NHEJ 
more efficiently than their derived progenitors (common myeloid progenitors, CMPs, and 
granulocyte/macrophage progenitors, GMP), and also display higher cell resistance to 
apoptosis than CMPs and GMPs (Mohrin, Bourke et al. 2010) (Biechonski, Olender et al. 
2018). Human HSCs that survived after irradiation were reported to be prone to carry 
chromosomal aberrations, which could explain the possible decline in the regeneration 
potential of these cells, and also the development of carcinogenesis in the hematopoietic 
system (Biechonski, Olender et al. 2018). High levels of chromosome aberrations have also 
been reported in murine HSCs upon irradiation. These genome modifications persist multiple 
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transplantations in mice, and provide a mechanistic base for hematological malignancies, 
although affected mice did not display increased levels of malignancies (Mohrin et al, 2010). 
 Unlike HSCs, hair follicle (HF) bulge stem cells are rather resistant to DNA damage 
induced cell death (Sotiropoulou, Candi et al. 2010). As mentioned earlier, HF bulge stem 
cells are a slow cycling and mostly quiescent sub-population of epidermal stem cells 
(Sotiropoulou and Blanpain 2012). HF bulge stem cells display higher expression of DNA-
PKcs and repair radiation-induced DNA damage by more efficient NHEJ compared to 
differentiated non-bulge cells. Moreover, HF bulge stem cells display increased resistance to 
cell death through expression of the anti-apoptotic Bcl2 factor, along with transient activation 
of p53 which is down regulated within 24 hours, unlike non-bulge cells in epidermis 
(Sotiropoulou, Candi et al. 2010).  
Interestingly, in the absence of BRCA1 (one of the key protein involved in HR), HF 
bulge stem cells are depleted in mice and display increased levels of endogenous DNA 
damage. These cells undergo p53-dependent cell death, possibly due to accumulated DNA 
damage (Sotiropoulou, Karambelas et al. 2013). BRCA1 is not essential for quiescent HF 
bulge stem cells, but it is important when these cells are activated for regeneration. This result 
may depend on the specific role of HR in proliferating cells, although it cannot be excluded 
that BRCA1 has other roles than HR repair in these cells. Indeed other stem cells present in 
the epidermis, like stem cells located in the interfollicular epidermis and in sebaceous glands 
are not affected by BRCA1 depletion.  
 In addition to altered efficiency of DNA repair and resistance to apoptosis, adult stem 
cells display diverse responses to DNA damage. For instance, melanocytes, which are also 
located in the hair follicle, similarly to bulge stem cells display Bcl2-dependent protection 
from apoptosis (Robinson and Fisher 2009). However, melanocyte stem cells undergo 
premature differentiation upon accumulated or unrepaired DNA damage, thereby reducing the 
stem cell pool, which finally results in increased grey hairs. However, the remaining 
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melanocytes maintain the stem cell fate, suggesting that the DDR of melanocytes tends to 
keep the stem cell pool DNA damage-free (Inomata, Aoto et al. 2009). 
Similar to bulge stem cells, mammary stem cells and mesenchymal stem cells also 
display high resistance to ionizing radiation by inducing the NHEJ repair (Vitale, Manic et al. 
2017). 
Because of being quiescent, which corresponds to G0 or prolonged G1, most non-
activated stem cells are assumed to repair radiation-induced DNA damage through NHEJ. As 
we have seen above, once cycling, HSCs as well as HF stem cells rather adapt HR as a repair 
mechanism. This seems also the case for intestinal stem cells (ISCs), which use both repair 
pathways: HR and NHEJ. Intestinal stem cells indeed consist of two sub-populations, 
quiescent and cycling cells, differently located in the crypt, and accordingly the quiescent 
population repairs DNA damage by NHEJ while cycling cells by HR.  
It was suggested that quiescent BMI+ ISCs are more resistant to DNA damage than 
cycling LGR5+ ISCs. In return BMI+ cells compensate for the loss of cycling cells upon 
radiation by re-entering the cell cycle. The Wnt signaling is implicated in high resistance and 
efficient NHEJ repair of DNA damage in quiescent ISCs, by upregulating Lig4 (Vitale, Manic 
et al. 2017). Conversely, high levels of Wnt would promote cycling ISCs cell death upon 
DNA damage. The response of ISCs to DNA damage has been controversial, since other 
studies suggest that, on the contrary, cycling ISCs are more resistant to DNA damage through 
HR repair than the quiescent population (Blanpain, Mohrin et al. 2011) (Metcalfe, Kljavin et 
al. 2014) (Vitale, Manic et al. 2017). However, the large plasticity as well as complicate 
lineage tracing of ISC subpopulations may account for different results in this field (Barker 
2014). 
Neural stem cells and their progenies display diverse DDR responses. Upon irradiation 
neural progenitors either undergo apoptosis, or proliferation arrest or commitment to 
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differentiation, whereas neural stem cells are more resistant to cell death and activate efficient 
DNA damage repair, thereby replacing the lost progenies (Barazzuol, Ju et al. 2017). 
Muscle stem cells, or satellite cells are also quiescent throughout life and activate 
upon muscle injury. It has been shown that upon irradiation in vitro and in vivo, isolated SCs 
and SCs within the myofiber display a more efficient DSB repair response than their 
committed progeny. Moreover, in vitro experiments indicate that SCs repair DNA damage 
extremely accurately, and through a DNA-PKcs dependent repair (Vahidi Ferdousi, 
Rocheteau et al. 2014). The repair efficiency of replication-induced DSBs in proliferating 
myoblasts remains high in aged animals (Cousin, Ho et al. 2013).  
The role and the mechanism(s) of DSB repair in satellite cells will be elaborated in the 
sections Result and Discussion. 
Functions of DNA damage repair proteins independently of their role in DDR 
 As we have briefly described above, the DNA damage response consists of a large and 
complex network of mechanisms and proteins that include chromatin modifiers, helicases, 
and kinases. Recently, several studies showed that a number of proteins implicated in the 
DNA damage response, also function in other mechanisms, and independently of processing 
the DNA damage.  
Several genetic disorders due to impairment of an essential DNA damage repair 
protein display a large variety of phenotypes on patients. For instance, patients with 
Xeroderma pigmentosum (XP) (mutated in a subset of proteins implicated in the NER 
pathway) have impaired NER (Spivak 2015). However, depending on the mutated XP protein, 
patients suffer from UV sensitivity, and may have pigmentation abnormalities or neuro-
degeneration, as well as susceptibility to skin cancer (Troelstra, van Gool et al. 1992).  
CSA and CSB proteins also play a role in NER. Cockayne syndrome patients, who are 
mutated in one of these proteins, generally, but not exclusively, display UV-hypersensitivity, 
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neurodegeneration, precocious ageing, with various combinations of these defects that 
additionally may vary from mild to severe (Wilson, Stark et al. 2016). In other cases, patients 
with mutations in the same proteins display only UV-hypersensitivity (Nardo, Oneda et al. 
2009). CSA and CSB are multifunctional proteins, being also transcription and chromatin 
remodeling factors. Recent evidences suggest that the cause of the disease may rather rely on 
mitochondrial defects due to altered proteostasis, in turn linked to epigenetic regulation 
(Chatre, Biard et al. 2015), which could also explain the variable clinical spectrum.  
Accordingly, in a model of progeroid Werner syndrome, mutated in the WRN helicase 
that is implicated in the repair pathways HR, NHEJ, and BER, the progeroid defect seems 
rather due to a distinct role of WRN in the maintenance of heterochromatin architecture 
(Zhang, Li et al. 2015).  
In the same line, ATM and DNAPKcs, essential proteins in DDR, are serine/threonine 
kinases belonging to the family of PI3K-related kinases (PIKK) (Hunter 1995). Although 
most studies concentrated on the role of ATM or DNA-PKcs in DDR, these kinases have also 
been implicated in other, DDR-unrelated, activities. For instance, ATM and DNA-PKcs play 
a role in phosphorylation of Akt in response to insulin (Halaby, Hibma et al. 2008) (Feng, 
Park et al. 2004), and DNAPKcs stimulates cancer cell proliferation (Zheng, Mao et al. 2016). 
Additionally both ATM (Choy and Watters 2018) and DNA-PKcs (Hunt, Fabb et al. 2013) 
(Woodbine, Neal et al. 2013) have been suggested to be implicated in neurological 
abnormalities and affected embryonic neural development, respectively, again based on a 
non-DDR defect. Similarly, ATM has been recently implicated in the mitochondrial ROS 
signalling pathway, and decline of this activity is proposed to be responsible for the 
accmulation of reactive oxygen species ROS in ataxia telangiectasia, the disease resulting 
from ATM mutation (Zhang, Lee et al. 2018).  
Thus, several key DNA repair proteins are actually multifunctional, and their non-
repair activity may have a prevalent function in physiopathological processes. A review on 
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the emerging field of multifunctional DNA repair proteins in the aetiology of diseases beyond 
DDR is in preparation. 
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Aims and objectives 
Genome integrity is crucial for all cells, but in particular for adult stem cells that are 
responsible for the regeneration of damaged tissues and tissue homeostasis throughout life. 
Indeed, these cells are at the top of cellular hierarchy and are expected to generate a large 
progeny of cells. To do this, stem cells undergo proliferation and differentiation, and also self-
renewal to maintain the stem cell pool for future needs. As it was previously shown in the lab, 
SCs display more efficient and accurate repair of radiation-induced DSBs than their 
committed progeny. Starting from these findings, the aims of this PhD project were: 
1) to investigate how the fate of SCs is affected when DSB repair is impaired, and which 
are the mechanism(s) and the consequences on muscle regeneration. I have investigated 
the role of the repair factors DNA-PKcs (Chapter I) and of ATM (Chapter II). 
2) addressing the mechanistics of DSB repair in SCs, and assess whether the DSB repair 
efficiency is correlated with the stemness of satellite cells sub-populations (Chapter III). 
During this project, the consequences of impaired DSB repair in myogenic 
differentiation of satellite cells were analysed. Taking advantage of Tg:Pax7-nGFP mice 
(Pax7 is a specific marker of stemness in myogenic cells) or, alternatively, established 
markers, SCs were isolated and differentiated in culture. Moreover, SCs have been analyzed 
in their niche, i.e. in the myofiber, which also contains differentiated cells, and in vivo, upon 
muscle injury in WT and DSB repair (ATM or DNA-PKcs) deficient mice. To impair DSB 
repair satellite cells were treated with either inhibitors of DNA repair factors (DNA-PKcs, 
ATM) or chromatin modifiers (PARP), or both, and key genes have been silenced in SCs with 
lentiviral vectors. The extent of DSB repair impairment, using DNA repair markers, was 
assessed along with their proliferation and differentiation potential. Different subpopulations 
of SCs (Pax7high, Pax7mid, and Pax7low) have been analyzed for their DSB repair capacity. 
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Materials and Methods 
Animal models  
For most in-vitro experiments and drug treatments SCs were isolated from the four 
limbs of Tg:Pax7-nGFP mice (Sambasivan, Gayraud-Morel et al. 2009, Gayraud-Morel, 
Chretien et al. 2012). Isolated fibers were obtained from EDL muscle of Tg:Pax7-nGFP mice. 
DNAPK-deficient SCs and TA cryosections were obtained from CB17/lcr-Prkdcscid/lcrlcoCrl 
(SCID, severe combined immunodeficiency) mice and Balb/cAnN (wild-type, WT, control) 
purchased from Charles River laboratories. For regeneration analysis of injured TA muscles, 
also Rag2-/- γc-/- and C57BL/B6 mice as control were used provided by Shahragim Tajbakhsh, 
Paris. The ATM+/- mice (Atmins5790neo/+) were provided by Ludovic Deriano, Paris and have 
been crossed with Tg:Pax7-nGFP mice to obtain Pax7nGFP/+:Atmins5790neo/+ (Table 1). 
Genotype Phenotype Genetic 
Background 
References 
Pax7nGFP/+ Pax7 – GFP positive B6D2/F1 (Sambasivan, Gayraud-Morel et 
al. 2009) 
CB17/lcr-
Prkdcscid/scid/lcrlcoCrl 
DNAPK deficient, B and T 
cell deficient 
Balb/c (Bosma and Carroll 1991) 
(Bosma, Custer et al. 1983) 
Balb/cAnN +/+ WT control for SCID Balb/c - 
Rag2-/- γc-/- Rag2 deficient, B, T cells  
and NK deficient 
C57BL/B6 (Colucci, Soudais et al. 1999) 
B6 +/+ WT control for Rag2-/- γc-/- C57BL/B6 - 
Pax7nGFP/+:Atmins5790neo/ins5790neo  ATM deficient, Pax7 – GFP 
positive 
B6.129S6 Reference for Atm Strains:  
(Barlow, Hirotsune et al. 1996) 
(Deriano, Chaumeil et al. 2011)  
 
Atm strains crossed provided by 
Ludovic Deriano crossed with 
Tg:Pax7-nGFP in the lab 
Pax7nGFP/+:Atm+/+ WT control for ATM 
deficiency, Pax7 – GFP 
positive 
B6.129S6 
Pax7nGFP/+:Atmins5790neo/+ Heteroygous control for 
ATM deficiency, Pax7 – 
GFP positive 
B6.129S6 
Table 1 List of mice strains used. Genotype, phenotype, and background of each strain have been 
indicated. 
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Ethics statement 
Animals were handled according to national and European community guidelines, and 
protocols were approved by the ethics committee at Institut Pasteur and the French Ministry. 
Satellite cell isolation by FACS 
SCs were freshly isolated from fore and hind limbs of ad hoc mice that express the 
Pax7 marker linked to the fluorescent label GFP (Tg:Pax7-nGFP mice), following the 
isolation protocol, as previously described (Gayraud-Morel, Chretien et al. 2007) and in more 
detail in (Gayraud-Morel, Pala et al. 2017). Briefly, initially the limbs were chopped off, 
minced into very small pieces and precipitated in DMEM Glutamax (GIBCO) with 1% 
Penicillin Streptomycin (Pen/Strep). The floating lipid particles were successively removed 
by discarding the excess medium. This step was followed by a digestion step with 0.1% 
Collagenase D (Roche), 0.25% Trpysin (GIBCO) and 0.1 mg/ml DNase I (Roche) in DMEM 
Glutamax (containing 1% Pen/Strep) for 30 min at 37°C, which was repeated 5 times until 
full digestion of the tissues. After each digestion step, where the tissue was placed in a foetal 
bovine serum (FBS) solution to inactive trypsin, the digested material (suspension) was 
filtered on ice through subsequently 100 µm, 70 µm, and 40 µm cell strainers. The filtered 
digests were then pre-spinned for 10 min at 50 x g (acceleration 5, deceleration 3) and the 
supernatant was collected. This step excluded fat and other unwanted materials in the digests. 
The collected supernatant was then centrifuged for 15 minutes at 550 x g at 4°C. The 
supernatant was discarded and the pellet resuspended in fresh DMEM Glutamax with 1% of 
Pen/Strep. Centrifugation was repeated 3 to 4 times until the resuspension was sufficiently 
transparent to proceed further. After the final spin, the pellet was resuspended in 600 µl of 
DMEM Glutamax (with 1% Pen/Strep) and 2% FBS. Finally samples were processed by 
FACS (ARIA III, BD Biosciences) to sort SCs, which are Pax7-nGFP+, using GFP as marker.  
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In the case of SCID mice, which SCs are not Pax7-nGFP+, the muscle bulk was 
digested with 2.4 U/ml of Dispase II (Roche), 0.2% of Collagenase A (Roche) and 0.1 mg/ml 
DNase I (Roche) in DMEM Glutamax (+1% Pen/Strep) for 2 hours at 37°C. Then filtration 
and centrifugation were performed as indicated above. At the final step, cells were labelled 
with receptor markers (conjugated antibodies) for 30 min at 4°C. Cells were then sorted with 
FACS ARIA III, gating the SC population for Sca1-, CD45- and CD31-, CD34+, and Itga-7+, 
as indicated in the published protocol (Gayraud-Morel, Pala et al. 2017).  
Cell culture 
Immediately after sorting, collected SCs were seeded at a density of 5000 cells/cm2 in 
Lab-TekTM chamber slides (Nunc) or cell dishes pre-coated with 0.1 mg/ml of poly-D Lysine 
(SIGMA) and Matrigel (Corning). The medium used consisted of: 40% of DMEM Glutamax 
with 1% Pen/Strep, 40% of MCDB (Sigma), 20% of FBS (fetal bovine serum), 2% of Ultraser 
G (Pall), and 10 µg/ml of insulin (Safc Biosciences) when indicated. Cells were incubated at 
37°C with 5% CO2 and 20% O2. 
The immortalized myoblast cell line C2C7 was used in several experiment. It is a 
subclone (as well as the C2C12 cell line) of C2-inducible myoblasts isolated from adult mice 
skeletal muscle cells (Yaffe and Saxel 1977) (Pinset, Montarras et al. 1988). C2C7 cells were 
incubated in the same condition as SCs, without pre-coating, in DMEM Glutamax with 1% 
Pen/Strep and 20% FBS.  
Isolation of fibers 
 Fibers were isolated from EDL muscle on the hind limbs of the mice following the 
protocol explained by Shinin et al., 2009 (Shinin, Gayraud-Morel et al. 2009). Initially the 
EDL muscles were dissected and digested in 0.1 % Collagenase 1 (SIGMA) in DMEM 
Glutamax medium (with 1 % Pen/Strep) for 60-90 minutes at 37°C. After digestion, fibers 
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from digested muscle were disassociated in serum-washed cell dishes with prewarmed 
DMEM Glutamax medium (with 1 % Pen/Strep) by pipetting the medium and the muscle up 
and down multiple times.  After myofiber disassociation the isolated individual fibers were 
transferred into clean cell dishes with fiber medium which consists of 40% of DMEM 
Glutamax with 1% Pen/Strep, 40% of MCDB (SIGMA), 20% of FBS (Fetal bovine serum), 
and were incubated in same conditions as indicated for myogenic cells. 
Treatment with inhibitors and irradiation  
Inhibitor Doses Supplier References 
DNAPKcs: NU7441- 
DNAPKi 
2.5 µM-5 µM-10 µM-20 µM (optimum dose:10 
µM) 
Axon 
medchem  
1463 
ATM: KU55933-ATMi 10 µM – 20 µM (optimum dose: 10 µM) Chemdea  CD0191 
Akt: MK2206-Akti 5 µM ApexBio  A3010 
PI3K: ZSTK  1 µM – 5 µM 
(optimum dose: 1 µM) 
Selleckchem  S1072 
PI3K: LY 294002 10 µM Selleckhem  S1105 
PARP: ABT-888- Veliparib 10 µM- 20 µM Selleckchem  S1004 
PARP: AZD2281- Olaparib 10 µM- 20 µM Selleckchem S1060 
Caspase: Q-VD-OPh  10 µM- 20µM- 30 µM ApexBio A1901 
Table 2. List of inhibitors. Name, dose, and supplier of the inhibitors used are listed. 
When indicated, one or more inhibitors (listed in Table 2) or the corresponding 
volume (0.1 -0.2 %) of vehicle (DMSO, diluent of the drugs) were added to the culture 
medium 1 hour before irradiation, at a final concentration indicated in Table 2. Cells were 
then irradiated at 5 Gy (with the Xstrahl RS320 Irradiator for X-ray), which is expected to 
induce approximately 200 DSBs (Rothkamm and Lobrich 2003) or were not exposed to 
irradiation (Control and Vehicle). Cells were incubated for different periods (from 1 hour to 7 
days) post-irradiation before assessing SCs/C2C7 cells differentiation, viability, repair 
efficiency and cell number. Two experimental plans were used (see Figures 9, 11, 16). In the 
first plan, cells were treated with inhibitor (or vehicle) 12 hours after seeding then analysed 1-
7 days post seeding (dps). In the second plan, cells were treated with inhibitor (or vehicle) 2.5, 
4.5, or 5.5 days after seeding then analysed at 5.5 or 7 dps. To assess proliferation, cells were 
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pulsed with the 1 µM of thymidine analogue EdU in cell culture medium, at 2 h before 
fixation (ThermoFisher Click-iT Plus EdU kit, C10640). 
shRNA cloning, transfection and transduction 
Lentiviruses were produced from the shRNA plasmids or scrambled (SCR) shRNA for 
control (Mission shRNA library, Sigma) cloned in Escherichia coli (Table 3). ShRNA 
plasmids, that carry ampicillin and puromycin resistance genes, were amplified in E. coli 
grown overnight in Luria Bertani (LB) broth medium with 100 µg/ml Ampicillin. ShRNA 
plasmids were extracted and concentrated with NulceoBond® Xtra Maxi Plus kit, Plasmid 
DNA purification kit (Macherey-Nagel, ref.: 740416.10) following the manufacturer’s 
protocol. Purified shRNA plasmids and plasmid coding for the viral particle (psPAX2-
packaging, pMD2.G-envelope) were co-transfected in HEK-293T cells treated with 25 µM of 
chloroquine diphosphate (Sigma), a DNA intercalator that increases the transfection 
efficiency, using the calcium phosphate transfection method (Kwon and Firestein 2013). Two 
days post transfection, the HEK-293T cell culture medium was harvested, filtered through 
0.45µm filters, and concentrated by ultra-centrifugation at 19,000 rpm for 90 min at 4°C. 
After centrifugation the supernatant was discarded and the pellet resuspended in phosphate 
buffered saline (PBS) in a final volume of 250 µl. For titration purposes, p24 viral particles 
were quantified by Virus and Immunity laboratory, directed by Dr. Schwartz, in Institut 
Pasteur. 
 SCs or C2C7 cells were transduced with concentrated viral particles 12 hours post 
seeding. The viral particles were added to the cell culture medium with 8 µg/ml of the 
transduction enhancer Polybrene (hexadimethrine bromide) (Sigma). Six to 8 hours post 
transduction the culture medium was refreshed (without viral particles and Polybrene), and 48 
hours post transduction, was again refreshed with 1 µg/ml puromycin containing medium for 
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selection. After 3 or 5 days of puromycin selection, i.e. 5 or 7 days post transduction, 
surviving cells were ready to be assessed. 
Mission shRNA Library (Sigma) Plasmid  Target gene 
Ref:SHC002 pLKO.1_Puro control shRNA (sh Control) (SCR) 
Ref:TRCN0000023860 pLKO.1_Puro DNAPKcs shRNA (sh DNAPKcs) 
Ref:TRCN0000023863 pLKO.1_Puro DNAPKcs shRNA (sh DNAPKcs) 
Ref:TRCN0000361373 pLKO.1_Puro DNAPKcs shRNA (sh DNAPKcs) 
Ref:TRCN0000310882 pLKO.1_Puro Akt2 shRNA (sh Akt2) 
Ref:TRCN0000301381 pLKO.1_Puro Akt2 shRNA (sh Akt2) 
Ref:TRCN0000304684 pLKO.1_Puro Akt shRNA (sh Akt1) 
Table 3. List of shRNAs used. Reference numbers, plasmid codes and targets are indicated 
Muscle injury 
 For regeneration analysis mice were anesthetized with 0.5% Imalgene + 2% Rompun 
and tibialis anterior (TA) muscles were injected with 50 µl of 10 µM of protein kinase-C 
specific inhibitor, cardiotoxin (CTX, Latoxan), as previously described (Dentice, Ambrosio et 
al. 2014). The TA muscles were harvested for analysis 5 days post injury. For repetitive 
injury, mice were injected 3 times with cardiotoxin during 89 days (the second and third 
injections were done 30 and 60 days after the first injection, respectively). For these 
experiments, TA muscles were dissected and frozen 29 days post-injury (1 injury), or 59 days 
post-injury (2 injuries), or 89 days post injury (3 injuries). 
Immunostaining and histology (cryosections) 
Satellite cell-derived cultures were fixed in 4% PFA for 5 min and permeabilized with 
0.5 % Triton X-100 for 5 min as previously described (Gayraud-Morel, Chretien et al. 2007). 
Upon permeabilization, samples were treated for antigen blocking with 2 % BSA and 5 % 
goat serum in PBS for 1h at room temperature. Primary antibodies (see Table 4) were 
incubated overnight at 4 °C, and secondary antibodies (conjugated with fluorophores) (see 
 53 
Table 4) and 5 µg/ml Hoechst 33342 (Sigma, ref.: 14533) (nuclear counterstaining) for 2h at 
room temperature. EdU staining was chemically revealed using the Click-iT Plus kit 
according to manufacturer’s recommendations (Life Technologies, C10640). 
Freshly dissected TA muscles were frozen in liquid nitrogen cooled isopentane for 30 
seconds. The frozen TA muscles were cryo-sectioned into 10 µm slices. These sections were 
fixed with 4% PFA for 15 minutes at room temperature and antigen unmasking was 
performed by incubating sections in boiling 10 mM citrate buffer pH 6 for 20 min before 
immunostaining, as described (Gayraud-Morel, Chretien et al. 2012). For regeneration 
analysis with embryonic Myosin heavy chain (eMHC) immunostaining, TA sections were left 
unfixed and treated with acetone for 10 min at -20 °C prior to immunostaining. All sections 
were permeabilized with 0.5 % Triton X-100 for 5 min, and antigen blocking was performed 
with 10% inactivated goat serum (or 2 % goat serum for eMHC staining) in 0.5% Triton X-
100 containing PBS for 1h at room temperature. Incubation with primary and secondary 
antibodies was performed as for cell immunostaining, see above. 
RNA extraction and RT-qPCR  
 Total RNA was isolated from cells using the RNAeasy extraction kit (Qiagen), and 
reverse transcribed with SuperscriptTM IV Reverse Transcriptase (Invitrogen, ref #18090010) 
following the manufactures’s instructions. The reaction mix consisted of 2.5 µM of Oligo 
d(T)20 primer, 0.5mM dNTPs, up to 1µg template RNA, 1x SSIV buffer, 5mM of DTT and 
10U/µl of SuperscriptTM IV Reverse Transcriptase. The cDNAs were quantified by real-time 
RT-qPCR using the Power SYBR Green Master mix (Applied Biosystems) on a StepOne Plus 
RealTime PCR system (Applied Biosystems). Primers used for RT-qPCR are listed in table 4. 
Gene Forward Primer Reverse Primer Reference 
Myogenin 5’GTGAATGCAACTCCCACAGC 5’CGCGAGCAAATGATCTCCTG (Baghdadi, Castel et 
al. 2018) Tbp 5’ATCCCAAGCGATTTGCTG 5’CCTGTGCACACCATTTTTCC 
Table 4. Primers used for RT-qPCR.  
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Western blots 
Cells were lysed in lysis buffer (5 mM EDTA, 50 mM Tris pH 8, 150 mM NaCl, 0.5% 
Triton X-100, 0.1% SDS) with 2x of cOmpleteTM protease inhibitor cocktail (Roche), 1x 
PhosSTOP (phosphotase inhibitor, Roche) for 30 min on ice. In order to get rid of viscosity 
due to DNA, the lysed samples were sonicated 5 times for 10 sec (with 10 sec intervals) at 
medium frequency in the sonicator bath. Samples were denatured in 1x Laemmli buffer 
(BIORAD, ref.: 161-0747) with 10% of b-mercaptoethanol (SIGMA, ref.:3148) for 5 min at 
95°C, and separated in NuPAGE 4-12% Bis-Tris Protein Gels (Invitrogen). Separated 
proteins were transferred and bound on a nitrocellulose membrane (0.2 µm porosity) by 
Trans-Blot Turbo system (BIO-RAD) or classical electro-transfer in 1x Tris-Glycine 
NuPAGE transfer buffer (with 20% ethanol) bound on an Amersham Protran nitrocellulose 
membrane (0.45µm porosity) (GE Healthcare, Life Sciences). The membranes were blocked 
with 5% nonfat dry milk for detection of non-phosphorylated residues or 5% BSA for 
detection of phosphorylated residues of proteins in 1x PBS with 0.1% Tween 20 for 1 hour at 
room temperature. Primary antibodies were incubated in the corresponding blocking buffer 
(milk or BSA in 1x PBS with 0.1% Tween 20) overnight at 4°C followed by 1h incubation 
with the secondary antibody (conjugated with either peroxidase [HRP] or fluorophore) at 
room temperature. 
Clonogenic assay 
 Freshly isolated SC or C2C7 cells were plated at very low density (≈ 40 cells/cm2) on 
10 cm diameter dishes. Seven days post-treatment and/or irradiation, cells were fixed with 2% 
PFA for 15 min. Immediately after fixation cells were stained with Crystal Violet (SIGMA) 
(0.1% Crystal Violet, 2% ethanol in water) for 2h at room temperature. Plates were washed 
with water and dried for colony quantification. 
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Antibodies 
Antibodies used in this study are listed below with the dilutions used for 
immunofluorescence labeling and for Western blots (Table 5).  
Primary antibodies 
Dilution 
IF 
Dilution 
WB 
Supplier References 
Mouse monoclonal a-Pax 7 1:20 1:40 Developmental Studies 
Hybridoma Bank 
AB_528428 
Mouse monoclonal a-Myogenin (F5D) 1:50 1:50 Developmental Studies 
Hybridoma Bank 
AB_2146602 
Mouse monoclonal a- myosin heavy 
chain (MF20) 
1:25 1:50 Developmental Studies 
Hybridoma Bank 
AB_2147781 
Mouse monoclonal a-embryonic myosin 
heavy chain (F1.652) 
1:2 n.a. Developmental Studies 
Hybridoma Bank 
AB_528358 
Rabbit polyclonal a- Myogenin 1:200 n.a. Santa Cruz sc-576 
Rabbit polyclonal a-MyoD 1:200 1:200 Santa Cruz sc-304 
Mouse monoclonal a-PCNA 1:200 1:500 Santa Cruz sc-56 
Rabbit polyclonal a-GAPDH n.a. 1:4000 Santa Cruz sc-25778 
Goat a-Rad50 1:200 n.a. Santa Cruz sc-74460 
Rabbit polyclonal a-cleaved-caspase 3 1:500 n.a. Cell Signaling 
Technology 
9661 
Mouse monoclonal a-Akt2 n.a. 1:1000 Cell Signaling 
Technology 
5239 
Rabbit polyclonal a-phospho-Akt2 
(Ser474) 
n.a. 1:1000 Cell Signaling 
Technology 
8599 
Rabbit polyclonal a-Akt1 n.a. 1:1000 Cell Signaling 
Technology 
C73H10 
Rabbit polyclonal a-phospho-Akt1 
(Ser473) 
n.a. 1:1000 Cell Signaling 
Technology 
9018 
Rabbit polyclonal a-phospho-Akt n.a. 1:1000 Cell Signaling 
Technology 
9271 
Rabbit polyclonal a-H2AX n.a. 1:1000 Cell Signaling 
Technology 
2595 
Mouse monoclonal a-phospho-
H2AX(Ser139) 
1:2500 1:500 Millipore 05-636 
Rabbit polyclonal a-53BP1 1:2000 1:1000 Novusbio NB100-304 
Chicken Polyclonal a-GFP 1:4000 n.a. abcam ab13970 
Rabbit polyclonal a-DNAPKcs n.a. 1:1000 abcam ab70250 
Rabbit a-Laminin 1:180 n.a. Sigma L9393 
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Secondary antibodies Dilution 
IF 
Dilution 
WB 
Supplier References 
Goat a-rabbit fluor 555 1:2000 n.a. Invitrogen A21428 
Goat a-rabbit fluor 488 
1:2000 n.a. Invitrogen A11034 
Goat a-mouse fluor 488 
1:2000 n.a. 
Invitrogen A11029 
Goat a-mouse fluor 555 
1:2000 n.a. Invitrogen A21425 
Goat a-mouse fluor cy5 
1:2000 n.a. Invitrogen A10524 
Goat a-chicken fluor 488 
1:2000 n.a. Invitrogen A11039 
Donkey a-goat fluor 488 
1:2000 n.a. Invitrogen A11055 
hFAB Rhodamine Anti-GAPDH IgG 
n.a. 1:5000 Biorad 12004168 
Goat a-mouse Starbright blue 700 n.a. 1:5000 Biorad 12004159 
Goat a-rabbit CF770 n.a. 1:20000 Biotium 10078-1 
Click- IT EdU-fluor- 647 n.a. n.a. Invitrogen C10640 
Goat a-mouse -HRP n.a. 1:10000 Invitrogen 31430 
Goat a-rabbit -HRP n.a. 1:10000 Invitrogen 31460 
Table 5. List of Antibodies. The name, type, dilution (for immunofluorescence imaging (IF) and 
Western blot (WB)) and reference number and supplier are indicated for each antibody. 
Imaging and enumeration of immunomarkers 
Cells were analysed with a fluorescence microscopy Zeiss Axioplan equipped with an 
Apotome and Axiovision software or Cell Voyager CV1000, confocal scanner box 
(Yokogawa). g-H2AX and 53BP1 foci (DSB markers) were enumerated in at least 30-50 
cells/condition, from 3 independent experiments. For DSB marker quantifications, Hoechst 
counterstained nuclei were held as a reference per cell and nuclear foci were enumerated from 
maximal projection of 10 Z-stack slice images of a nucleus. For differentiation analysis, cells 
positive for one or more myogenic markers were enumerated per condition, and the 
percentage was evaluated on the total number of nuclei (Hoechst staining), by assessing 
2,000-5,000 nuclei/condition and 5-10 fields/condition. The fusion index was calculated with 
the number of nuclei/myosin heavy chain positive myotubes, by assessing 2,000-5,000 
nuclei/condition and 5-10 fields/condition. Image analyses were performed with the ImageJ 
2.0 software. 
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Western blots were either exposed on films and scanned, followed analysis of protein 
signal intensity by ImageJ 2.0 software when needed or expose by Chemidoc (BIORAD) and 
in this case protein signals were analysed by Imagelab software. 
Cell counting to assess proliferation 
Cells in culture were washed with PBS, trypsinised with 0.05% Trypsin in EDTA for 
5 minutes at 37°C. Cell counting was performed either 1) with Scepter, Handheld-automated 
Cell counter (Millipore), which gives the cell count/ml, detected by 60 mm sensors, or 2) 
manually with the cell counting chambers (KOVA international, ref.: 87144) and counting 
under light microscope. When the Scepter was used, at the beginning of each experiment a 
triple counting was performed to validate the reproducibility of the measurement, then 
counting was done 1 time/sample. In several cases counting was performed with both 
methods to validate the cell number. 
Statistical analysis 
 Statistical analyses were performed using the Graphpad Prism (version 6) software. 
For multiple grouped data was applied a multiple comparison analysis: 2-way Anova coupled 
with Dunnett test; for the other experiments non-parametric Mann-Whitney test or Student T-
test were performed. Significance indicated as p* <0.05, **<0.01, ***<0.001. 
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Results 
Chapter I: Impact of impaired DNA damage repair proteins on myogenic cell 
viability and differentiation: DNA-PKcs 
The aim was to evaluate the impact of impaired DSB repair on viability, proliferation, 
and differentiation of adult muscle stem cells. Not only DSB repair proteins (ATM and 
DNAPK) but also chromatin remodellers (PARPs), which may also affect the repair process, 
have been analysed. These experiments also aimed to assess whether it is possible to 
modulate the differentiation of the myogenic cells by treatment with DSB repair inhibitors or 
chromatin modifiers.  
Differentiation of myogenic cells is severely reduced or blocked in the presence of DSB 
repair inhibitors DNAPKi and ATMi 
The effect of irradiation and DNA repair inhibitors on myogenesis was initially 
investigated on C2C7 cells that are immortalized activated myoblasts. To assess the 
consequences of impaired DSB repair in survival and differentiation of myoblasts, C2C7 cells 
were pre-treated with 10 µM of ATM inhibitor (ATMi, KU55933) or DNAPK inhibitor 
(DNAPKi, NU7441) for 1h, then exposed to 5 Gy of X-ray irradiation (IR) to induce DNA 
damage, in particular DSBs. Cells were kept in culture in the presence or in the absence of 
inhibitor, and examined at periods ranging from 1 day to 5 days post-irradiation (scheme in 
Fig. 8a). Cells were quantified with the Scepter cell counter. Differentiation was evaluated 
through immunolabeling of the myogenic markers MyoD and Myogenin, and subsequent 
quantification of positive cells. C2C7 cells constitutively express MyoD, but they lose this 
marker as cells differentiate. Committed cells are defined here as MyoD+-Myogenin+, and 
differentiated cells as MyoD--Myogenin+. The number of cells at different stages of 
myogenesis was then extrapolated on the total number of cells (see Methods). 
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As shown in Figure 8b-c, under these conditions non-irradiated control cells (in the 
absence and in the presence of DMSO, named control and vehicle, respectively) essentially 
proliferated during the first 3 days and started differentiating by the third day (purple and 
black portions of the columns, Fig. 8c), with at least 28% committed cells (MyoD±-
Myogenin+) by 5 days in culture. Surprisingly, ATMi treatment resulted not only in reduced 
proliferation (by 37%), but almost blocked differentiation (10% of committed cells, MyoD+-
Myogenin+, and no MyoD--Myogenin+cells) by 5 days in culture. This was also the case for 
DNAPKi treatment that resulted in only 9% of MyoD+-Myogenin+ cells (Fig. 8b-c).  
In addition to specific myogenic markers, the presence of myotubes is a strong 
indicator of ongoing differentiation of muscle cells. Figure 8b shows the formation of 
polynucleated myotubes, with aligned 10±5 nuclei, by the end of 5th day in control cells. 
Conversely, myotubes were absent from cells treated with either ATMi or DNAPKi, a further 
indication of the reduced or blocked differentiation with each of these treatments. 
 Irradiation (5 Gy, X-ray) affected the number of control cells and also the extent of 
differentiation by 5 days. This reduction was expected since radiation-induced DSBs decrease 
the proliferation rate, due to the necessity of repairing the DNA damage, and may also induce 
cell death when DNA damage is too extensive and cannot be repaired (Puri, Bhakta et al. 
2002). Treatment with ATMi not only dramatically reduced the cell number but almost 
completely blocked differentiation (3 % of MyoD+-Myogenin+ cells versus 15% in vehicle). 
Treatment with DNAPKi was even more severe, with no increase in the cell number and 
completely blocked differentiation, as survivor cells were only MyoD+ (Figure 8d).  
These results indicate that in immortalized myoblasts inhibition of DNA-PKcs and 
ATM repair factors dramatically affects myogenesis also in the absence of IR-induced DNA 
damage.  
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Figure 8. DSB repair inhibitors block early differentiation of C2C7 cells in the presence and in the 
absence of irradiation. a) Schematic representation of the experiment. Immortalized myogenic C2C7 
cells were pre-treated with 10 µM of ATMi or 10 µM of DNA-PKi before irradiation (or no-IR) and 
kept in culture for 1 to 5 days before analysis. b) Representative merge images of immunofluorescent 
labelling of C2C7 cells 5 days post-IR (and non-irradiated controls). Proliferation was evaluated by 
the cell number and differentiation by myogenic markers. MyoD (red), Myogenin (green), and nuclei 
are counterstained with Hoechst (blue). Representative cells with progressively increasing levels of 
differentiation (from bottom to top) are indicated: red arrows (MyoD+/Myogenin- cells, myoblasts, in 
red), yellow arrows (MyoD+/Myogenin+ cells, committed cells, in yellow), and white arrows (MyoD-
/Myogenin+cells, differentiated cells, in green). Undifferentiated C2C7 myoblasts are originally 
MyoD+. Histograms of myogenic differentiation and growth curves of c) non-irradiated and d) 
irradiated C2C7 cells ± ATMi or DNAPKi. Significance by 2-way ANOVA, Dunnett’s multiple 
comparisons test, p* <0.05, **<0.01, ***<0.001. Significance bars and stars are of the same colour 
as the category that is compared. n=3 experiments per condition, mean ± SD. Myogenic markers have 
been analysed in 5-10 fields/condition (2000-5000 cells), and extrapolated to the total cell number. 
Differentiation of primary satellite cells is severely reduced or blocked in the presence of 
DSB repair inhibitors DNAPKi and ATMi 
The effect of irradiation and repair inhibitors on myogenesis was then assessed in 
primary satellite cells. SCs are Pax7+, become also MyoD+ upon activation, and progressively 
lose the Pax7 marker in proliferating myoblasts. GFP+ SCs isolated by FACS from Tg:Pax7-
nGFP mice were treated with ATMi or DNAPKi then exposed to irradiation in similar 
conditions as C2C7 cells. Cells were left in culture and examined at periods ranging from 4 
hour to 5 days post-irradiation (scheme in Fig. 9a). It should be noted that five days in culture 
(the longest post-irradiation time tested here) correspond to early differentiation of satellite 
cells as these cells fully differentiate and form myofibers by 11 days in culture. The aim of 
this experiment was indeed to assess whether early steps of differentiation were affected by 
treatments.  
In control conditions SCs divide several times before starting to differentiate and 
forming polynucleated myofibers (Yoshida, Yoshida et al. 1998). Proliferation and 
differentiation that define the regeneration capacity of stem cells were evaluated as in Figure 
8. Figure 9b, d shows that from 2 to 5 days post-irradiation, in all conditions (untreated 
controls, cells in the presence of vehicle (DMSO) or DNAPKi) irradiated satellite cells were 
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lower in number compared to non-irradiated cells (Fig. 9b, c). From 3 days post-IR the cell 
number was particularly reduced in irradiated cells treated with DNAPKi, consistent with 
diminished cell viability because of impaired DSB repair. 
In irradiated SCs (X-ray, 5 Gy), we observed reduced labeling of the commitment 
marker MyoD and to a larger extent of the differentiation marker Myogenin (11% less in 
control cells and in the presence of vehicle (DMSO) after 5 days) compared to the same time 
points in non-irradiated cells (Fig 9b-d). This result indicates that irradiation impairs SCs 
differentiation, as it has been previously shown for the C2C12 myogenic cell line 
(immortalized myoblast line, an independent subclone as the C2C7 cell line) (Puri, Bhakta et 
al. 2002), and for C2C7 (see Fig. 8c, d above). In the presence of DNAPKi, the effect was 
markedly more pronounced since no Myogenin+ cells (purple and black portions of the 
column in Fig. 9d) were observed, suggesting arrest of differentiation upon DNA damage 
(Fig. 9a-c).  
Irradiation additionally resulted in ≈ 50% decrease of the satellite cells number 
compared to non-irradiated cells (control and vehicle) by 5 days, whereas C2C7 cells did 
reach the values of non-irradiated cells by this time; see Fig. 8 above. However, we should 
consider that under these conditions C2C7 cells, that are already myoblasts at the origin, and 
are actively proliferating from the beginning of the experiment, display more advanced 
myogenesis than primary SCs, which were quiescent at the beginning of the experiment and 
took 25-30 hours to be activated (see also Figure 32). In agreement with this notion, upon 5 
days in culture, SCs display little formation of polynucleated myotubes (Fig 9b) compared to 
C2C7 cells (Fig 8b above). Treatment with ATMi was similar to treatment with DNAPKi, 
despite myoblast proliferation (cell number) was more severely affected between 2 and 3 days 
after IR in DNAPKi-treated cells. 
Although treatment with ATMi and to a larger extent DNAPKi resulted in dramatic 
reduction in the SC cell number, irradiated SCs did not completely stop increasing in number, 
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as it was the case for C2C7 cells, indicating that at least some cells escaped the proliferation 
blockage (Fig. 9d) triggered by impaired DSB repair. This escape is possibily due to repair of 
DSBs by other mechanisms such as alt-NHEJ or HR.    
The most surprising result observed in C2C7 cells, namely affected myogenesis with 
DNA repair inhibitors in the absence of irradiation, was confirmed in SCs. Indeed cell number 
(indicator of proliferation capacity) was reduced by 50% and 37% at 5 days with DNAPKi 
and ATMi, respectively compared to vehicle. Differentiation of SCs was also severely 
affected upon treatment with ATMi, and to a larger extent with DNAPKi. Indeed, as in C2C7 
cells, primary SCs proliferated until the stage of commitment (MyoD+), but successive 
differentiation was dramatically impaired (11% of Myogenin+ cells versus 43% in vehicle, 
purple and black portions of the column in Fig. 9c) upon DNAPKi treatment. ATMi treatment 
had less pronounced effect, but differentiation was nevertheless affected with 32% of 
Myogenin+ cells.  
In conclusion, these findings show that radiation-induced DNA damage affects 
proliferation and differentiation of primary SCs and C2C7 cells in a similar manner. This 
reduction is in agreement with the literature, since a large number of DSBs as upon robust 
irradiation are expected to decrease the proliferation rate of dividing cells, due to the necessity 
of repairing the DNA damage. Moreover, these conditions may also induce cell death when 
DNA damage is too extensive and cannot be repaired (Puri, Bhakta et al. 2002). As a 
consequence, unrepaired DNA damage because of treatment with DSB repair inhibitors 
results in reduced or almost blocked proliferation and differentiation, with a stronger effect on 
C2C7 than primary SCs. Importantly, in the absence of irradiation, progression from 
commitment (MyoD) to differentiation (Myogenin) was largely or essentially blocked in the 
presence of ATMi and DNAPKi, respectively, whereas proliferation of committed (MyoD+) 
cells was not affected.  
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Figure 9. DSB repair inhibitors reduce or block differentiation of satellite cells in the presence and 
in the absence of irradiation (induced DSBs). a) Schematic representation of GFP+ SCs isolated by 
FACS from Tg:Pax7-nGFP mice were seeded overnight (≈12 hours) before 5 Gy of X-ray IR (or no-
IR). SCs were pre-treated for 1h with 10 µM of either ATM or DNAPKcs inhibitor or the 
corresponding volume of vehicle (0.2 % DMSO) before irradiation, then kept in culture from 4 hours 
until 5 days before analysis. The expected level of differentiation at these time points and the 
corresponding myogenic markers for untreated, non-irradiated cells are schematized below. b) 
Proliferation was evaluated by the cell number, and differentiation was assessed with 
immunofluorescence of myogenic markers (Pax 7, MyoD, Myogenin). Representative merge images of 
immunofluorescent labelling of cells 5 days post-IR (and non-irradiated controls): MyoD (red), 
Myogenin (green), and nuclei are counterstained with Hoechst (blue). Representative cells with 
progressively increased levels of differentiations are indicated: red arrows (MyoD+/Myogenin- cells, 
in red), yellow arrows (MyoD+/Myogenin+ cells, in yellow), and white arrows (MyoD-
/Myogenin+cells, in green). Histograms of myogenic differentiation and growth curves of c) non-
irradiated and d) irradiated cells ± ATMi or DNAPKi. Each condition was tested with SC derived 
from n=3-7 mice, mean ± SD. Myogenic markers have been analysed in 5-10 fields/condition, and 
extrapolated to the total cell number. Significance evaluated by 2-way ANOVA, Dunnett’s multiple 
comparisons test, p* <0.05, **<0.01, ***<0.001. Significance bars and stars are of the same colour 
as the category that is compared. 
Altogether these results raise the possibility that DNA-PKcs and ATM have a function 
in myogenesis independent of their role in NHEJ repair. These data are in agreement with 
those obtained in C2C7 cells, indicating that the C2C7 cell line is to a reasonable extent 
valuable to study the effect of DNA repair factors in myogenesis. 
I describe in this Chapter experiments performed with DNAPKi, and in Chapter II 
those performed with ATMi.  
C2C7 and SCs have reduced capacity of forming colonies upon inhibition of DNA-PKcs  
 Reduced myogenic capacity and cell viability can also be evaluated by clonogenic 
assay that consists in re-seeding cells at a density that allows the formation of distinct and 
isolated colonies, originated from a single cell, upon growth in culture. Colonies are then 
fixed, stained with cristal violet and counted. Freshly FACS-sorted SCs were seeded for 24h, 
then re-seeded at low density (≈ 40 cells/cm2) and kept 12h in culture. C2C7 cells were 
seeded once at low density (≈ 40 cells/cm2) for 12h.  SCs and C2C7 cells were then treated or 
not with 10 µM of DNAPKi (or 0.1% DMSO, vehicle) for 1h, followed by irradiation (or 
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non-irradiated cells), incubated in culture and analysed 5.5 days (C2C7 cells) and 7.5 days 
(SCs) post seeding (corresponding to 5 days post-IR for C2C7 cells, and 7 days post-IR for 
SCs). Upon 24h + 12h seeding, SCs are no longer quiescent and become activated. 
Irradiation/treatment is therefore performed on activated SCs. This procedure is necessary 
because 12h seeding (as in previous experiments) is not compatible with SCs 
survival/amplification for clonogenic assays (not shown), probably because of the low density 
of cells; conversely after 12h (or less) seeding at regular density (≈ 5,000 cells/cm2) SCs are 
fully viable for experiments as those shown in Fig. 9, and in agreement with the literature 
(Vahidi Ferdousi, Rocheteau et al. 2014). These conditions are similar to experiments 
performed in Fig. 8 (for C2C7 cells), and are comparable to conditions used in Fig. 9 (for 
SCs).   
After DNAPKi treatment, both non-irradiated C2C7 (Fig. 10a) and SCs (Fig. 10b) 
displayed a lower number of colonies, which were also smaller in size, compared to untreated 
control/vehicle. Moreover, inspection of the colonies shows that DNAPKi-treated C2C7 cells 
and SCs lacked differentiated myotubes (white arrow-head in representative images in Fig. 
10a-b) that are present in control/vehicle. These data are in agreement with reduced 
proliferation and differentiation of DNAPKi-treated myogenic cells seen above (Figs. 8 and 
9). Upon irradiation, non-treated SCs and C2C7 cells displayed not more than half the number 
of colonies, which were also smaller in size, than their respective non-irradiated cells, again in 
agreement with the abovementioned experiments. Irradiated DNAPKi-treated C2C7 and SCs 
cells formed a negligible number of colonies, as expected (Fig. 10a-b). This experiment 
shows that individual SCs or C2C7 myoblasts have reduced proliferation and differentiation 
capacity upon DNAPKi treatment, in agreement with experiments of myogenesis in culture. 
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Figure 10. Reduced clonogenic activity of C2C7 and SCs upon inhibition of DNA-PKcs. Primary 
SCs and C2C7 myoblasts were seeded at a low density (≈ 40 cells per cm2) and irradiated (or not), 
with or without DNAPKi. Representative images of colonies on left panels (white arrow-head 
indicates myotubes), and histograms of the number of colonies for a) C2C7 cells with or without 
DNAPKi 5-days post-IR, b) activated SCs with or without DNAPKi 7 days post-IR Significance by 2-
way ANOVA, Tukey’s test, *≤0.05, **≤0.01, ***≤0.001. Mean ± SD, n=3-4 plate/condition, n=3-4 
mice. 
Inhibition of DNA-PKcs affects committed myogenic cells and advanced myogenesis 
In the previous experiments, SCs and C2C7 cells were treated (± inhibitors, ± 
irradiation) before proliferation and differentiation in order to assess the effect of these 
treatments at the earliest steps in myogenesis. From the previous experiments, however, it is 
not clear whether the effect of DNAPKi or ATMi on myogenic differentiation was due to 
bona fide inhibition of differentiation or, alternatively, was a consequence of reduced cell 
number that resulted from slow proliferation or cell death. Indeed, cell confluence is 
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necessary for differentiation of myogenic cells. To exclude effects due to poor cell number, I 
designed experiments to assess differentiation in confluent cells. Myogenic cells were thus 
allowed to proliferate exponentially up to confluency, and were then treated with inhibitors 
and/or irradiated. These experimental procedures allow also focusing on the effect of 
treatments on advanced myogenesis.  
Highly proliferative C2C7 cells were treated (irradiation and/or inhibitors) either 2.5 
days post seeding (dps), when they reached 80-100% confluency, or 4.5dps when there were 
100% confluent, and in both cases the proliferation phase is mainly over. In the first 
conditions, referred here as mid-myogenesis, cells are expected to be committed/engaged in 
differentiation; in the second condition, referred here as advanced myogenesis, cells are 
expected to be engaged in differentiation and formation of myotubes. C2C7 cells were treated 
with DNAPKi in either conditions and left in culture until 7dps, as shown in Fig. 11a and e. 
For simplification, differentiation was evaluated considering Myogenin+ (purple column) 
versus Myogenin- (orange column) cells, and independently of the earlier (commitment) 
marker MyoD, which is not relevant in this phase (Fig. 11c-d, g-h).  
At 2.5dps when the treatment was introduced (control 1), there were almost no 
Myogenin+ cells (1-2% of the total cell population), Fig. 11b. C2C7 cells still proliferated 
since in the absence of treatment (control 2) their number increased 5dps and 7dps, and they 
did differentiate since the fraction of Myogenin+ cells (purple part of the column) increased to 
24% and 35% of the total cell population at 5dps and 7dps, respectively (Fig. 11b, c). In the 
absence of irradiation, DNAPKi treatment reduced proliferation of C2C7 cells (by 48% at 
5dps and 66% at 7dps, compared to vehicle), and blocked the differentiation, as Myogenin+ 
cells were at maximum 2% 7dps (Fig. 11b, c), compared to 35% in vehicle. 
Thus, this situation was similar to treatment with DNAPKi shortly after cell seeding 
(Fig. 8), but did not fully answer our question, since despite being expanded to a large number 
(100k ± 20k cells per cm2) than in Fig 8 (5k cells per cm2), we have no evidence that the 
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density of C2C7 necessary to promote differentiation was reached yet. These data however 
support the notion that DNA-PKcs intervenes also upstream of Myogenin expression. In 
agreement with experiment in Fig. 8, irradiation at 2.5dps reduced the proliferation and 
slightly delayed differentiation of C2C7 cells, and DNAPKi treatment that impairs DSB 
repair diminished the number of irradiated cells and blocked differentiation (Fig. 11b-d).  
In the second experimental paradigm, (Fig. 11e) at 4.5dps (before 
treatment/irradiation) C2C7 cells were already 100% confluent and, accordingly Myogenin 
immunolabeling was observed in 10% of cells (control 1). Upon 2.5 more days in culture (or 
7dps, control 2) the cell number slightly increased (15% more than Control 1), indicating 
some residual proliferation and, importantly, Myogenin+ cells reached 33%, indicating 
ongoing differentiation. Under these conditions, DNAPKi treatment, strongly reduced the cell 
number (by 50% compared to vehicle), and only 10% Myogenin+ cells were detected (Fig. 
11f,g), indicating a dramatic effect on myogenesis, that exceeds the one observed with 
treatment in proliferating Myogenin- cells (Fig. 8 and Fig. 11a-c). This result indicates that 
DNAPKi impairment of myogenesis is authentic and not due to poor cell density. It also 
indicates that inhibition of DNA-PKcs has a more dramatic effect if administered when 
differentiation is ongoing than in committed cells, suggesting a direct impact on early 
myogenesis.  
To complete our paradigm, C2C7 cells irradiated at 4.5dps displayed a mild reduction 
in number (control and vehicle, Fig. 11h), and a slight decrease of Myogenin- cells (13%, Fig. 
11f, h), compared to non-irradiated cells (Fig. 11f, g). Upon treatment with DNAPKi, the cell 
number was reduced by 29%, and Myogenin+ cells are almost negligible (6% of the total 
population) compared to vehicle. This result indicates that irradiation has a minor effect in 
slowly cycling, differentiating, myogenic cells than in cycling myoblasts, and that unrepaired 
DNA damage further affects the myogenic population and thereby myogenic differentiation. 
. 
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Figure 11. DNAPKi affects mid and advanced myogenesis by reducing cell proliferation and 
impairing differentiation. Treatment with DNAPKi in committed C2C7 cells (a-d) and during 
differentiation (e-h). a) Schematic representation of the experiment. At 2.5dps, during mid myogenesis 
cells were pretreated for 1h with 10 µM of DNAPKi or the corresponding volume of vehicle before 
irradiation (or no-IR), and then analysed 5 and 7dps. b) Proliferation was evaluated by the cell 
number and differentiation was assessed with immunofluorescence of myogenic markers (MyoD, 
Myogenin). Representative merge images of immunofluorescent labelling of cells at 2.5dps and 7dps: 
MyoD (red), Myogenin (green), and nuclei are counterstained with Hoechst (blue). Representative 
cells with progressively increased levels of differentiations are indicated: red arrows 
(MyoD+/Myogenin- cells, in red), yellow arrows (MyoD+/Myogenin+ cells, in yellow), and white 
arrows (MyoD-/Myogenin+cells, in green). Histograms of the cell number and differentiation state of 
c) non-irradiated and d) irradiated C2C7 cells treated or not with DNAPKi. The differentiation state 
is defined by Myogenin immunolabeling: Myogenin- cells [undifferentiated] and Myogenin+ 
[differentiated] cells are shown in orange and in purple, respectively, in the histogram. e) Schematic 
representation of the experiment. At 4.5dps during advanced myogenesis, cells were pretreated for 1h 
with 10 µM of DNAPKi or the corresponding volume of vehicle before irradiation (or no-IR), and then 
analysed at 7 dps. f) Representative merge images of immunofluorescent labelling of cells at 4.5dps 
and 7 dps: the indications are in same colour as in panel b. Histograms of the cell number and 
differentiation state of g) non-irradiated and h) irradiated C2C7 cells treated (or not) with DNAPKi 
and defined as in panels c and d. Significance by 2-way ANOVA, Dunnett’s multiple comparisons test, 
p* <0.05, **<0.01, ***<0.001. n=3 experiments. The MyoD marker has not been considered in 
quantification in panels c, d and g, h. The Myogenin marker has been analysed in 5-10 
fields/condition corresponding to n=2,500-5,000 cells /condition, and extrapolated to the total cell 
number; mean ± SD. 
It should be noted, however, that the most unexpected effect of DNAPKi primarily 
concerns non-irradiated cells, suggesting that DNA-PKcs plays a key role not only in 
differentiation but also in maintenance of myogenic cells 
DNAPKi severely affects the cell cycle progression during myogenesis 
In previous experiments we observed reduced cell number in non-irradiated myogenic 
cells in the presence of DNAPKi. To verify whether this effect was due to blocked cell cycle 
division or apoptosis, C2C7 cells were treated with DNAPKi from 2.5dps to 5dps following 
the experimental scheme in Fig. 11a. The proliferation state of the cells was analysed via 
immunolabeling of proliferating cell nuclear antigen (PCNA), a scaffolding protein that has a 
central role in DNA replication. Indeed the nuclear localization and distribution of PCNA 
indicate several phases of the cell cycle, with poor and broad distribution of nuclear signal in 
G1/G2, and distinct bright foci in the S-phase (Schonenberger, Deutzmann et al. 2015).  
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In Figure 12a, several PCNA profiles corresponding to the S-phase are indicated with 
yellow arrows, and the G1 phase with red arrows. Enumeration of cells shows that at 2.5dps 
25% of non-irradiated, untreated cells were in the S-phase (control 1, Fig. 12b), and this 
fraction was reduced to 5% at 5dps (control 2 and vehicle), in both cases compatibly with the 
cell number variation observed in Fig. 11c. Treatment with DNAPKi dropped the number of 
cells in the S-phase to 3%.  
 
Figure 12. DNAPKi impacts on cell cycle progression. C2C7 cells were treated with 10µM of 
DNAPKi, following the experimental scheme shown in Figure 11a. a) PCNA (green) 
immunofluorescent labelling at 2.5dps and 7dps; nuclei are counterstained with Hoechst (blue). 
Representative cells in the S-phase are indicated with yellow arrows and in the G1-phase with red 
arrows. b) Histograms of non-irradiated (full green columns) and irradiated (hatched green columns) 
C2C7 cells in the S-phase (PCNA+ nuclear foci) at 2.5dps and 7dps (for irradiated cells, these time 
points correspond to 1h and 2.5 days post-irradiation, respectively). c) Immunolabeling of 
representative cleaved caspase-3+ cells (red). Note that apoptotic cells display intense and broad 
signal (left panel), clearly distinct from cleaved caspase-3 signal displayed by some differentiating 
myoblasts (right panel, as reported in the literature) (Hunt, Upadhyay et al. 2011). Only apoptotic 
cleaved caspase-3+ cells have been considered for quantification d) Histograms of non-irradiated (full 
red columns) and irradiated (hatched red columns) apoptotic C2C7 cells (cleaved caspase-3+ cells) at 
2.5dps and 7dps. n=1, 200-1,000 cells/condition analysed 
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Irradiation dramatically decreased the number of S-phase cells 1h post-IR (control 1, 
Fig. 12b), probably due to cell cycle arrest by induced DNA damage and lack of recovery 
time. At 5dps, when DNA damage might have been repaired, irradiation reduced to 2% cells 
in the S-phase 5dps (control 2 and vehicle) (for the absence of DNA damage see also figure 
29b), and there were no cell detected in S-phase upon DNAPKi treatment.   
Thus, the essential lack of cell number increase upon DNA-PKcs inhibition is 
consistent with the collapse of the fraction of cycling cells, and this situation is exacerbated in 
the presence of radiation-induced DNA damage. The proportion of cycling cells is being 
analyzed more in detail through immunolabeling of cyclin A that is highly expressed in the S 
and G2 phases of the cell cycle (ongoing experiment). 
Apoptosis assessed through cleaved caspase-3 immunolabeling was very low in all 
conditions tested, with less than 2% of cleaved caspase-3+ cells in all conditions (Fig. 12 c-d), 
suggesting that the abovementioned reduction in cell number is not primarily dependent on 
apoptosis. Apoptosis is being verified through TUNEL experiments that detect DNA 
fragmentation generated during apoptosis (ongoing experiment). 
Inhibition of DNA-PKcs affects SC-derived myoblasts during late myogenesis 
I assessed whether impairment of advanced myogenesis by inhibition of DNA-PKcs 
was also operative in myogenic cells derived from primary SCs. FACS-sorted GFP+ SCs were 
seeded and allowed proliferating in the absence of treatment until they reached confluence 
(>80 %) and were thus ready to commit to differentiation. SCs generate activated myoblasts 
(MyoD+) that proliferate and differentiate, and late myogenesis is characterized by expression 
of Myogenin and/or MHC (myosin heavy chain, a structural marker for myotube formation). 
The time point to start treatment was delayed in primary cells compared to C2C7 myoblasts 
(5.5dps in SCs versus 2.5 dps in C2C7) since freshly isolated SCs are not activated yet, and  
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they start the first cell division ≈ 30h post seeding, followed by multiple cell divisions that 
require about 10h each (Rocheteau, Gayraud-Morel et al. 2012).  
SC-derived myoblasts at 5.5dps, were at a differentiation stage comparable to C2C7 
cells in the experimental plan in Fig. 11a, as verified by being 88% Myogenin- and MHC-, see 
Fig 13b). Cells were treated with inhibitors (or vehicle) for 1h and then irradiated (Fig. 13a). 
In parallel, cells were submitted to the same treatment but without irradiation. Two days later 
(i.e. 7.5dps) cells were counted, and differentiation was first evaluated with myogenic 
markers (Pax7, Myogenin, MHC) and then with the fusion index, i.e. the number of nuclei per 
myotube. Figure 13c shows that 7.5dps non-irradiated control and vehicle cells progressed to 
differentiation with Myogenin+ cells (in red in the histogram) largely increasing in number 
compared to 5.5dps (by 6 to 10-fold, Fig. 13b, c). Moreover, at this time point cells fused into 
multi-nucleated myotubes (25% of cells were fused into 5-20 nuclei containing myotubes, 
Fig. 13e).  
Treatment with DNAPKi (in non-irradiated cells) resulted in reduced proliferation 
(≈1/3 of the cell number at 7.5dps compared to vehicle), as it was also the case when the 
treatment was administered to myogenic cells not at confluence (see above, Fig. 9c). 
Importantly, the reduction in cell number essentially concerned differentiated cells 
(Myogenin+, either MHC- or MHC +), whereas Myogenin- cells were as numerous as in the 
presence of vehicle (Fig. 13b, c) Moreover, the fusion index was dramatically reduced 
compared to vehicle (80% of the few MHC+ cells are mononucleated in the presence of 
DNAPKi, whereas 60% of MHC+ cells contain 2-20 nuclei in the absence of treatment, Fig. 
13e), as if it remained at the condition before treatment.  
These experiments show that impaired differentiation of non-irradiated primary 
myogenic cells in the presence of DNAPKi is not due to reduced cell number, confirming data 
obtained with the immortalized cell line C2C7 (cf. above, Fig. 11). These data also reveal that 
DNAPKi affects prevalently differentiating (Myogenin+) rather than non-committed 
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(Myogenin-) cells, and essentially blocks all further steps of differentiation (MHC expression, 
myotube fusion). 
Irradiated control and vehicle cells showed a similar differentiation profile than non-
irradiated cells, although the total cell number was severely reduced (by 68%, Fig. 13b,d) and 
the fusion index slightly decreased (Fig. 13b, f), as expected from the cells undergone DNA 
damage (Puri, Bhakta et al. 2002). In irradiated cells, DNAPKi treatment blocked 
proliferation and differentiation, with the cell number and the level of differentiation at 7.5dps 
being essentially unchanged compared to 5.5dps when the treatment started (Fig. 13b, d). 
Moreover, upon DNAPKi treatment the fusion index dramatically dropped (Fig. 13b, f), as it 
was also the case in non-irradiated cells (Fig. 13e). These results underscore the relevance of 
efficient DSB repair in the progression of differentiation of myogenic cells. They also suggest 
that DNAPKi treatment blocks myogenesis by inhibiting the expression of the transcription 
factor Myogenin, including in the absence of induced DNA damage. 
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Figure 13. DNAPKi blocks myogenic differentiation. a) Schematic representation of the experiment: 
GFP+ SCs isolated by FACS from Tg:Pax7-nGFP mice were seeded and let exponentially proliferate. 
At 5.5dps cells were pre-treated for 1h with 10µM of DNAPKi or the corresponding volume of vehicle 
before irradiation (or no-IR) and cells were analysed 48h later, i.e. 7.5dps. b) Immunolabeling of SC-
derived cells at 5.5dps without DNAPKi treatment (control 1) and 7.5dps (with and without [control 2 
and vehicle, respectively] DNAPKi treatment). Merge of MHC (yellow), Myogenin (red), Pax7-nGFP 
(green) immunostaining and Hoechst counterstaining (nuclei, blue). Representative MHC+ structures 
are indicated with a white arrow, Myogenin+ cells (red) with a red arrow, and Pax7-GFP+ (satellite) 
cells (green) with a green arrow. Histograms represent the cell number and the differentiation state of 
c) non-irradiated and d) irradiated SC-derived cells treated or not with DNAPKi, and defined by the 
distinct combinations of myogenic markers. The colour code indicates the differentiation state, with 
progressive increase from Pax7/GFP+ [not differentiated] to MHC+ [the most differentiated]. At 
5.5dps, before treatments, the SC-derived population was heterogeneous (e.g. up to 10% Myogenin+ 
cells [i.e. committed to differentiation], in red in the histogram), in agreement with published data 
(Urbani, Piccoli et al. 2012). Myogenic markers have been analysed in 5-10 fields/condition and 
extrapolated to the total cell number. Mean ± SD for each category. Significance by 2-way ANOVA, 
Dunnett’s multiple comparisons test, p* <0.05, **<0.01, ***<0.001. Fusion index of e) non-
irradiated and f) irradiated SC-derived cells by quantification of nuclei/myotube. Significance by 2-
way ANOVA, Dunnett’s multiple comparisons test, p* <0.05, **<0.01, ***<0.001. Significance bars 
are of the same colour as the category that is compared. n=3 experiments, n=2,500-5,000 cells 
analysed/condition, mean ± SD.  
Inhibition of DNA-PKcs depletes Myogenin protein 
 Previous experiments showed that impairment of DNA-PKcs strongly limits or blocks 
differentiation of primary myogenic cells and C2C7 cells. Myogenesis appeared prevalently 
affected during the progression of differentiation, since the Myogenin+ population was 
strongly reduced or missing. To verify that DNAPKi affects Myogenin expression, we treated 
C2C7 cells with different doses of DNAPKi (5-20 µM), following the experimental scheme in 
Fig. 11a. Since DNA-PKcs is a PI3K-related kinase, [(phosphoinositide 3-kinase)-related 
kinase)] (Abraham 2004) (Hunter 1995), we also tested the effect of inhibitors of PI3Ks, and 
of the downstream Akt kinases on Myogenin expression. Akt kinases are phosphorylated (and 
thereby activated) by PI3Ks (at Ser473 and Thr308), and are also major regulators of 
myogenesis. PI3K-related kinases, like DNA-PKcs, can also phosphorylate Akt (at Ser473) 
upon DNA damage.  
The levels of the myogenic markers Myogenin and MyoD were assessed by Western 
blots at 5dps (corresponding to 2.5 days post treatment with the inhibitor). In Figure 14 
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control and vehicle cells display robust Myogenin signal that progressively decreases with 
increasing concentrations of DNAPKi until disappearance at the highest doses of the 
inhibitor. Treatment with the PI3K inhibitor (PI3Ki, ZSTK474) mildly affected Myogenin 
expression, whereas the inhibitor of Akt kinases (AKTi, MK2206) almost depleted Myogenin 
expression (Fig. 14).   
 
Figure 14. Myogenin expression is inhibited by DNAPKi and AKTi. C2C7 cells treated with 2.5 µM, 
5 µM, 10 µM (the standard concentration used in this study) and 20 µM of NU7441 (DNAPKi), or 1 
µM of ZSTK474 (PI3K inhibitor), or 5 µM of MK2206 (Akt inhibitor) from 2.5dps until 5dps. Western 
blots at 5dps of Myogenin (MyoG), MyoD, and GAPDH as a reference protein. Multiple bands for 
Myogenin and MyoD are compatible with the literature (Zhan, Jin et al. 2007) (Sartorelli, Puri et al. 
1999) (Tintignac, Sirri et al. 2004).N=3 experiments.  
The commitment protein MyoD was present in control and vehicle, indicating that at 
5dps a fraction of cells was just committed or not differentiated, compatibly with results in 
Fig. 8 and Fig. 11. The two bands of MyoD (Tintignac, Sirri et al. 2004), may represent the 
phosphorylated (upper band) and the unphoshphorylated (lower band) forms. At increasing 
doses of DNAPKi, the upper band was progressively depleted and the lower band enriched, 
suggesting a change in MyoD phosphorylation (which was, however, not verified), but not an 
increase in the global levels of the protein, when Myogenin is absent. Conversely, in the 
presence of the PI3Ki as well as AKTi the global MyoD signal was stronger than in control 
and vehicle (Fig. 21), compatibly with G1 or G2 arrest (Tintignac, Sirri et al. 2004). Thus, in 
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C2C7 cells DNAPKi as well as AKTi almost blocked the expression of Myogenin, whereas 
PI3Ki reduced the levels of this differentiation factor.   
Inhibition of DNA-PKcs blocks Myogenin expression in Akt-dependent manner 
The effect of DNAPKi on Myogenin was then tested on SCs, where additionally the 
levels of Akt and phospho-Akt (p-Akt) were assessed. Akt is indeed primarily phosphorylated 
by PI3Ks, and the purpose of the present experiment was to see whether inhibition of DNA-
PKcs directly impacted on the levels of the Akt kinases and their activation. Following the 
experimental scheme shown in Fig. 13, SC-derived myoblasts were treated with increasing 
doses of DNAPKi (from 2.5 µM to 20 µM) at 5.5dps and two days later were harvested and 
assessed for Myogenin, Akt, and p-Akt signal. 
Figure 15a shows that in control 1, therefore at 5.5dps before cells were treated with 
DNAPKi, Akt was present (but not its phosphorylated form) and Myogenin was absent, 
compatibly with these cells having not differentiated yet. The levels of Akt decrease in 
control 2 and vehicle with the highest concentration of DMSO (two concentrations of DMSO 
were used corresponding to the volumes used for various DNAPKi treatments), concomitantly 
with high expression of Myogenin. 
This data indicates robust differentiation of untreated cells after two more days in 
culture. In these cells the levels of p-Akt increased, indicating activation of this kinase 
concomitantly with myogenic differentiation. Vehicle with the lowest dose of DMSO showed 
high levels of Akt, no p-Akt and little Myogenin, suggesting either no differentiation, which 
however was not confirmed by microscopic analysis of the cells before harvesting (not 
shown), or a technical problem with this sample. This experiment is being repeated (ongoing 
experiment). Experiment in C2C7 cells (Fig. 15b) confirmed blocked Myogenin expressions 
and Akt phosphorylation with DNAPKi, already at low doses. This experiment also indicates 
correct expression of markers in the presence of 0.05% DMSO. 
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Figure 15. DNA-PKcs-dependent and Akt-dependent expression of Myogenin in primary (SC-
derived) and C2C7 myogenic cells. Exponentially proliferating myogenic cells treated with increasing 
doses of DNAPKi 2.5 µM, 5µ M, 10 µM and 20 µM, or two doses of vehicle corresponding to the final 
volume of 5µM (0.05%) and 10 µM (0.1%) DNAPKi. a) SC-derived cells. Control 1 represent 
harvested at 5.5dps before treatment. Control 2 and other cells were harvested 2 days later (if treated, 
2 days post-treatment), corresponding to 7.5 dps. b) C2C7 cells harvested at 5dps (if treated, 2.5 days 
post-treatment). In both panels, samples assessed by Western blot for p-Akt, Akt, Myogenin, and 
GAPDH as reference protein. N=3 experiments. 
DNAPKi-treated cells displayed no Myogenin signal, confirming the blockage of 
differentiation by this primary transcription factor in primary cells, and to a much larger 
extent than in C2C7 cells. Interestingly, DNAPKi decreased Akt levels already at the lowest 
dose, whereas p-Akt was redyced in a dose dependent manner (Fig. 15a). These results were 
confirmed in C2C7 cells harvested 5dps (experimental plan as in Fig. 11a), where reduced or 
blocked Myogenin expression upon increasing doses of DNAPKi was associated with 
reduced phosphorylation of Akt (Fig. 15b). 
 These results associate depletion of Akt with DNAPKi-dependent depletion of 
Myogenin. When not specified “Akt” means “Akt kinases”, therefore both Akt1 and Akt2, 
without distinction. Under these conditions, residual levels of p-Akt remained when 
Myogenin was no longer expressed, but this antibody does not separate the different Akt 
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members. I therefore analysed the individual levels of Akt1 and Akt2 (and their respective 
phosphorylated forms). 
Following the experimental plan in Fig. 11a, C2C7 cells were treated at 2.5dps and let 
differentiating in culture until 7dps before harvesting. Figure 16 shows that at 7dps control 
and vehicle displayed Myogenin signal, indicating differentiation, as expected, concomitantly 
with the expression of Akt1 and Akt2 and their respective phosphorylated forms. In 
agreement with the previous experiment, DNAPKi treatment depleted Myogenin. 
Importantly, DNAPKi-treated cells displayed reduced levels of Akt1 and p-Akt1, and to a 
larger extent of Akt2 and in particular of p-Akt2, suggesting a strong decline of activated 
Akt2 as a major effector in the blockage of Myogenin expression (Fig. 16). 
In parallel, PI3Ki resulted in moderate reduction of Myogenin, in agreement with the 
previous experiment (see Fig. 14 above), but the levels of Akt1, p-Akt1, and Akt2 were not 
affected, whereas phosphorylation of Akt2 was slightly reduced (Fig. 16). It is thus possible 
that the lesser effect of PI3Ki on Myogenin expression compared to DNAPKi, is due to 
modest inhibition of p-Akt2 and absence of reduction of Akt1/p-Akt1, which are conversely 
much more affected upon DNAPKi treatment.  
To assess whether DNAPKi-dependent (strong) reduction of p-Akt2 and PI3K-
dependent (moderate) reduction of p-Akt2 are independent processes, cells have been treated 
with both inhibitors at the same time. Figure 16 shows that the double treatment results in a 
larger reduction of p-Akt2 than DNAPKi alone, suggesting independent processes for the 
activation of Akt2, whereas the levels of Akt1/pAkt1 and global Akt2 were not changed. 
Since Myogenin was already fully depleted in the presence of DNAPKi, we did not observe 
further differences in the presence of both inhibitors. These data indicate that blockage of 
Myogenin expression, and thereby differentiation, is only to a minor extent, and not 
prevalently, due to PI3Ks, a known effector of myogenesis through Akt kinases (Jiang, Aoki 
et al. 1999). 
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Figure 16. Akt1- and Akt2-mediated Myogenin expression. C2C7 cells treated with 10 µM of 
DNAPKi (NU7441), and/or 5 µM of AKTi (MK2206), or 10 µM PI3Ki (LY294002) from 2.5dps until 
7dps. Western blot at 7dps (5 days post treatment) of Myogenin, Akt1, and Akt2 as well as their 
phosphorylated forms (p-Akt1 and p-Akt2, respectively), and GAPDH as reference protein. N=3 
experiments. 
Finally, AKTi alone or in combination with DNAPKi blocked Myogenin expression, 
and alone inhibited Akt1 and Akt2 phosphorylation (Fig. 16) to a larger extent than DNAPKi. 
DNAPKi also depleted Akt1 and Akt2, whereas AKTi, which inhibits protein 
phosphorylation, obviously did not affect the levels of Akt. However, the two inhibitors 
combined resulted in the lowest levels of Akt1 and Akt2, probably because lack of 
phosphorylation has a negative effect on the stability of these kinases (Liao and Hung 2010). 
Despite some cumulative effect on phosphorylation of Akt2 and Akt1 (combined AKTi and 
DNAPKi result in undetectable phosphorylation of Akt1 and Akt2), these two inhibitors 
display a large overlap on Myogenin expression, suggesting that they act on the same 
pathway. It is thus possible that Myogenin expression depends prevalently on Akt, fully 
activated through DNA-PKcs rather than PI3Ks. 
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 In conclusion, experiments with multiple inhibitors of kinases, alone and in 
combination, indicate that DNA-PKcs affects the fate of myogenic cells upstream of 
Myogenin expression largely depending on Akt2 and Akt1 activation. This effect does not 
seem due, at least to a large extent, to PI3K-dependent activation of Akt during myogenesis 
(Jiang, Aoki et al. 1999), but is consistent with activation of Akt (in particular Akt2) by DNA-
PKcs.  
shDNA-PKcs validates the DNAPKi-dependent suppression of myogenic differentiation 
 To confirm that impairment of myogenic differentiation by DNAPKi and AKTi is due 
to bona fide inhibition of DNA-PKcs and Akt, the expression of DNA-PKcs, Akt1, and Akt2 
was independently silenced in SCs by shRNAs lentivirus transduction. Freshly FACS-sorted 
SCs were put in culture for 12h then re-seeded at a density of 5,000 cells/cm2, and 12h later 
transduced with shDNAPKcs_1 or shDNAPKcs_2 or SCR (scrambled non-targeting shRNA) 
viral particles for 6h, followed by lentivirus-free medium replacement. Two days later (or 
2.5dps, considering re-seeding as the starting point) cells were treated with puromycin for 
selection of cells stably expressing the shRNA, and harvested 5.5dps (corresponding to 5 days 
post transduction) (Fig. 17a). In parallel, a first sample of cells was harvested 2.5dps and a 
second sample 5.5dps, in the absence of puromycin treatment and shRNA transduction 
(control 1 and control 2, respectively). 
  Western blot in figure 17b shows multiple shRNA clones. Silencing with 
shDNAPKcs_1 and shDNAPKcs_2 resulted in undetectable DNA-PKcs, whereas residual 
protein was present with shDNAPKcs_3 (Fig. 17b, c). Both shAkt2-1 and shAkt2-2 
efficiently silenced Akt2, but traces of the protein were observed with shAkt2-2, whereas the 
protein was undetectable with shAkt2-1 (Fig. 17b, d). ShAkt1 resulted in depletion of >90% 
of Akt1 (Fig. 17 b,d).  
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 Control 1 displays a strong signal of Pax7 and MyoD (Fig. 17b, e) confirming the 
myoblast state at 2.5dps; the proliferative condition of these cells was verified by strong 
signal of cyclin A2 (Fig. 17b, c) that is expressed in dividing cells. As expected, the 
proliferation marker cyclin A2 dropped in control 2 and SCR samples (Fig. 17b, c), and 
advanced differentiation of these cells was monitored by high levels of MHC (MF20), 
concomitantly with reduction of MyoD and depletion of Pax7 (Fig. 17b, e). Curiously, MyoD 
levels remained relatively high in SCR, perhaps as a consequence of the lentiviral and 
selection procedure (see below). Myogenin levels were relatively low in control 2 and SCR, 
probably as a result of advanced differentiation of this population that strongly expresses 
MHC.  
 Silencing of DNA-PKcs resulted in strongly reduced or undetectable MHC (MF20) 
and Myogenin, with a larger effect for clones with more efficient silencing (shDNAPK_1> 
shDNAPK_2 > shDNAPK_3), demonstrating that indeed impairment of DNA-PKcs affects 
myogenesis (Fig. 17b, e). Although DNA-PKcs was undetectable with both shDNAPK_1 and 
shDNAPK_2, the former also dramatically reduced Akt1 and Akt2 and their phosphorylated 
forms, whereas the latter only mildly reduced Akt1 (Fig. 17b, d). 
 It is unclear whether shDNAPK_1 is indeed a more efficient silencer of DNA-PKcs 
than shDNAPK_2 (the WB signal for this protein is physiologically low in the absence of 
DNA damage) or it silences also other kinases, probably as a consequence of the homology 
among PI3K-related and PI3K kinases. In the first case, this experiment shows that DNA-
PKcs also regulates the levels of Akt kinases. In the second case, if shDNAPK_2 efficiently 
silences DNA-PKcs, and does not affect Akt, one should conclude that silencing of DNA-
PKcs does not affect Akt levels. Although the second hypothesis looks more realistic, further 
experiments are necessary to clarify this point.  
 To assess whether silencing of DNA-PKcs has also a direct effect on the level of 
phosphorylation of Akt, we analysed shDNAPK_3 (that did not completely deplete 
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DNAPKcs on WB), that had almost no effect on the global levels of Akt kinases but showed 
depletion of p-Akt1 that exceeded reduction of Akt (Fig. 17b, d), suggesting that DNA-PKcs 
is indeed implicated in phosphorylation of Akt1. Thus, reduction of Akt2/p-Akt2 is observed 
essentially with shDNAPK_1, which may, however, directly affect these kinases. 
 In agreement with previous findings (Matheny, Geddis et al. 2018), silencing of Akt1 
only mildly affected myogenic markers compared to SCR and control 2, indicating that at the 
time it was silenced (starting in myoblasts) this kinase was not determinant for myogenesis 
(Fig. 17b, d). Conversely, shAkt2-2, which silenced Akt2 as expected, but also mildly 
reduced the levels of Akt1, did not affect myogenin but reduced MyoD and the late myogenic 
factor MHC (MF20). This result suggests that at the time it was silenced Akt2 kinase was 
implicated in late myogenic differentiation. ShAkt1 and to a lower extent shAkt2-2 also 
resulted in mild expression of Cyclin A2, indicating progression in the cell cycle, at least for a 
fraction of cells. This could be due to decreased stability of the Ccnd1 mRNA (coding for 
Cyclin A2) upon loss of interaction with Pitx2 that is phosphorylated by Akt. Indeed, 
interaction of Pixt2 with Ccnd1 maintains stable this transcript that keeps cells in the 
proliferative stage (Gherzi, Trabucchi et al. 2010). 
 Interestingly, shAkt2-1 depleted not only Akt2 but also Akt1, probably as a 
consequence of the homology of these two isoforms, and constitutes therefore a double 
Akt1/Akt2 silencing (Fig. 17b, e). Furthermore, shAkt2, also depleted DNA-PKcs, 
compatibly with the notion of multiple silencing by this shRNA. With ShAkt2-1 all tested 
myogenic markers were almost undetectable (see also quantification in Fig 17e), with the 
exception of residual MHC (MF20), indicating almost complete loss of myogenesis in these 
non-proliferating cells (confirmed by lack of expression of Cyclin A2), (Fig. 17b, d). 
Altogether these data confirm that DNA-PKcs is responsible for impaired myogenesis, 
as anticipated by inhibition experiments above. It is still unclear whether DNA-PKcs is 
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implicated in regulating the levels of Akt, but there are evidences that it phosphorylates Akt in 
myogenic cells in the absence of induced DNA damage.  
 
 
 87 
Figure 17. Effect of DNA-PKcs, Akt1, and Akt2 silencing on myogenesis. Western blot analysis of 
Myogenic factors and Akt kinases upon shRNA-dependent silencing of Akt1, Akt2, or DNA-PKcs. a) 
Experimental plan (see text), SCR (scrambled non-targeting shRNA). b) WB of myogenic factors 
(differentiation markers: MHC (MF20) and Myogenin, myoblast marker MyoD, and the stem cell 
marker Pax7), kinases (Akt and phospho-Akt, DNA-PKcs), and Cyclin A2. Reduced protein levels of 
shDNAPKcs-1 and shAKT2-1 were due to low cell survival in these conditions. Normalisation of 
protein levels with the reference protein GAPDH upon quantification of bands with Imagelab 
(BIORAD) for c) DNAPKcs, d) individual Akt kinases and their phosphorylated forms, and cumulative 
p-Akt and, e) Myogenic factors. N=3 experiments; quantification on the blot shown here. 
Insulin-induced differentiation rescues DNAPKi-blocked myogenesis through the 
PI3K/Akt pathway 
 To verify that DNAPKi-dependent impairment of myogenesis occurs through the Akt 
pathway, and whether Akt kinases can be alternatively activated than by DNA-PKcs in 
myogenesis, insulin was added to the DNAPKi treatment. It has been indeed shown that 
insulin-like growth factors (IGFs) and insulin regulate and activate PI3K (Conejo, Valverde et 
al. 2001) (Sumitani, Goya et al. 2002). I expected to rescue Akt activation and DNAPKi-
dependent myogenic alterations in the presence of insulin, through alternative activation of 
Akt by PI3Ks. Previous results (Figs. 14 and 16) indeed suggest that Myogenin expression is 
at least partially dependent on PI3K, but it is unclear whether this activity relies on the same 
targets as DNA-PKcs and whether it can compensate for the lack of DNA-PKcs activity.  
C2C7 cells were treated with increasing doses of DNAPKi and/or inhibitors of the 
PI3K/Akt pathway (PI3Ki or AKTi), as in previous experiments (see Figs. 14-16), in the 
presence and in the absence of 10 µg/ml of insulin. Treatment was applied 2.5dps for 2.5 
further days and cells were harvested 5dps, following the experimental plan in Fig. 11a.  
Figure 18a shows a 3 to 4-fold increase of the cell number (plain grey columns) in 
non-irradiated control 2 and vehicle, i.e. cell proliferation, from 2.5dps (control 1) to 5dps, 
independent of the presence of insulin. Treatment with the highest concentration of DNAPKi 
resulted in reduction in the cell number, confirming dose-dependent inhibition of 
proliferation. AKTi and PI3Ki showed similar reduction in the cell number as the standard 
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concentration of DNAPKi (10 µM). Only combined DNAPKi and AKTi dramatically 
dropped the cell number, suggesting not only fully blocked proliferation but also cell loss. 
Insulin (plain green columns) rescued to a large extent proliferation of cells treated 
with DNAPKi or AKTi (2-fold increase in the cell number), and in particular with the two 
combined inhibitors (3-fold increase in the cell number) in conditions where proliferation was 
the most dramatically affected. Conversely, insulin did not improve proliferation of cells 
treated with PI3Ki, indicating that rescue of cell proliferation in the presence of DNAPKi and 
AKTi requires indeed PI3Ks.  
Irradiation decreased the number of cycling cells (control 2 and vehicle at 5dps, 
dashed grey columns, Fig. 18a) independently on insulin (dashed green columns). Increasing 
doses of DNAPKi validated 10 µM as the optimal dose for inhibiting DNA repair in C2C7 
cells, since this was the lowest concentration of the molecule that almost depleted the cell 
population after irradiation, reasonably as a consequence of impaired DNA repair. 
Conversely, AKTi or PI3Ki did not result in further reduction of cell number upon 
irradiation (compared to respective non-irradiated cells), consistently with the notion that Akt 
and PI3Ks are poorly implicated in the repair of DNA damage, at least in this context. Insulin 
did not affect the cell number of AKTi-treated irradiated cells, whereas it surprisingly 
increased the number of PI3K-treated irradiated cells. Insulin also increased the number of 
irradiated cells treated with DNAPKi (alone or combined with AKTi), suggesting that it 
promotes DNA repair, in agreement with recent findings (Meyer, Chibly et al. 2017) (Chua, 
Lin et al. 2015). 
Altogether, these data suggest prevalent DNA-PKcs phosphorylation of Akt in 
myogenesis instead of phosphorylation by other PI3K as previously hypothesized (Sumitani, 
Goya et al. 2002).  
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Figure 18. Insulin rescues DNAPKi-dependent and AKTi-dependent inhibition of myogenesis. Non-
irradiated and irradiated C2C7 cells treated with 2.5 µM, 5 µM, 10 µM and 20 µM DNAPKi 
(NU7441), and/or 5 µM of AKTi (MK2206) or 1 µM PI3Ki (ZSTK474) in the presence and in the 
absence of insulin (10µg/ml). Control 1 corresponds to 2 hours post-treatment (± inhibitor, ± 
irradiation) at 2.5dps, and Control 2, as well as the remaining samples correspond to 2.5 days post-
treatment. a) Histogram of non-irradiated or irradiated (IR) C2C7 cell number in the presence of 
DNAPKi and/or AKTi and PI3Ki and ± 10µg/ml of insulin (n=3, mean ± SD, ANOVA & Dunnett-s 
post-hoc test, p* <0.05, **<0.01, ***<0.001, significance test against the corresponding vehicle 
conditions; additional comparisons are indicated by horizontal lines. b) mRNA fold changes of Myog 
(Myogenin) expression in C2C7 cells (n=3), mean ± SD normalised to TBP-housekeeping gene. 
Unpaired T-test, P **<0.01).  c) Rescue by insulin of expression of Myogenin and Akt2 upon DNAPKi 
treatment by Western blot. N=3 experiments. 
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We showed above that DNAPKi affects myogenesis by blocking the expression of 
Myogenin in an Akt2-dependent manner (see Figures 14-16). Myogenin expression has been 
reported to correlate with expression and activation of Akt2 (Vandromme, Rochat et al. 
2001). We confirmed by RT-qPCR that the expression of Myog (the gene coding for 
Myogenin) is reduced in the presence of DNAPKi (and AKTi), and is rescued in the presence 
of insulin (Fig. 18b). Moreover, insulin rescues the expression of Myogenin and Akt2 that 
were depleted upon treatment with DNAPKi (Fig. 18c). Thus, insulin reverts DNAPKi-
dependent/AKTi-dependent depletion of Myogenin. This rescue requires activation of a 
pathway alternative to DNA-PKcs/Akt2, likely implicating a kinase of the PI3K family.  
DNA-PKcs deficient SCs from SCID mice are delayed in differentiation but myogenesis 
is not blocked in vitro 
To further assess the impact of DNA-PKcs impairment on myogenesis, activation and 
differentiation of SCs from severe combined immune-deficiency (SCID) mice have been 
analysed. SCID mice are naturally mutated for DNA-PKcs. These mice are immunodeficient 
since they lack V(D)J recombination, for which DNA-PKcs is essential, and therefore cannot 
generate B- and T-cells (Bosma and Carroll 1991). Although lacking lymphocytes, these mice 
grow postnatally and represent a good model for transplantation and engraftment experiments, 
including of muscle (Bosma and Carroll 1991). SCID mice are able to develop muscle, which 
is an apparent contradiction with data above that show SCs from WT mice being severely 
affected in proliferation and displaying reduced or blocked differentiation when DNA-PKcs is 
impaired. 
To address this point, SCs have been isolated from SCID mice and the corresponding 
wild type (WT) mice. Since SCID mice are not Tg:Pax7-nGFP, other markers have been used 
to isolate SCs, notably Sca1-, CD31-, CD45- (non-myogenic, endothelial, HSPC cell markers 
respectively), Integrina-7+ (SC-specific), and CD34+ cell population were FACS-sorted.  
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To verify that SCs isolated from SCID mice were impaired in DSB repair, clonogenic 
assay performed on these cells as well as WT mice upon irradiation. The experiment was 
performed as in SCs in Fig. 10b above.  Figure 19 shows that 7 days post irradiation, SCs 
derived from SCID mice essentially did not form colonies, as it was the case with DNAPKi-
treated WT cells (see Fig. 10b above). However unlike DNAPKi treated cells, non-irradiated 
SCID or WT cells were able to form a similar number of colonies, although myotubes 
appeared less complex in mutant mice (Fig. 19a). These data suggest that SCs derived by 
SCID mice may have different myogenic defects than DNAPKi-treated SC. 
 
Figure 19. SCs from SCID mice are sensitive to IR-induced DNA damage. Clonogenic activity of 
SCs from SCID and WT mice, seeded at a low density (≈ 40 cells per cm2) and irradiated (or not). a) 
Representative images of colonies (white arrowheads indicate myotubes) and b) histograms of the 
number of colonies for SCID and WT SCs 7 days post-IR. Significance by 2-way ANOVA, Tukey’s test, 
*≤0.05, **≤0.01, ***≤0.001. Mean ± SD, n=3-4 plates/condition, n=3-4 mice.  
 
 Freshly isolated SCs were plated and assessed from 1.5 to 7.5dps. Proliferation and 
differentiation analysis were performed as in previous experiments above (for instance, see 
Fig. 9). At 1.5 and 2.5dps, the stem (Pax7) and myogenic commitment (MyoD) marker were 
assessed, whereas and at 5.5dps and 7.5dps, Pax7, and the differentiation markers Myogenin 
and MHC were assessed. The combination of these markers allows dissecting seven different 
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populations (see legend in Fig. 20b), with particular focus on the commitment/differentiation 
progression. 
Figure 20 a and b shows that SC derived from either WT or SCID mice display 
comparable proliferation rates until 5.5dps, although at this time point about 10% less 
Myogenin+ cells (red and violet fraction of the column in Fig. 20b) were present in SCID- 
than WT-derived cells. Myogenin+ cells progress in differentiation and fuse into myotubes, 
(Yoshida, Yoshida et al. 1998), labeled here by MHC. From 5.5dps to 7.5dps the MHC+ 
population (violet fraction of the column) increases in both samples, but to a lower extent in 
cells derived from SCID mice. Moreover, the fusion index, assessed by counting 
polynucleated structures defined by MHC immunostaining, shows that 80% of SCID MHC+ 
cells are still mononucleated 5.5dps compared to 60% of in WT cells (Fig. 20c). Such 
difference in myotube size is recovered providing longer differentiation time (7.5dps in Fig. 
20c). 
During differentiation, a subpopulation of mononucleated cells, called reserve cells, 
self-renew by exiting the cell cycle and maintaining Pax7 expression (Yoshida, Yoshida et al. 
1998, Zammit, Golding et al. 2004). At 7.5dps, SCID-derived reserve SCs (green fraction of 
the column) were 2.5% of the total cell population against 4% of in the WT (Fig. 20b), 
indicating that in addition to affected proliferation and delayed differentiation, the reserve SC 
population was slightly depleted in SCID-derived cells. 
Thus, DNAPK deficiency in SCID mice affects myogenesis to a lower extent than 
DNAPKi treatment and DNA-PKcs silencing, in agreement with the observation that SCID 
mice do develop muscles in the absence of DNA-PKcs. However, the modest delay in 
differentiation and reduction of reserve SCs in vitro might be responsible of more severe 
consequences in vivo. Moreover, myogenesis in SCID mice may rely on alternative pathways 
that compensates for the crucial role of DNA-PKcs in myogenesis (see discussion). 
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Figure 20. SCs derived from SCID mice differentiate and fuse into myotubes in a slightly delayed 
manner. SCs isolated from SCID and corresponding WT mice. a) Immunofluorescent labelling of WT 
or SCID SCs with: Pax7 (green), MyoD (red), Myogenin (red), and MHC (yellow); nuclei are 
counterstained with Hoechst (blue). Pax7+ cells are indicated with a green arrow, MyoD+ cells with a 
red arrow, Myogenin+ cells with white arrow, and MHC+ cells with an orange arrow. b) Histograms 
of myogenic differentiation of SC derived from WT and SCID mice. Combination of myogenic markers 
reveals several myogenic or differentiated subpopulations, indicated in the legend of the histogram, 
and displayed with increasing differentiation level from bottom to top. n=3-4 mice, 5-10 
fields/condition, mean ± SD. Significance by 2-way ANOVA, Dunnett’s multiple comparisons test, 
Significance stars are same colour as the categories compared, p* <0.05, **<0.01, ***<0.001.  c) 
Fusion index 5.5-7.5 days post-seeding. The number of nuclei/structure have been arbitrarily defined, 
and vary from 0 to >20. n=3-4 mice, 5,000 nuclei/condition, mean ± SD. Significance by 2-way 
ANOVA, p* <0.05, **<0.01, ***<0.001.  
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Delayed and altered muscle regeneration in SCID mice in vivo  
In vitro data reported above suggest that SCs derived from SCID mice rely on 
alternative mechanisms to compensate for DNA-PKcs-dependent activation of Myogenin in 
muscle differentiation. To assess the myogenic capacity of SCID SCs in vivo, I analysed the 
regeneration capacity of injured muscle in SCID mice. Despite these mice are broadly used 
for muscle regeneration experiments in vivo, they essentially serve as a tool to assess the 
regeneration capacity of engrafted exogenous SCs, and very little is known on their own 
capacity of muscle regeneration. 
One tibialis anterior (TA) muscle, (TA muscle is located in each of the posterior 
limbs), was injured with 10 µM of cardiotoxin (CTX) in SCID and corresponding WT mice. 
The uninjured TA, located on the other limb, served as a control. TA muscles were dissected 
for analysis 5 days post injury (5dpi) (Fig. 21a), when the myoblast population proliferates 
and starts differentiating (Murphy, Keefe et al. 2014). For a note, complete muscle 
regeneration requires about 28 days (Hardy, Besnard et al. 2016). Regeneration was 
investigated in TA muscles sections immunostained for myogenic markers that define three 
key myogenic cells/structures: Pax7+ SCs, Myogenin+ differentiating cells, and embryonic 
myosin heavy chain+ (eMHC+) fibers (myofibers), with eMHC being expressed only during 
regeneration in the adult (Carraro, Dalla Libera et al. 1983). Laminin immunolabeling was 
used to border the extracellular matrices and assess the size and number of fibers per cross-
sectional area of TAs.  
Figure 21b and c shows that TA muscles of SCID mice display a higher number of 
(regenerating) eMHC+ fibers (29% increase) compared to WT. According to the established 
scheme of muscle regeneration (Murphy, Keefe et al. 2014), 4-5dpi the number of total fibers 
increases during regeneration, which was actually the case both in WT and SCID TA muscles, 
but SCID mice displayed a higher number (15 % increase) of total fibers/mm2 (Fig. 21d). 
Moreover, since the original number of fibers was lower (10.7%) in SCID mice (429 
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fiber/mm2 versus 480 fibers/mm2 in WT), at 5dpi these mice increased the number of 
fibers/mm2 by 68% compared to 31% for the WT. 
Conversely, the cross-sectional area (C.S.A) of the fibers, that is a measure of their 
size, decreased in both mice upon injury, but at a higher extent in SCID mice (Fig. 21e). 
Moreover, since originally (in the absence of injury) fibers from the TA muscle of SCID mice 
were significantly smaller than WT, upon injury the C.S.A. decreased by 40.1% in SCID mice 
compared to 22.3% in WT (Fig. 21e). Thus, SCID mice have originally slightly less fibers 
than WT, but these fibers cover a larger surface than in WT. Upon injury, the situation is 
reversed and fibers become more numerous and cover a smaller surface in SCID than in WT 
mice. These changes may reflect more intensive regeneration activity in SCID mice, 
compatible with the reported higher number of regenerating fibers (see above, Fig. 21c) in 
mutant mice or, alternatively a delay in myogenesis, where cells peak in number at a later 
time in SCID mice (see discussion). 
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Figure 21. In vivo TA muscle regeneration in WT and SCID mice 5 dpi. a) Experimental scheme: 10 
µM of cardiotoxin injury followed by TA dissection 5 dpi, along with un-injured TA from the same 
mouse. b) Representative images of un-injured and regenerating TA sections of WT or SCID mice 
5dpi. Extracellular matrices bordered by laminin (green) and regenerating fibers marked with eMHC 
(red), nuclei counter-stained with Hoechst. Histograms of c) number of regenerating eMHC+ 
fibers/mm2, d) number of total fibers/mm2 and e) cross-sectional surface area (C.S.A.) of fibers on TA 
sections. f) Representative images of Pax7+ SCs (in red, left panels) and Myogenin+ differentiating 
cells (red, right panels) indicated with arrowheads in un-injured and 5dpi TA sections. Histograms of 
g) number of Pax7+ SCs/mm2 and h) number of Myogenin+ cells/mm2 on TA sections. n=3 mice, 10 
sections/condition, mean ± SD. Significance Mann-Whitney Test, Significance p* <0.05, **<0.01, 
***<0.001.  
Since muscle regeneration obviously relies on SCs, I analysed these cells and their 
committed progeny in these sections. Pax7+ SCs and Myogenin+ differentiating cells are 
expected to increase in number 5dpi (Murphy, Keefe et al. 2014), and immunostaining of TA 
sections confirms that this is the case for both mice (left and right panel in Fig. 21f, 
respectively). However, SCID mice that originally (in the absence of injury) have a lower 
density of SCs (number of Pax7+ cells/mm2), at 5 dpi increase their density by 17.9-fold, 
whereas in WT mice they increase by 7.3-fold (Fig. 21g).  
Differences between SCID and WT mice were less accentuated for Myogenin+ cells, 
which density increased 18.9-fold in SCID mice versus 15.2-fold in WT and were comparable 
in the absence of injury (Fig. 21h). The higher density of SCs and differentiating cells in 
SCID mice is compatible with a larger number of eMHC+ (regenerating) fibers, see above 
(Fig. 21c).  
Altogether, the dynamics of muscle regeneration in vivo display relevant differences in 
SCID versus WT mice, which may indicate increased regeneration activity probably to 
compensate for a less efficient process in mutant mice or, alternatively, delayed regeneration 
dynamics (see below).  In an established regeneration scheme, the myogenic markers (Pax7, 
Myogenin and eMHC) reach the peak between 4 and 5dpi, then decrease during muscle 
regeneration (Murphy, Keefe et al. 2014). Accordingly, the data presented above may also 
suggest that SCID mice have delayed muscle regeneration compared to WT, which correlates 
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with the reduced differentiation potential observed in vitro (see Figure 36 in discussion). In 
order to verify whether SCID have increased regeneration capacity or delayed regeneration 
kinetics, a later time point, namely 7dpi, should be analysed (ongoing experiment). 
As mentioned earlier, SCID mice are immunodeficient, and immune cells have been 
reported to play a role in myogenesis (Tidball 2017). In order to uncouple potential 
regeneration defects due to immunodeficiency (Brzoska, Ciemerych et al. 2011, Grabowska, 
Mazur et al. 2015), Rag2-/-γc-/- immunodeficient mice have been also analysed. Rag2-/-γc-/- 
mice are immunodeficient as SCID mice are, since they lack the Rag2 protein that is essential 
for the formation of DSBs during V(D)J recombination and also plays a role in the choice of 
the repair mechanism. Rag2 acts therefore upstream of DNAPKcs during B and T cell 
production; these mice also carry the γc-/- mutation that results in natural killer cells 
deficiency (Mazurier, Fontanellas et al. 1999). TA sections from Rag2-/-γc-/- mice have been 
assessed in parallel with the experiment reported above in Figure 21. We did not observe 
differences in the number of (regenerating) eMHC+ fibers 5dpi compared to WT (Fig. 22), 
indicating that immunodeficiency per se is not responsible for altered myogenesis observed in 
SCID mice. 
 
 
Figure 22. Regeneration potential of WT and Rag2-/-gc-/- 
mice. Histogram of the number of regenerating eMHC+ 
fibers/mm2 on TA sections. n=3 mice, 10 sections/condition, 
mean ± SD. Significance Mann-Whitney Test. 
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Multiple cycles of muscle injury exacerbate regeneration delay and altered fiber 
dynamics in SCID mice 
We demonstrated above ongoing muscle regeneration 5dpi in SCID mice, through 
enhanced activity of myogenic cells that were initially lower in number, compared to WT 
mice. We also observed that the process exacerbated alterations in the fiber size and fiber 
number compared to WT, and wondered how muscle regeneration was completed four weeks 
post-injury. We also addressed the question whether SCID mice can sustain multiple cycles of 
regeneration, as it is the case for WT mice (Hardy, Besnard et al. 2016) (Fukada, Morikawa et 
al. 2010). 
To activate multiple regeneration cycles, TA muscles of WT and SCID mice were 
subject to repetitive injury, namely they were injured 3 successive times in 89 days with 
cardiotoxin. Since complete regeneration requires about 28 days, the second and third injuries 
were done 30 and 60 days after the first injection, respectively (Fukada, Morikawa et al. 
2010). Three sets of mice were used: one set undergoing a single muscle injury, and whose 
TA muscles were dissected and frozen 29 days post-injury (1 injury), another set undergoing 
two muscle injuries, and whose TA muscles were dissected and frozen 59 days post-injury (2 
injuries), and finally a third set undergoing three muscle injuries and whose TA muscles were 
dissected and frozen 89 days post injury (3 injuries) (Fig. 23a). The first injury was performed 
when the animals were 7 weeks old and, accordingly, TA muscles injured 3 times (the last 
time point) were dissected from 19 weeks old mice.  
The initial observation in this experiment was the total weight of the mice in the 
absence of injury. Although the weight of both WT and SCID mice physiologically increased 
from 7 weeks until 19 weeks, WT mice weighted 23g and 29g, respectively, and were 
significantly heavier than SCID mice, which weighted 21g at 7 weeks and 26g at 19 weeks 
(data not shown, n=4-5/condition). Differently from the total body weight, uninjured TA 
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muscles did not significantly increase in weight in this time period, and remained of 63 ± 6 
mg on average in the WT and on 57 ± 7 mg on average in SCID mice.  
However, injured WT TA muscles gradually increased in weight with increasing 
number of injuries, and reached up to 85 ± 3 mg after 3rd injury, whereas TA from SCID mice 
were 69 ± 5 mg in weight after 3rd injury (data not shown). Accordingly, cross-sectional 
surface area (C.S.A.) of the entire TA muscle, measured from representative images of TA 
sections in Figure 23b, essentially did not change after the 1st injury but increased after 2nd 
injury in the WT. Conversely, in SCID mice C.S.A. slightly increased after the 1st injury, but 
after 2 additional injuries and in all conditions remained lower in SCID than WT mice (Fig. 
23 b, d).  
For a more in-depth investigation, the dynamics of individual fibers in the TA muscle 
have been then analysed. The number of fibers/mm2 increased at a larger extent in SCID than 
WT mice 5dpi (see Fig. 21d above), whereas at 29 dpi, once the first regeneration was 
completed, the number of fibers remained as high as before in WT mice (665 fibers/mm2), 
whereas it dropped to pre-injury levels in SCID mice (480 fibers/mm2), Fig. 23e.  In WT mice 
the number of fibers/mm2, remained similarly high after the 2nd injury and slightly decreased 
after the 3rd injury (22 fibers/mm2). On the contrary, in SCID mice the number of fibers/mm2 
kept increasing after the 2nd and 3rd injury, accounting for 624 fibers/mm2, and 758 
fibers/mm2, respectively (Fig. 23e). Thus, after the 3rd injury, the fiber density was finally 
higher in SCID than WT mice. 
Not only the number of fibers, assessed above, is relevant but also their size. At 5dpi 
the cross-sectional surface area of individual myofibers in TA was smaller in injured than in 
uninjured controls (WT as well as SCID, see Fig 21e above). In WT mice, the CSA of fibers 
remained low at 29dpi, not only after the first cycle of regeneration was completed, but also 
after three successive cycles of regeneration (Fig. 23f). On the contrary, in SCID mice, 
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already 29 dpi the CSA of fibers increased to almost pre-injury levels, but decreased again 
with successive injuries. 
 Finally, in WT mice the number of Pax7+ SCs/mm2 increased from 19/mm2 in 
uninjured mice to 58/mm2 (after the 1st injury), a number that remains stable after the 2nd and 
3rd injury. Conversely, SCID mice SCs keep increasing after each injury/regeneration event 
and increased from 43/mm2 after the 1st cycle of regeneration to 67/mm2 and 87/mm2 after the 
second and third cycle of regeneration, respectively, thereby exceeding the number in WT 
under the same conditions (Fig. 23c, g), Globally, in both WT and SCID mice changes in the 
number of Pax7+ SCs upon injury had a similar profile as changes in fiber density. 
Thus, upon multiple injuries, TA of WT mice have a higher density of fibers but their 
size is smaller, compared to uninjured muscle (for an overview, see Fig. 37 in Discussion). 
This is also the case for SCID mice after the 3rd cycle of regeneration, whereas after the 1st 
cycle of regeneration, the number of fibers and their size was comparable to uninjured TAs. 
We observe therefore delayed dynamics in fiber regeneration in SCID mice that catch up with 
WT mice only upon multiple injuries, although their muscle remains smaller. As a 
consequence, multiple injuries exacerbate the delay in regeneration observed at 5 dpi in vivo, 
and in SCID SCs in vitro.   
Delayed and altered myogenesis in SCID mice is nevertheless effective, suggesting 
that these mice have developed alternative, compensatory mechanisms to cope with the 
absence of DNA-PKcs in myogenesis (see Discussion).  
 
A manuscript on this part of the study is going to be finalized (see Annexes) 
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Figure 23. Marked decrease of muscle mass and increased SC population in SCID mice after 
multiple regeneration event. a) Experimental planning of repetitive cycles of muscle injury and 
regeneration. WT and SCID mice were alternatively injected 1 or 2 or 3 times with cardiotoxin during 
89 days (the second and third injections were done 30 and 60 days after the first injection, 
respectively). For these experiments TA muscles were dissected and frozen either at 29 days post-
injury (1 injury), or 59 days post-injury (2 injuries), or 89 days post injury (3 injuries). b-c) Cross 
sectional TA muscle images used for the analysis, Laminin (green), Pax7 (red), Hoechst (blue). b) 
Complete section images c) zoomed images. Histograms of d) cross sectional area of TA muscles e) 
number of fibers per mm2 f) cross sectional surface area of TA fibers g) number of Pax7+ SCs per 
mm2. n=4-5 mice/condition, 5 sections/condition, mean ± SD. Significance Mann-Whitney Test, 
Significance p* <0.05, **<0.01, ***<0.001.  
Chapter II: Impact of impaired DNA damage repair proteins on myogenic cell 
viability and differentiation: ATM 
We reported above that not only inhibition of DNA-PKcs, but also inhibition of ATM 
affects myogenesis. In non-irradiated C2C7 cells ATMi blocks the progression of MyoD+ 
cells into Myogenin+ cells (differentiation), and upon irradiation blocks the proliferation of 
myoblasts (MyoD+ cells), displaying a similar dramatic effect as DNAPKi, although to a 
lesser extent (see Figure 8 above). This effect was recapitulated in primary SCs where 
progression into differentiation (Myogenin expressing cells) was strongly reduced in non-
irradiated cells, and blocked in irradiated cells, again in a very similar manner as for DNAPKi 
(see Figure 8 above). These experiments suggest that ATM plays a role in myogenesis 
independent of its function in DNA repair. 
 Several DNA damage-independent functions of ATM have been described, affecting 
various stress-response and metabolic pathways (Shiloh and Ziv 2013). In myogenesis, 
defects due to ATM inhibition were exacerbated upon irradiation, suggesting that ATM 
regulation of myogenesis in the absence of DNA damage relies on processes that are indeed 
normally activated by DNA damage. ATM has been shown to interact with the chromatin 
modifier PARP1 in the absence of DNA damage and that this association increases after 
irradiation (Aguilar-Quesada, Munoz-Gamez et al. 2007). We therefore assessed whether 
PARP is implicated in ATM-dependent defects in myogenesis. As we have seen above, 
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PARP1/2 are chromatin modifiers that also act in multiple DNA repair mechanisms and 
promote the choice of HR versus NHEJ (Ciccia and Elledge 2010) (Fouquin, Guirouilh-
Barbat et al. 2017) . 
Inhibitors of the chromatin modifiers and repair proteins PARP1/2 affect or block 
proliferation of C2C7 cells 
C2C7 cells were treated with 10 µM of PARP inhibitors (Olaparib and Veliparib) for 
1h prior to irradiation, following the experimental scheme described in Figure 8a. Despite that 
the PARP inhibitors Olaparib and Veliparib target the same proteins (they inhibit both PARP1 
and PARP2), they differently affect cell proliferation, since Olaparib induces mitotic arrest 
whereas Veliparib does not (Jelinic and Levine 2014). The effect of these inhibitors was 
verified in C2C7 cells, analysed 1-7 days post-irradiation. Treatment with Olaparib resulted in 
full blockage of C2C7 proliferation in irradiated as well as non-irradiated cells, as expected. 
Conversely, in the presence of Veliparib, C2C7 proliferation of non-irradiated cells was 
initially reduced but at 7 days post-IR the cell number was as high as in control/vehicle cells 
(Fig. 24a). Upon irradiation, proliferation of C2C7 cells was dramatically reduced, in the 
presence of Veliparib essentially due to a dramatic blockage until by 5 days post-IR, followed 
by a reprisal (Fig. 24b). Thus, cell proliferation is blocked in the presence of Olaparib, 
independently from irradiation, whereas Veliparib affects proliferation essentially in the 
presence of DNA damage.  
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Figure 24. Effect of two PARP inhibitors on C2C7 proliferation in the presence and in the absence 
of irradiation. Proliferation curves of C2C7 cells in the presence of 10 µM of Veliparib or Olaparib 
0-7 days of treatment a) without irradiation and b) with irradiation. n=3 experiments per condition, 
mean ± SD. 
PARP inhibitors affect proliferation and differentiation of C2C7 cells during mid and 
advanced myogenesis 
We assessed whether the effect of ATMi on myogenesis was dose-dependent and 
whether it was affected the presence of PARP inhibitors (PARPi) that have been shown to 
activate ATM (Aguilar-Quesada, Munoz-Gamez et al. 2007) (Watanabe, Fukazawa et al. 
2004). Differentiation of C2C7 cells was assessed in the presence of ATMi ± Veliparib (2 
doses) or Olaparib (2 doses) added either upon 2.5dps (during active myoblast proliferation) 
or 4.5dps (when essentially proliferation ceased and differentiation was ongoing), following 
the two experimental plans in Fig. 11a and Fig. 11e, respectively. Consequently, upon 
treatment at 2.5dps cells were harvested and assessed for proliferation and differentiation at 
5dps, and upon treatment at 4.5dps cells were harvested and assessed at 7dps. 
 In non-irradiated cells treated at 2.5 days post seeding cell proliferation and 
differentiation were affected by each single inhibitor (at one or both doses), but in the case of 
Veliparib the reduced number of Myogenin+ cells (differentiation), seems a consequence of 
the reduction in the total number of cells rather than inhibition of differentiation. Combination 
of ATMi and Veliparib, resulted in an additive effect, fully blocking cell proliferation and 
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further dropping the number of Myogenin+ cells at 5dps as well as at 7dps (red arrows in Fig. 
25b), indicating that ATMi and Veliparib act (at least in part) via non-overlapping pathways 
in this phase of myogenesis.   
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Figure 25. ATM and PARP inhibitors affect proliferation and in differentiation of C2C7 cells 
during mid and advanced myogenesis. C2C7 cells treated with 10 µM and 20 µM of ATMi or PARP 
inhibitors (Veliparib and Olaparib), alone or combined (10 µM ATMi +10 µM of PARPi), following 
the experimental scheme shown in Figure 11a (panels b and d, treatment at 2.5dps) and Figure 11e 
(panels c and e, treatment at 4.5dps). a) Representative merge images of immunofluorescent labelling 
of cells treated at 2.5dps and analysed 7dps: MyoD (red), Myogenin (green), nuclei counterstained 
with Hoechst (blue). Representative cells with progressively increased levels of differentiations are 
indicated with red arrows (MyoD+/Myogenin- cells, in red), yellow arrows (MyoD+/Myogenin+ cells, 
in yellow), and white arrows (MyoD-/Myogenin+cells, in green). Myotubes are shown with a white 
arrowhead in the ATMi + Veliparib panel, and are not indicated in control and vehicle, where they 
occupy most of the surface of the image. Histograms of the cell number and differentiation state of b) 
non-irradiated and c) irradiated C2C7 cells treated or not with inhibitors at 2.5dps until 7dps. The 
differentiation state is defined by Myogenin immunolabeling: Myogenin- [undifferentiated] cells and 
Myogenin+ [differentiated] cells are shown in the histogram in orange and in purple, respectively. 
Histograms of the cell number and differentiation state of d) non-irradiated and e) irradiated C2C7 
cells treated (or not) with inhibitors at 4.5dps until 7dps and defined as in panels c, and d. 
Significance by 2-way ANOVA, Dunnett’s multiple comparisons test, p* <0.05, **<0.01, ***<0.001. 
Significance stars are of the same colour as the category that is compared to the vehicle of the 
corresponding time point, or indicated by bars. n=3 experiments. The Myogenin marker has been 
analysed in 5-10 fields/condition corresponding to n=2,500-5 000 cells /condition, and extrapolated 
to the total cell number; mean ± SD. 
 Conversely, combined treatment with ATMi and Olaparib partially rescued the 
dramatic reduction of proliferation and differentiation observed at 5dps with Olaparib alone 
(green arrow in Fig. 25b); these data indicate that in this phase of myogenesis the two 
inhibitors act, at least in part, on overlapping or competing pathways. It is indeed possible that 
in the absence of PARP, ATM operates on a downstream PARP effector, partially rescuing 
myogenesis. This effect was however lost at 7dps, where ATMi no longer rescued Olaparib’s 
inhibition of myogenesis, perhaps as a consequence of the sustained cell proliferation required 
at this point and that Olaparib fully blocks.   
Proliferation, assessed by PCNA immunolabeling, shows that at the time of treatment 
(2.5dps) cells were cycling (22% in the S-phase) and at the end of (5dps) they were mostly 
non-cycling (5% cells in vehicle), in agreement with ongoing differentiation at the late time 
point. Treatment with most inhibitors reduced even more (until 0.3 %) the number of cells in 
the S-phase (Fig. 26b). However, combined Olaparib and ATMi treatment maintained the 
fraction of cells in the S-phase as in vehicle, indicating that improved myogenesis observed 
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under these conditions (see section 5dps in Figure 25b above) was linked to the reprisal of the 
cell cycle. Upon Veliparib treatment at the dose (10 µM) that did not affect myogenesis, the 
number of cells in the S-phase increased as in vehicle, and viceversa this number decreased at 
20 µM, associated with affected myogenesis (Figure 26b). In all conditions, irradiation 
dramatically decreased the number of cycling cells, as expected (Fig. 26b, green hatched 
columns). 
Thus, the effect of inhibitors on myogenesis was directly correlated with their impact 
on the cell cycle, with the exception of the double treatment ATMi + Veliparib. This 
treatment resulted in further reduction in the cell number and blocked differentiation (Fig. 
25b), but was associated with a larger number of cycling cells. It is tempting to speculate that 
these cells are blocked in the S-phase. These cells also displayed very low levels of apoptosis 
at 5dps (measured by cleaved Caspase-3) (Fig. 26c), in all conditions, suggesting that at this 
phase of myogenesis, inhibitors did not prevalently promote cell death, in agreement with the 
maintenance or increase in the cell number two days later in culture (7dps, Figure 25b).  
The effects of PARPi and ATMi on myogenesis reported above seem prevalently (but 
not exclusively) dependent on reduced/blocked proliferation of myogenic cells rather than 
inhibition of myogenesis. In agreement with this notion, non-irradiated cells treated with one 
or two inhibitors at 4.5dps, when cell proliferation decreases or ceases, displayed less 
pronounced inhibition of myogenesis. Remarkably, the proportion of Myogenin+/Myogenin-
cells, that indicates myogenesis, was reduced in the presence of ATMi (20 µM) or Olaparib 
(20µM), therefore at the highest concentration tested, or both inhibitors combined (Fig. 25d). 
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Figure 26. ATMi and PARPi impacts on cell cycle progression. C2C7 cells treated with 10 µM and 
20 µM of ATMi or PARP inhibitors (Veliparib and Olaparib), alone or combined (10 µM ATMi +10 
µM of PARPi) following the experimental scheme shown in Figure 11a. a) PCNA (green) 
immunofluorescent labelling at 2.5dps and 7dps; nuclei are counterstained with Hoechst (blue). 
Representative cells in the S-phase are indicated with yellow arrows and in the G1-phase with red 
arrows. b) Histograms of non-irradiated (full green columns) and irradiated (hatched green columns) 
C2C7 cells in the S-phase (PCNA+ nuclear foci) at 2.5dps and 5dps (for irradiated cells, these time 
points correspond to 1h and 2.5 days post-irradiation, respectively). d) Histograms of non-irradiated 
(full red columns) and irradiated (hatched red columns) apoptotic C2C7 cells (cleaved caspasis-3+ 
cells) at 2.5 dps and 5dps; immunofluorescent images not shown; n=1, 200-1,000 cells/condition 
analysed. Control 1, control 2 and vehicle are the same as in Fig 12, since the experiments reported in 
Fig. 12 and Fig. 26 were done at the same time. 
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Irradiation at 4.5dps, therefore on cells that are poorly cycling, had a mild effect on 
myogenesis (see vehicle in Fig. 25e, compared to Fig. 25d). Treatment with ATMi and 
Olaparib (at 20 µM concentration) or both combined, not only reduced the number of 
Myogenin- cells, that are therefore lost perhaps by apoptosis (not tested), but also blocks the 
residual cells from progressing into differentiation, as observed by unchanged number of 
Myogenin+ cells compared to vehicle (Fig. 25e). ATMi and Olaparib therefore fully block 
differentiation of myogenic cells in the presence of DNA damage. Veliparib (at 20 µM 
concentration) had a similar but less pronounced effect than the other two inhibitors.  
Taken together, these experiments suggest that when administrated during mid or 
advanced myogenesis, Olaparib has a similar effect on myogenesis as ATMi, reducing cell 
proliferation and differentiation, and in this case affecting not only Myogenin expression but 
also the advanced phase of myotube formation.  
On the contrary, Veliparib affects cells proliferation, although at a lower extent than 
the other inhibitors, and has a milder effect on differentiation, allowing Myogenin expression 
and, in some cases the formation of structures compatible with myotubes. Combination of 
ATMi and PARPi has additive effect on myogenesis on the longterm, whereas during early 
myogenesis ATMi could transitory compensate for the impaired differentiation by Olaparib. 
Finally, these effects are exacerbated in the presence of irradiation, demonstrating that 
undifferentiated myogenic cells cannot differentiate in the presence of unrepaired DNA 
damage. 
PARP inhibitors affect proliferation and differentiation of SCs-derived primary cells 
during mid and advanced myogenesis 
 We tested the effect of ATMi and PARPi also on cells derived from primary SCs, with 
immunolabeling of multiple myogenic markers, to better identify the categories of cells 
affected by the treatment. The experimental plan was as described in Fig. 13, with treatment 
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(inhibitors) at 5.5dps and harvesting and analysis at 7.5dps, therefore on cells that were 
largely not cycling, and committed to differentiation. This experimental plan was chosen 
since ATMi and PARPi strongly affect or block cell proliferation, and we intended focusing 
here on evaluating the impact of these inhibitors on myogenic differentiation.  
Treatment of non-irradiated cells with 10 µM ATMi (a dose that inhibits ATM 
phosphorylation during DSB repair, affects 30-40% of DNA repair) (Hickson, Zhao et al. 
2004) (Jeggo, Geuting et al. 2011) essentially affected committed cells (Myogenin+ and 
MHC+ cells, see Fig. 27a, and red and purple parts of the column in Fig. 27b). These effects 
were exacerbated with 20 µM ATMi that, additionally, reduced the number of myogenic 
(MyoD+/Myogenin-) cells. Veliparib reduced the cell number by almost two thirds, and all 
myogenic populations, in particular Myogenin+ cells (red parts of the column). This effect 
was much more pronounced than in C2C7 cells, where Veliparib was almost ineffective (see 
Fig. 25d, above). Similarly, Olaparib had a much more dramatic effect on SCs than on C2C7 
cells, by reducing the cell number more than 7-fold (versus a 2-fold reduction in C2C7 cells, 
see Fig. 25d, above).  
The effects of Veliparib and Olaparib were essentially not dose-dependent, indicating 
full inhibition already at the lowest dose. Accordingly, combined treatment with PARPi and 
ATMi did not worsen the situation, neither compensation nor improvements were observed.  
Beyond myogenic markers, the fusion index that assesses the size of myotubes, shows 
that Olaparib, and to a larger extent ATMi, had the most dramatic effect on differentiation of 
non-irradiated cells, limiting the size of myotubes to 5-nucleated structures at best (against 
≥20 nuclei/myotube at best in vehicle, black part of the column, Fig. 27d), and accounting for 
81% and 87% of mononucleated cells (no myotube) against 65% in vehicle (white part of the 
column, Fig. 27d).  Conversely, Veliparib, despite having a strong effect on the cell number 
(Fig. 27a,b above), essentially did not affect the fusion index compared to vehicle, confirming 
the effect observed in C2C7 cells (see Fig. 25a above). Veliparib also succeeded in improving 
 112 
the fusion index of ATMi-treated cells, when used in combination with this inhibitor  (Fig. 
27d).  
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Figure 27. ATMi and Olaparib affect proliferation and differentiation of SC-derived cells and 
Veliparib essentially affects cell proliferation. SC-derived cells were treated with 10-20 µM of either 
ATMi, Veliparib, Olaparib or simultaneously with 10 µM of ATMi and 10 µM of either PARPi. The 
experimental planning was shown in Figure 13a. a) Immunolabeling of SC-derived cells at 5.5dps 
without inhibitor (control 1) and 7.5dps with and without [control 2 and vehicle] inhibitor. Merge of 
Myosin HC (MHC, yellow), Myogenin (red), Pax7-nGFP (green) immunostaining, and Hoechst 
counterstaining (nuclei, blue). MHC+ structures are indicated with a white arrow, Myogenin+ cells 
(red) with a red arrow, and Pax7-GFP+ cells (green) with a green arrow. Histograms of the cell 
number and differentiation state of b) non-irradiated and c) irradiated SC-derived cells treated or not 
with inhibitors, and defined by the indicated combinations of myogenic markers. The colour code 
indicates the differentiation state (from Pax7/GFP+ [not differentiated] to MHC+ [the most 
differentiated] state). Myogenic markers analysed in 5-10 fields/condition and extrapolated to the 
total cell number. Mean ± SD for each category. Significance by 2-way ANOVA, Dunnett’s multiple 
comparisons test, p* <0.05, **<0.01, ***<0.001. Significance stars are of the same colour as the 
category compared against vehicle.  Fusion indexes of d) non-irradiated e) irradiated SC-derived 
cells by quantification of nuclei/myotubes. Significance by 2-way ANOVA, Dunnett’s multiple 
comparisons test, p* <0.05, **<0.01, ***<0.001. Significance stars are of the same colour as the 
category that is compared, or indicated with bars. Stars within the columns compare each category 
against Vehicle. n=3 experiments, n=2,500-5,000 cells analysed/condition, mean ± SD. 
Irradiation reduced the cell number of each sample (Fig. 27a, c), compared to the 
corresponding non-irradiated sample (Fig. 27a, b), essentially maintaining the proportion of 
the different cell populations, with the exception of Olaparib (and also 20 µM ATMi) that 
almost depleted Myogenin+ cells. The fusion index was not changed (Fig. 27e) compared to 
the same cells in the absence of irradiation (Fig. 27d), with the exception of Olaparib that 
further impoverished the myotube population.  
In conclusion, in SC-derived myogenic cells in the absence of irradiation, both PARPi 
had a larger effect than on C2C7. Moreover ATMi and Olaparib, in addition to affecting the 
cell number, also dramatically affected myogenic differentiation, whereas Veliparib 
essentially reduced the cell number but not much differentiation. 
ATM deficient SCs appear to recapitulate delayed myogenesis 
To validate the effect of ATMi treatment on myogenesis, I assessed proliferation and 
differentiation of Atm-deficient SCs. To be able to isolate SC using the Pax7 marker, I 
crossed Atm+/-, Atmins5790neo/+ mice  (from Dr. Ludovic Deriano (Barlow, Hirotsune et al. 
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1996) (Deriano, Chaumeil et al. 2011)) with Tg:Pax7-nGFP, Pax7GFP/+ mice. F1 progenies 
were re-crossed to generate ATM-deficient mice which were also Tg:Pax7-nGFP. For 
simplicity these mice, that express Pax7, will be defined only according to the Atm genotype, 
therefore as Atm+/+, Atm+/-, and Atm-/-. 
SCs were isolated from Atm+/+, Atm+/-, and Atm-/- mice, using the GFP marker. FACS 
sorted GFP+ SCs were seeded, later cells were irradiated (or not irradiated), and analysed 
2.5dps, 5.5dps, and 7.5dps (in irradiated cells corresponding to 2 days, 5 days, and 7 days 
post-IR). The total cell population per field was quantified by Hoechst nuclear 
counterstaining. To assess the level of differentiation at the various time points after 
irradiation, immunolabeling with early myogenic markers of Pax7 and MyoD was performed 
for samples at 2.5dps, and late myogenic markers Myogenin and MHC for samples at 5.5dps 
and 7.5dps.  
In the absence of irradiation, upon 2.5dps SCs with the three different genotypes 
displayed similar cell number and early myogenic markers (Fig. 28a, b), but at 5.5dps, Atm+/- 
and Atm-/- myogenic cells had reduced MHC+ and Myogenin+ populations (purple and red part 
of the column, respectively) despite unchanged levels of Myogenin- (undifferentiated 
myoblasts) cells compared to the wild type. Specific reduction in the number of differentiated 
cells was exacerbated 7.5dps, but only for Atm-/- cells, indicating that heterozygote cells catch 
up on the initial defects, but mutant cells do not (Fig. 28a, b). Interestingly, the fraction of 
Myogenin- cells was not changed, suggesting that the myogenic defect in the absence of ATM 
specifically concerns differentiation.   
This result was confirmed by analysis of the fusion index that reveals depletion of the 
longest myotubes (≥20 nuclei/structure) and enrichment of shorter myotubes (1-10 
nuclei/structure) in Atm+/- cells and, to a larger extent, in Atm-/- cells, thereby suggesting ATM 
dose-dependent inhibition of myotube formation (Fig. 28a, d).  
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According to this experiment, Atm+/- myogenesis results in a similar number of cells 
but shorter myotubes compared to wild type, whereas Atm-/- myogenesis displays reduced 
number of differentiated cells and less compelled myotube structure compared to the wild 
type. These data support the notion that myogenesis is affected upon ATM impairment in the 
absence of induced DNA damage. Effects on myogenesis in mutant mice are rather 
straightforward, although less dramatic than in SCs treated with ATMi (see Fig. 27b, c 
above). 
Irradiation affects all samples, but only about 7.5 days post irradiation Atm+/- and Atm-
/- cells displayed a strong reduction of all cell populations, in particular of differentiated cells 
(Fig. 28a, c), and dramatic depletion of myotubes (Fig. 28a,d). Thus irradiation exacerbates 
the myogenic defect but unexpectedly seems to affect Atm+/- as much as Atm-/- cells.  
In conclusion this experiment with Atm-/- SCs supports the notion of reduced 
differentiation of myogenic cells observed with ATMi, and suggest a dose-dependent role for 
this kinase in myogenesis in vivo, which appears distinct from its role as sensors of DSBs. 
These results need nevertheless to be confirmed by analysis of a larger number of mice 
(ongoing) [this experiment was conceived for n=3 mice per condition, but several mice 
become no longer available due to external reasons]. 
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Figure 28. Myogenesis is affected in Atm+/- and Atm-/- SCs in vitro. SCs were isolated from Atm+/+, 
Atm +/- or Atm-/- mice. Cells were irradiated (or not) 12h post seeding a) Immunofluorescent labelling 
of non-irradiated and irradiated (Atm+/+, Atm +/- or Atm-/-) SCs with: Pax7 (green) indicated with 
green arrows and MyoD (red) indicated with red arrows [2 days post-irradiation= 2.5dps], or 
Myogenin (red) indicated with yellow arrows and Myosin HC (green) indicated with white arrows [5 
and 7 days post-irradiation; 5.5dps and 7.5dps, respectively]; nuclei are counterstained with Hoechst 
(blue). Histograms of myogenic differentiation of b) non-irradiated and c) irradiated SCs. n=1 
mouse/condition, 5-10 fields/condition. d) Fusion index 7.5dps 1 mouse/condition, 5,000 
nuclei/condition. 
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Chapter III: DSB repair mechanism of myogenic cells 
 It has been previously shown in the lab that SCs have more efficient and accurate 
repair of (IR) radiation-induced DSBs than their committed progeny, and that this repair is 
remarkably accurate (Vahidi Ferdousi, Rocheteau et al. 2014). With the use of inhibitors it 
has also been shown that the accuracy of repair relies on DNA-PKcs, and thereby on NHEJ 
(meaning classical NHEJ, c-NHEJ). Despite that NHEJ is expected to be the prevalent DSB 
repair mechanism of IR-induced DSBs, there is still no explanation why this mechanism is so 
efficient and accurate in SCs. To help elucidating the mechanism of DSB in SCs, I focused on 
large part on factor, ATM, a key regulator of DSB signaling as well as a checkpoint protein, 
and DNA-PKcs, an essential protein involved in c-NHEJ.  
C2C7 myogenic cells repair radiation-induced DSBs in DNAPKcs-dependent manner  
 A first set of experiments was performed on C2C7 myogenic cells, before assessing 
primary SCs. After seeding, C2C7 cells were treated with 10 µM of the ATM inhibitor 
(ATMi) KU55933 that specifically affects ATM phosphorylated at position 1981 (Ser 1981), 
or p-ATM. This phosphorylation, a consequence of DSBs, represents the active form of this 
kinase (Hickson, Zhao et al. 2004). C2C7 cells were alternatively treated with 10 µM of 
DNAPKi (NU7441), that specifically affects DNA-PKcs, and thus c-NHEJ (Leahy, Golding 
et al. 2004). Note that a part of the following experiment constitutes also a control for the 
topic developed in Chapter I (see below).  
 As in experiments in Chapter I, 1h after inhibitor treatment cells were exposed to 5 Gy 
of X-ray, that are expected to induce approximately 200 DSBs, in agreement with previous 
assessments (30-40 DSBs/Gy (Rothkamm and Lobrich 2003)). C2C7 cells were fixed at 4h, 1 
day and 2 days post-irradiation and assessed for DSB repair markers (gH2AX and 53BP1) by 
immunofluorescence. In the presence of a DSB, the histone H2AX becomes phosphorylated 
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(gH2AX) for a few kilobases in the vicinity of the damaged site. Conversely, 53BP1 is 
specifically recruited at the site of the DNA lesion. The disappearance of gH2AX or 53BP1 
foci, after irradiation, measures the efficiency of repair at each given time post-IR (Goodarzi 
and Jeggo 2013, Popp, Brendel et al. 2017).   
 Figure 29 shows very little signal of either DSB repair markers in all conditions 
without irradiation, namely 1±1 53BP1 foci/cell (nucleus) and 2±1 gH2AX foci/cell 
(nucleus). C2C7 cells are cycling cells, and occasional replication-dependent DSBs should be 
rather repaired by homologous recombination (HR). HR does not require 53BP1, but DSBs 
will be signaled by gH2AX. We conclude that there is little ongoing DNA damage in these 
cells, as expected. Moreover, given that neither ATMi nor DNAPKi significantly impact on 
the number of foci of either marker, we consider then ATM and DNA-PKcs do not intervene 
in the repair of replication-dependent DNA damage in C2C7 cells. This result supports the 
notion that the effect of DNA-PKcs on myogenesis described in Chapter I does not depend on 
activation of this kinase by replication-dependent DNA damage. This point was also 
supported by inhibition of myogenesis by DNAPKi in essentially non-cycling cells C2C7 and 
SCs (see above Fig. 11g, and Figs. 13 and 9). 
 Four hours post irradiation the number of gH2AX (Fig. 29a, b) and 53BP1 (Fig. 29a, 
c) foci/nucleus was high in all conditions, as expected. The larger number of foci of both 
markers 4h post irradiation in DNAPKi-treated cells likely accounts for impaired DSB repair 
in this time frame (under normal conditions many DSBs should have been repaired by 4h) 
(Dong, Ren et al. 2018) (Sharma, Ponnaiya et al. 2015). Accordingly, in cells not treated with 
inhibitors (control and vehicle) the number of foci of both markers gradually decreases from 
4h to 2 days post irradiation, almost reaching the levels of non-irradiated cells, thereby 
confirming efficient repair (Fig.29 b, c). The residual number of gH2AX and 53BP1foci 
indicates severely impaired repair in the presence of DNAPKi, confirming the working 
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paradigm. In the presence of ATMi the decrease in gH2AX foci was severely slowed down, 
indicating largely delayed but almost complete repair compared to untreated cells. 
Conversely, the disappearance of 53BP1 foci was not only slowed down but also largely 
incomplete compared to untreated cells. 
 
Figure 29. Efficiency of DSB repair in C2C7 cells evaluated by disappearance of repair factors in 
the presence and in the absence of DNAPKi and ATMi.  Analysis of non-irradiated and irradiated (5 
Gy) C2C7 cells in the presence and in the absence of repair inhibitors (ATMi, DNAPKi) or DMSO 
(Vehicle), [(control = culture medium without DMSO]. a) Representative images (merge) of C2C7 
cells 4h post irradiation (upper panel) and non-irradiated controls (lower panel) immunostained with 
the DSB repair markers gH2AX (green) and 53BP1 (red) used for foci enumeration. Nuclei are 
counterstained with Hoechst (blue). In each panel the inlet shows enlargement of a representative 
nucleus with the individual labelling, indicated below, and the merge. Histograms report the number 
of b) gH2AX foci/cells (nucleus) and c) 53BP1 foci/cell (nucleus) in non-irradiated (Non-IR) and 
irradiated (IR) cells from 4h to 2 days post irradiation. Mean ± SEM for each condition. Significance 
by unpaired T-test, *≤0.05, **≤0.01, ***≤0.001, n=30 cells/condition.  
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  These results confirm the implication of DNA-PKcs (and therefore of c-NHEJ) in the 
repair of radiation-induced DSBs in myogenic cells. These results also show delayed repair 
when ATM is inhibited as expected but, surprisingly, also persistence of DSBs labeled by 
53BP1 immunofluorescence. This result is intriguing since 53BP1 is normally recruited to the 
site of DNA damage in an ATM-dependent manner (Rappold, Iwabuchi et al. 2001, Noon and 
Goodarzi 2011), raising the possibility of 53BP1 having an ATM-independent role in DSB 
repair of myogenic cells. 
SCs repair radiation-induced DSBs in DNA-PKcs dependent manner 
 We then assessed DSB repair in primary satellite cells. Freshly isolated SCs were 
seeded overnight (12h) treated or not with 10 µM DNAPKi for 1h then irradiated (or not) and 
analysed for immunostaining of the DSB repair markers gH2AX and 53BP1 1h, 4h, 6h and 
24h later. Figure 30a shows representative images of non-irradiated and irradiated individual 
SCs marked with gH2AX (green) and 53BP1 (red). Enumeration shows high number of 
gH2AX foci 1h post-irradiation (post-IR), that gradually decreased but remained high until 
24h post-IR in control and vehicle, indicating that repair of DNA damage is active but not 
completed yet in this time frame (see Figure 30 below).  
In the presence of DNAPKi, the decline of gH2AX foci was largely impaired, 
confirming DNA-PKcs-dependent repair in SCs (Fig. 30a, b). A more complex scenario was 
observed for 53BP1, since the number of foci remained almost constant, despite a slight 
reduction at 24h (Fig. 30a, c) suggesting low implication of 53BP1 in early DSB repair in 
SCs. Surprisingly, 53BP1 foci kept increasing until 24h post-IR in cells treated with 
DNAPKi, indicating not only impaired repair in these cells, but also the presence of a second, 
slower, phase of formation of 53BP1-linked DSBs. Non-irradiated cells displayed a negligible 
number of 53BP1 foci in all conditions. 
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Figure 30. Efficiency of DSB repair in SCs evaluated by disappearance of repair factors in the 
presence and in the absence of DNAPKi. DSB repair marker analysis on irradiated (5 Gy, X-ray) 
SCs in the presence and absence of 10 µM of DNAPKi (NU7441) or 0.1% DMSO (vehicle), [control = 
culture medium instead of DMSO] from 1h until 24h post-IR. a) Representative image of SCs non-
irradiated 6h, or 1h, 4h, 6h, 24 h post-IR for the DSB repair markers gH2AX (green) and 53BP1 
(red). Nuclei are counterstained with with Hoechst (blue). Enumeration of b) gH2AX foci/cell and c) 
53BP1 foci/cells. n=3 mice, 100-150 cells/condition, Mean ± SEM. 
 Curiously, non-irradiated SCs displayed a negligible number (1±1) of gH2AX foci in 
all conditions but after 24h in culture (Fig 30a,b), which was not the case for C2C7 cells (see 
above, Fig. 29a, b). At this time point untreated SCs were already cycling (12h seeding + 24h 
in culture) since SCs undergo the first division about 30h after isolation. It is thus possible 
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that gH2AX foci label replication-dependent DSBs, although this was not the case for highly 
cycling myogenic C2C7 cells. It is also possible that these foci represent alternative chromatin 
structures, reported in various stem cells and involving phosphorylation of the histone H2AX 
(Turinetto and Giachino 2015) (see also Fig. 32a, in the next section).  
Altogether these experiments confirm that the repair of IR-induced DSBs in SCs is 
dependent on DNA-PKcs. They also indicate that upon inhibition of DNA-PKcs, a fraction of 
DSBs becomes processed by 53BP1 at 24h post-IR. 
To confirm results obtained above with DNAPKi, we analysed DSB repair in SCs 
isolated from SCID (DNAPK deficient) mice, and corresponding WT mice for control. In WT 
SCs the number of gH2AX foci/cell was high upon irradiation (5 Gy) and then decreased until 
24h post-IR, confirming ongoing DSB repair (Fig. 31a), as it was also the case above (see Fig. 
30b). In SCID SCs, rather than the expected poor decline in gH2AX foci number due to 
impaired DSB repair, we observed an increase at 6h post-IR that remained constant until 24h 
post-IR. Non-irradiated WT and SCID cells displayed low but not negligible gH2AX signal 
(≈5 foci/cell), which slightly increased at 24h, as it was also the case in the previous 
experiment (see above, Fig. 30b). 
This experiment thus confirms the role of DNA-PKcs in the repair of IR-induced 
DSBs in SCs (i.e. by classical NHEJ), supporting data obtained with DNAPKi, (Fig. 30). This 
experiment also suggests that DNA-PKcs deficiency results in a more pronounced DSB repair 
defect than inhibition of this kinase, due either to delayed phosphorylation of histone H2AX 
or a fraction of late DSB repair events.  
Figure 31b shows in WT SCs an increase in the number of 53BP1 foci 6h and 24h 
after irradiation, in contrast with early appearance (≤1h) of the gH2AX signal (see Fig. 31a). 
The increase in 53BP1 foci number in WT cells is consistent but more pronounced than the 
one observed in Fig. 30c, performed with SCs isolated from WT mice with a different genetic 
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background (see Table 1). SCID SCs display a more extensive increase in the number of 
53BP1 foci upon irradiation, exceeding the increase observed upon inhibition of DNA-PKcs. 
 
Figure 31. Impaired DSB repair in SCs derived from SCID (DNA-PKcs-deficient) mice and late 
involvement of 53BP1. Enumeration of foci upon immunofluorescent labeling of DSB repair markers; 
gH2AX and 53BP1 in irradiated (IR) and non-irradiated (Non-IR) WT and SCID (DNAPK deficient) 
myogenic cells. a) gH2AX foci number per SC. b) 53BP1 foci number per SC. n=3 mice, 100-150 cells 
per condition, mean ± SEM. c) Representative images of individual WT and SCID SCs immunostained 
with 53BP1 (red) and Rad50 (green), and counterstained with Hoechst (blue, nuclei), and merge. 
Images of gH2AX immunostaining (for panel a) are not shown. Immunostaining (as in panel c) of 
irradiated d) C2C7 cells (immortalized myoblasts), and e) WT myofibers. SC were isolated by FACS 
and irradiated in vitro after seeding. Myofibers were extracted from the EDL muscle. n=3 mice, 100-
150 cells/condition, Mean ± SEM. Scale bar = 10 µm.  
Altogether, inhibition and deficiency of DNA-PKcs both confirm that this enzyme 
(and by extrapolation c-NHEJ) plays a key role in the repair of HR-induced DSBs in SCs. 
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These data also suggest that 53BP1 is recruited unusually late for repair in these cells, 
whereas it was not the case in myogenic C2C7 cells.  
53BP1 is implicated in DSB repair of cycling SCs  
The late involvement of 53BP1 in response to irradiation in SCs is unusual, since in 
other cells in culture the 53BP1 immunofluorescence signal appears in less than 1 hour 
(Anderson, Henderson et al. 2001, Markova, Schultz et al. 2007). 53BP1 is present in the 
nucleus before irradiation, and distinct foci upon immunostaining result from the protein 
accumulation at DNA damage sites (Hu, Wang et al. 2014). We wondered whether 53BP1 
recruitment at DSB sites, as it is detected by immunofluorescence, depends on the cell cycle. 
Quiescent SCs undergo a first division about 30h after isolation and then they cycle 
each 10h, becoming activated. In agreement with this notion, SCs at 1h and 6h post-
irradiation (thereby at 13h and 19h after isolation, respectively, considering 12h seeding) 
displayed little 53BP1 foci, whereas SCs at 24h (therefore at 36h after isolation) displayed a 
large number of 53BP1 foci (Figure 31c, see also Fig. 31b for foci quantification). Moreover, 
nuclei in polynucleated myofibers that represent the end-point of myogenesis are fully post-
mitotic, and display little or no 53BP1 foci 1h after irradiation, as non-cycling SCs do (Fig. 
31e). Conversely, cycling C2C7 myoblasts display a large number of 53BP1 foci 1h post-
irradiation (Fig. 31d). 
Figure 31 c and d shows large colocalization of 53BP1and Rad50 foci in SCs, C2C7, 
and differentiated myonuclei. Rad50 is a key protein in the MRN complex, and an early 
sensor of DSBs) (Lee, Goodarzi et al. 2010) (Fig. 31c-e). The MRN complex activates ATM 
that in turn helps recruiting 53BP1 at damage sites (Blackford and Jackson 2017). 
To confirm the intervention of 53BP1 in radiation-induced DSBs in cycling cells, I 
assessed the level of this marker in dividing and non-dividing cells labeled by EdU. Freshly 
isolated SCs were seeded overnight (12h) treated or not with 10 µM DNAPKi for 1h then 
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irradiated (or not) and kept in culture for 1h, 4h, 6h, and 24h post-IR. At each time point, 2h 
before fixation 1 µM of EdU (a nucleoside analog of thymidine) was added to the medium. 
EdU will be incorporated into DNA during replication, and thereafter the EdU chemical 
labeling will serve to estimate the proliferation state of cells at any given condition. For cells 
examined 1h post-IR, EdU has been added 1h prior irradiation, at the same time as DNAPKi 
or (DMSO or medium, in vehicle or control, respectively). Cells were then fixed and analysed 
for co-immunostaining of gH2AX/EdU and 53BP1/EdU (Fig. 32). 
EdU chemical-labeling shows 4±% EdU+ (cycling) SCs at 6h in the absence of 
irradiation (vehicle, dotted blue line) that rise to 52% at 24h, indicating that at the late time 
point about half cells are cycling, Fig. 32b. No EdU+ cells were observed before 6h. Upon 
irradiation, no detectable EdU+ cells were observed up to 6h post-IR, and they accounted for 
26% at 24h (blue line). In the presence of DNAPKi, with or without irradiation, cycling 
(Edu+) cells accounted for about half of the corresponding controls: 22% in non-irradiated 
cells and 14% in irradiated cells (dotted red line and red line, respectively, in Fig. 32b). 
Altogether the EdU labeling confirms that control cells at 24h, under whatever treatment, are 
cycling, although the fraction of cycling cells depends on the treatment, and that at earlier 
time points they essentially do not cycle (only 4% are cycling at 6h in non-irradiated vehicle). 
In agreement with our hypothesis, gH2AX/EdU and 53BP1/EdU colocalization 
experiments show that non-irradiated EdU+ cells had larger number of gH2AX foci compared 
to EdU- cells, and that these EdU and gH2AX foci essentially did not colocalize (Fig. 32a). 
The increase in gH2AX foci number in non-irradiated cells at 24h (also observed in Fig. 30b) 
could be due to phosphorylation of H2AX during mitotic progression independently of DNA 
damage (Tu, Li et al. 2013) (Turinetto and Giachino 2015), or to replication-dependent DNA 
damage. No 53BP1 foci were detected in these cells, as expected (not shown). 53BP1 foci did 
not colocalize with EdU foci in irradiated cells (not shown). 
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Although we cannot exclude that the increase in gH2AX foci in EdU+ cells is due to 
the treatment (EdU incorporation has been shown to induce DNA damage), we believe that 
this is not the case here because of the short pulse treatment, likely not followed by a cycle of 
cell division (Kohlmeier, Maya-Mendoza et al. 2013). However, experiments in the absence 
of EdU, by colabeling gH2AX and/or 53BP1 with Cyclin A2 (present in the S-phase) should 
address this question (ongoing experiment).  
 
Figure 32. Assessment by EdU incorporation of the cycling condition of non-irradiated and 
irradiated SCs treated or not with DNAPKi. a) Representative images of non-irradiated EdU- (left 
panels) and EdU+ (right panels) Vehicle SCs form the same culture at 24h. Upper panels: merge of 
EdU (purple), gH2AX (green) and 53BP1 (red) immunostaining, and Hoechst counterstaining (blue) 
for nuclei; lower panels: gH2AX immunostaining. Independent 53BP1 immunostaining is not shown. 
Non-irradiated and irradiated control (no inhibitor, no DMSO), black and dotted black line 
respectively, had similar results as vehicle (blue and dotted blue line), and only vehicle was discussed 
in the text. b) Percentage of EdU+ SCs for each condition. n=3 mice, 100-150 cells/condition, mean. 
Scale bar = 10 µm. 
53BP1 intervenes in very slow repair of IR-induced DSBs and independently of ATM  
 To investigate whether 53BP1 has indeed an ATM-independent role in the repair of 
DSBs, as it seems the case in C2C7 cells, and also to assess whether this role is linked to the 
repair of a specific fraction of DSBs that are processed by DNA-PKcs, I monitored DSB 
markers in SCs derived from Atm-/- mice, described above (see pages 111-114). FACS-sorted 
SCs isolated from Atm+/+, Atm+/-, and Atm-/- mice were seeded overnight, exposed to 5 Gy of 
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irradiation, and assessed for gH2AX and 53BP1 immunolabeling from 1h until either 2 days 
or 5 days post irradiation. 
Figure 33 shows a peak of gH2AX foci from 1h post-IR in Atm+/+ cells, and 6h post-IR 
in Atm+/- and Atm-/- cells compatibly with the depletion and absence, respectively, of ATM 
that is the primary kinase that phosphorylates histone H2AX. In the absence of ATM, other 
PI3K-like kinases, for instance DNA-PKcs or ATR, phosphorylate H2AX, in a delayed 
manner (Burma, Chen et al. 2001, Mukherjee, Kessinger et al. 2006). Normally in WT cells 
gH2AX is detectable shortly after irradiation, and persistent foci are observed in the time 
frame of hours and days. In all cells the highest peak was followed by a decline in the number 
of gH2AX foci/cell, indicating DSB repair, until 24h post-IR.  
In control Atm+/+ cells repair was not completed 48h post-IR since the number of foci 
did not return to the level of the corresponding non-irradiated cells, compatibly with a 
previous experiment (see above, Fig. 30b). At 48h, the number of residual gH2AX foci was 
slightly higher in Atm+/- and in particular Atm-/- cells, indicating slightly impaired repair in 
these cells. Altogether, ATM did not seem to play a major role in the repair of IR-induced 
DSBs in SCs (Fig. 33a).  
In Figure 33b, analysis of the DSB marker 53BP1 was extended to 5 days (120h) post-
IR to assess the fate of DSBs that persist (or appear) after 24h, as in Fig. 30c above.  In Atm-
proficient SCs 53BP1 foci peaked not earlier than 6h post-IR, remained high until 2 days 
post-IR, then slowly decreased in number and returned to control levels by 5 days post-IR 
(Fig. 33b), indicating that 53BP1 is implicated in the late repair of DSB, in agreement with 
the literature (Goodarzi, Jeggo et al. 2010). A similar profile was observed in Atm+/- cells 
whereas, surprisingly, in Atm-/- SCs the number of 53BP1 foci/cell kept increasing until 2 
days post-IR, and at a larger extent than in the presence of Atm. After 24h the number of foci 
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decreased and by 5 days post-IR they almost returned to control levels, indicating that the 
repair of certain DSBs was not finalized earlier than 48h post-IR in these cells. 
 
Figure 33. 53BP1 intervenes in late repair of DSB in SCs and independently of activation by ATM. 
DSB repair markers in irradiated (IR) and non-irradiated (non-IR) Atm proficient (Atm+/+ and Atm+/-) 
and Atm deficient (Atm-/-) SCs. a) Representative images of individual SCs immunostained for gH2AX 
(red), nuclei are counterstained with Hoechst (upper panels), and enumeration of foci/cell (lower 
panels). b) Representative images of individual SCs immunostained for 53BP1 (red), nuclei are 
counterstained with Hoechst (upper panels) and enumeration of foci /cell (lower panels). Left: Atm+/+, 
center: Atm+/-, right: Atm-/- SCs. 50-150 cells per condition, mean ± SEM. Scale bar =10µm. SC were 
isolated by FACS and irradiated in vitro after seeding. n=3; n= 50-150 cells analysed/condition. 
Altogether, late repair of IR-induced DSBs in SCs seems to a large extent independent 
of ATM. Notably, 53BP1 intervenes in the repair of residual damage after 48h from 
irradiation, and is implicated in a larger number of events when ATM is absent. Thus, in a 
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fraction of DSBs 53BP1 appears independent from ATM activity. As we have seen above, the 
presence of 53BP1 becomes relevant to DSBs in cycling cells. 
DSB repair efficiency is correlated to stemness in subpopulations of SCs 
 SCs can be split into 3 sub-populations depending on the expression level of the Pax7 
(stemness) gene: Pax7high, Pax7mid and Pax7low SCs (Rocheteau, Gayraud-Morel et al. 2012). 
Several studies have shown that SC subpopulations display a variety of distinct 
characteristics, e.g. metabolic state, stemness, resistance to stress (Latil, Rocheteau et al. 
2012, Ricchetti 2016, Sutcu and Ricchetti 2018). Importantly, Pax7high (highest levels of 
Pax7) are more stem-like and enter the first mitotic cycle later, whereas the Pax7low 
population (lowest levels of Pax7) is more prone to commit to differentiate (Rocheteau, 
Gayraud-Morel et al. 2012).  
To assess whether the efficiency of DSB repair is correlated with stemness of SCs, 
three sub-populations of SCs have been FACS-isolated from Tg:Pax7nGFP mice. These SCs 
sub-populations consisted of: 10% with the lowest GFP (Pax7-GFP) intensity (Pax7low), 65% 
with intermediary intensity (Pax7mid) and 10% with the highest (Pax7high) intensity of GFP, 
which should correlate with Pax7 levels in these cells (Figure 34). The remaining 15% of SCs 
were compromised between each two sub-populations and were excluded to avoid 
contaminations among sub-populations. These cells, as well as non-irradiated controls, were 
fixed at 1h, 4h, 6h, 28h, 48h and 55h post irradiation (5 Gy), and analysed with 
immunofluorescent DSB repair markers 53BP1, γ-H2AX. 
The plots of γ-H2AX foci over time reveal that SC sub-populations respond with 
different intensity to IR-induced DSBs, with globally more rapid disappearance of foci the 
higher the level of Pax7, and thereby the “stemness” of the SCs (Fig. 34b). This is the case for 
the early phases as well as for the later phases of repair. It can be argued from these data that 
the Pax7high population, is either more protected from DSBs or repairs DSBs more efficiently 
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than the other subpopulations (Pax7mid to Pax7low). The initial number of foci (at 1h) is indeed 
lower for Pax7high SCs than for the other populations, indicating either a lower number of 
DSBs, or a faster repair (foci disappearance) earlier than 1h. In this context however, previous 
experiments of comet assay in the lab had shown that SCs and activated myoblasts displayed 
the same extent of DSBs shortly upon irradiation, despite different levels of DSB repair 
markers (Vahidi Ferdousi, Rocheteau et al. 2014), suggesting that indeed the foci number is 
rather correlated with repair DSB repair efficiency.  
Despite quantitative differences, however, the repair profiles looked very similar 
among the three SC populations, see for instance a persistent increase in foci number at 4h 
post-IR, suggesting that the same repair pathways and regulation are operating in all cells. 
This is also the case in the absence of irradiation since the three SC populations show a slight 
increase up to 5 γ-H2AX foci/cell, from 28h until 55h, compatible with cell activation and 
cell cycle entry (Fig. 34b) (see also Fig. 32a, b).   
Figure 34c shows a similar profile as for γ-H2AX foci and 53BP1 foci with higher 
repair efficiency (or more efficient foci disappearance) for the cells with the highest levels of 
Pax7. 
These data show that indeed SCs with the highest stemness potential also better repair 
radiation-induced DSBs, a finding that may have implications for therapeutic and regenerative 
approaches. 
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Figure 34. DSB repair efficiency is correlated with the stemness potential of different SC 
subpopulations. a) Gates used for FACS sorting SCs with Pax7high, Pax7mid, and Pax7low levels by 
GFP signal. DSB repair efficiency evaluated by disappearance of immunofluorescent the DSB repair 
markers, b) γ-H2AX and c) 53BP1. Foci enumeration of Pax7high (black), Pax7mid (blue), and Pax7low 
(red), SC populations with or without irradiation. Mean ±SEM n=3-5 mice / condition, 50-150 cells / 
condition. Significance by unpaired T-test, *≤0.05, **≤0.01, ***≤0.001. Sigficance Pax7high vs Pax7low 
indicated by “*”, Pax7high vs Pax7mid indicated by “$” and Pax7mid vs Pax7low indicated by “t”. 
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Discussion 
 Genomic integrity is very important for all cells and in particular for stem cells, which 
are responsible for the generation of a large progeny. Several studies have analyzed the fate of 
stem cells upon DNA damage in the context of proficient or impaired DNA repair. DNA 
double-strand breaks are perhaps the most severe type of DNA damage. Impaired DSB repair 
can cause genomic instability, one of the most dramatic event being chromosomal 
translocations, cell cycle arrest, and apoptosis (Hakem 2008). Genomic instability generated 
by impaired non-homologous end-joining (NHEJ) during V(D)J recombination in B- and T-
cells at the stage of stem or progenitor cells, in the absence of p53, is a major initiating event 
in the development of cancer of blood cells (Sishc and Davis 2017). Moreover, highly active 
and aberrant NHEJ plays a role in genomic instability, and may induce cancers such as 
colorectal cancer (Sishc and Davis 2017).  
Different types of stem cells have been reported to face DNA damage with a variety of 
mechanisms that include susceptibility to undergo DNA damage, efficiency of repair, and 
choice of the DSB repair pathway (homologous recombination, classic-NHEJ, alternative-
NHEJ) (Blanpain, Mohrin et al. 2011). As a consequence of this response the fate of stem 
cells can be affected, for instance by undergoing premature differentiation. Finally, these 
events may affect tissue renewal, of which adult stem cells are responsible. 
Impact of impaired DSB repair proteins on myogenic cell fate 
 In the context of the importance of genomic integrity and the diversity of DSB repair 
response in stem cells, during this project I investigated the impact of impaired DSB repair on 
viability, proliferation, and differentiation of adult muscle stem cells (SCs) in mice. DNA 
damage repair and muscle differentiation seem to be linked by special ties. Indeed, previous 
studies have shown that upon genotoxic stress the myogenic factor MyoD fails activating 
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transcription of downstream muscle genes, since it is inhibited by c-Abl phosphorylation 
during G1 arrest, whereas chromatin modifications during the G2/M inhibit MyoD occupancy 
of target genes (Simonatto, Giordani et al. 2011). These authors also suggested a DSB repair-
stimulating role of MyoD during the S-phase of myogenic cells (Simonatto, Marullo et al. 
2013). 
 In the present study, the SCs fate was assessed in the presence and in the absence of 
radiation-induced DSBs, and repair was impaired with specific inhibitors (ATMi, DNAPKi, 
PARP inhibitors), or silencing of repair proteins, or using mutant mice. In agreement with 
efficient and accurate repair of radiation-induced DSBs (Vahidi Ferdousi, Rocheteau et al. 
2014), upon irradiation SCs and the myogenic C2C7 cell line continued proliferating and 
successfully differentiated, although both events were delayed compared to non-irradiated 
cells, as expected because of temporary the cell cycle arrest upon irradiation to provide time 
for the repair of DNA damage (Puri, Bhakta et al. 2002) (Simonatto, Giordani et al. 2011). 
Treatment with the DSB repair inhibitors, ATMi, DNAPKi, or with different PARP inhibitors 
(Olaparib and Veliparib), resulted in distinct effects on myogenic cell fate for each inhibitor 
upon irradiation and, surprisingly, also without. Indeed, these inhibitors also affected the 
myogenesis at the level of cell proliferation or differentiation or both. I summarize these 
effects below. 
ATM 
  SC cells treated with ATMi (ATM inhibitor) at different stages of myogenesis 
revealed that ATM affects distinct myogenic populations, and in a specific manner. Indeed, 
irradiated Pax7+ SCs cells treated with ATMi were severely affected in proliferation and 
almost blocked in differentiation 5 days later, due to impaired DSB repair. When 
exponentially proliferating myogenic cells, therefore at later stages of myogenesis (i.e. 
committed to differentiate), were treated ATMi did not affect undifferentiated cells (MyoD+), 
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but rather impaired differentiation (reduced number of Myogenin+ and MHC+ cells, reduced 
fusion index that measures the size of newly formed myotubes) in a dose-dependent manner. 
Therefore, in the presence of DNA damage, SCs were affected at a larger extent than late 
myogenic cells, and in both cells differentiation was more affected than proliferation. 
Altogether, these data indicate that ATM plays a role in DSB repair of cycling myoblasts.  
 Surprisingly, the ATM inhibitor affected myogenesis, in a dose-dependent manner 
also in the absence of irradiation. Impaired progression to differentiation was observed upon 
irradiation of SCs as well as late committed myoblasts, suggesting that ATM plays a role in 
myogenesis. These effects were exacerbated in C2C7 cells.  
The effects of ATMi were apparently confirmed with Atm+/- and Atm-/--derived SCs, 
where terminal myogenic differentiation (MHC+ cells, myotube formation) was delayed or 
reduced, respectively, compared to Atm+/- SCs, which also indicates an ATM dose-dependent 
effect. Interestingly, Atm+/- and Atm-/- derived SCs displayed similar reduction in 
differentiation upon irradiation, suggesting that myogenic cells require full doses of ATM to 
ensure radiation-induced DSB repair. Although very interesting, results with SCs derived 
from ATM proficient or ATM deficient mice need to be confirmed by experiments with a 
larger number of mice. 
 The principal role of ATM is considered to date its kinase activity in DNA damage 
repair as a sensor of DSBs. However, ATM is a PI3K-related kinase (like ATR and DNA-
PKcs) that actually controls the global DNA damage response and is implicated in several and 
diverse functions, such as the establishment and maintenance of checkpoint proteins during 
the cell cycle, response to oxidative stress, insulin-dependent responses (Ditch and Paull 
2012, Ching, Spears et al. 2013). In some studies, ATM has been shown to be involved in 
upregulation of Akt kinases in response to IGF1. Additionally, it has been suggested that 
ATM plays a role on fast glycolytic muscle type. Indeed, ATM was linked to glucose 
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transport in glycolytic myofibers through full activation of Akt kinases, and also influencing 
AS160 phosphorylation downstream of Akt. Phosphorylated AS160 prevents GLUT4 (insulin 
regulated glucose transporter) extocytosis (Ching, Spears et al. 2013). Moreover, it has been 
shown that Akt phosphorylation is stimulated by ATM in cancer cells. In this case, ATM 
induces Akt-dependent anti-apoptotic response as well as cell cycle progression (Li and Yang 
2010). 
 It is thus possible that defective myogenic differentiation when ATM is impaired is 
linked to cell cycle progression and anti-apoptotic regulation of myogenic cells. Moreover, 
ATM may be involved in in glucose transport during differentiation of muscle cells.  
PARPs 
 PARPs are chromatin modifiers that also act in alternative DNA damage repair 
pathways (Ciccia and Elledge 2010). It was suggested that the PARP activity is also required 
for efficient ATM-dependent repair (Aguilar-Quesada, Munoz-Gamez et al. 2007). 
Additionally, PARP has a function in alternative NHEJ repair, which also repair DSBs. 
Consequently, PARP inhibition (for instance by anti-cancer drugs) induces DNA-PKcs 
phosphorylation and thus promotes c-NHEJ instead of homologous recombination repair 
(O'Sullivan, Moon et al. 2014).  
 Veliparib and Olaparib are the PARP inhibitors (PARPi) used here for the analysis of 
the fate of myogenic cells. Although these inhibitors target the same PARP1 and PARP2 
proteins, these inhibitors have distinct effects. Indeed, in addition to inhibiting PARP, 
Olaparib induces mitotic arrest in a p53-dependent manner by promoting accumulation of 
phosphorylated Chk1 (checkpoint kinase 1) protein and inducing S-G2 phase cell cycle arrest, 
observed in several cancer cell lines (Jelinic and Levine 2014). Consequently, we observed 
mitotic arrest of myogenic cells (C2C7 and SCs), independently at which myogenic stage the 
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treatment was administered. Residual cells were nevertheless able to proceed to 
differentiation and also fuse into myotubes. 
 Conversely, Veliparib treatment essentially did not affect cell cycle progression of 
myogenic C2C7 cells, either treated shortly after seeding or at later stages in culture. 
However, proliferation of SC-derived cells was dramatically reduced by Veliparib, in a dose-
dependent manner. Despite reduction in cell number, C2C7 and SC-derived cells were able to 
progress well into differentiation, as observed by expression of MHC and fusion into 
myotubes. Interestingly, this was also the case for irradiated cells treated with Veliparib, 
whereas residual cells treated with Olaparib displayed strongly reduced differentiation 
markers. 
 Interestingly, reduced myotube fusion in the presence of ATMi was rescued to a 
certain extent upon combined treatment with Veliparib. This result suggests that inhibition of 
PARP induces differentiation and myotube fusion, which could be linked to PARP down-
regulation observed in C2C12 cell line during differentiation (Olah, Szczesny et al. 2015). 
 It is difficult to decipher the role of PARPs on myogenesis, since these PARP 
inhibitors are not specific for a given PARP, but block the activity of the PARP family. It has 
been indeed shown that PARP1, PARP2, and PARP3 have diverse functions during DNA 
damage repair (Beck, Robert et al. 2014). Additionally, PARP proteins are not only chromatin 
modifiers, but play also a role in several metabolic activities, and are competitors for NAD+ 
stocks in the cell (NAD+ is required for generating ADP-ribose units, that are a substrate of 
PARPs catalytical activity). The competition on NAD+ consumption does in turn affect the 
activity of the sirtuin (SIRT) family, that are NAD+-dependent protein deacetylases  playing a 
crucial role in metabolic activities, oxidative stress responses, and redox balance (Canto, 
Sauve et al. 2013). In this context, SIRT1 has been shown to be implicated in myogenesis 
(Hong, Kim et al. 2014). Further studies are thus necessary to understand how myogenesis is 
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modulated by PARPs, which should also take into account metabolic factors. These data 
nevertheless help linking PARP with myogenesis. 
 DNA-PKcs 
 The most severe phenotype of DSB repair inhibitors on myogenic cell fate was 
observed in the presence of the DNA-PKcs inhibitor, NU7441, and I have studied this event 
in more detail. DNAPKi was expected to affect to some extent myogenesis upon irradiation, 
since all cells are affected by impaired DSB repair. We indeed showed that myogenesis is 
severely affected in irradiated myogenic cells treated with DNAPKi, with reduction of 
proliferation and blockage of differentiation.  
 Surprisingly, DNA-PKcs inhibition reduced to some extent proliferation (cell 
number), and severely blocked C2C7 and SCs differentiation (almost no Myogenin+ cells) 
also in the absence of irradiation. DNAPKi-treated cells did not show a significantly larger 
number of gH2AX or 53BP1 foci (DSB markers) than non-treated cells, suggesting that this 
effect was not due to replication-dependent DNA damage. Additionally, EdU 
immunolabeling, in combination with gH2AX foci analysis, confirmed that at the time of 
treatment, cells were not cycling. This double EdU/gH2AX labeling also suggested that 
cycling (and therefore SCs activation) was delayed in the presence of DNAPKi, possibly 
explaining the lower number of cells in the next time points.   
 DNAPKi treatment at later phases of myogenesis on proliferating MyoD+ cells and on 
essentially confluent committed cells (presence of some Myogenin+ cells), at 2.5dps and 
4.5dps, respectively, also blocked differentiation of myogenic cells. This result shows that 
impaired differentiation in the presence of DNAPKi was a bona fide inhibition event and was 
not due to poor cell density because of impaired proliferation. Indeed myogenic 
differentiation in vitro, in particular at the later phases, requires cell density. Thus, these 
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results raise the question whether DNA-PKcs is implicated in myogenesis independently of its 
role in DSB repair.  
 To identify the role of DNA-PKcs in myogenesis, we first demonstrated that DNAPKi 
blocks the expression of Myogenin, whereas a general PI3K inhibitor had only a minor effect, 
thereby showing a DNA-PKcs specific inhibition of myogenesis at its earlier step. Cells 
retained the MyoD marker, indicating that myoblasts were essentially unaltered.  
Inhibition of Akt blocks myogenic differentiation in a DNA-PKcs-dependent manner 
I then investigated the function of DNA-PKcs as a PI3K-like kinase. It has been 
shown that DNA-PKcs phosphorylates Akt kinases in cancer cells (Stronach, Chen et al. 
2011) and in HEK293 cells (Feng, Park et al. 2004). We observed that inhibition of Akt also 
resulted in repressed Myogenin expression in C2C7 and SC-derived cells, suggesting that Akt 
and DNA-PKcs act on the same pathway(s) in myogenesis. We then assessed the levels of 
Akt and phosphorylated Akt (p-Akt) during myogenesis. Our data show that in the presence 
of DNAPKi, and to a much lesser extent of a general PI3K inhibitor, not only the levels of 
Akt1 and Akt2, but also their phosphorylated forms p-Akt, in particular p-Akt2, were strongly 
reduced in parallel with blocked expression of Myogenin. Reduction of Akt2 and p-Akt2 was 
particularly interesting since this kinase plays a role during differentiation in myogenesis. 
 We confirmed the role of DNA-PKcs in the expression of Myogenin and Akt 
activation by lentiviral silencing DNA-PKcs in SCs that, as predicted, resulted in blocked 
Myogenin expression and diminished expression of Akt and their phosphorylated forms. 
Reduction of Akt and p-Akt was directly correlated with the silencing efficiency of the 
different clones. Differently from inhibition of DNA-PKcs in C2C7 cells, silencing of DNA-
PKcs in SCs particularly affected p-Akt1 levels. Silencing of Akt1 and Akt2 that displayed 
higher and lower levels of DNA-PKcs, respectively, than in controls did not repress 
Myogenin expression, in contrast with C2C7 cells upon Akt inhibition. These data confirm 
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that inhibition of DNA-PKcs is responsible for repressed Myogenin expression, in a Akt-
dependent manner, although the distinct role of Akt1 and Akt2 is not clear yet.  
 As mentioned earlier, regulation of Akt2 in myogenesis has not be clearly elucidated, 
except the implication of Akt2 phosphorylation mediated by mTORC2 (Shu and Houghton 
2009), a key regulator of cellular metabolism. Compatibly with the finding that DNA-PKcs 
overexpression induces mTORC2-mediated Akt activation in renal cell carcinoma (Zheng, 
Mao et al. 2016), I suggest that DNA-PKcs plays a role in regulation of the Akt2 kinase 
during myogenic differentiation, either through mTORC2 or via direct interaction (Fig. 35). 
 
Figure 35. Schematic representation of the roles of DNAPK-cs in DSB repair by NHEJ and 
myogenesis. a) Prevalent role of DNAPK-cs as an essential protein in NHEJ. DNA-PKcs forms a 
complex with Ku70/80 heterodimers and initiates NHEJ repair. DNA-PKcs and Akt1/2 interact at 
multiple levels and the presence of both Akt1 and Akt2 is necessary for NHEJ b) Model for DNA-PKcs 
in myogenesis independent of induced-DNA damage (this study). DNA-PKcs, instead of classical PI3K 
or PDK1, regulates and activates Akt2 (hatched red arrow). It is not known whether DNA-PKcs 
directly activates (phosphorylates) Akt2 or requires an intermediary kinase, perhaps mTORC2, (see 
text). 
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In a recent study, DNA-PKcs has been implicated in DNA damage-dependent, 
caspase-dependent myogenic differentiation (Connolly and Fearnhead 2016). This study 
suggested that DNA-PKcs plays a role in H2AX phosphorylation, due to caspase-dependent 
DNA fragmentation during myogenesis. Such DNA fragmentation has been reported earlier, 
based on gH2AX immunostaining, to rely on caspase-dependent DNase activity during 
myogenesis (Larsen, Rampalli et al. 2010, Connolly and Fearnhead 2016). In this study 
(Connolly and Fearnhead 2016), inhibition of DNA-PKcs lowered the gH2AX signal, 
suggesting a correlation between DNA-PKcs and caspase-induced DSBs during 
differentiation. It has been also shown that in the absence of caspase 3 activity (by a specific 
inhibitor or the use of a caspase 3 mutant mice), or in the presence of a DNA-PKcs inhibitor, 
the myogenic cell fusion was severely affected (Fernando, Kelly et al. 2002, Connolly and 
Fearnhead 2016).  
In those studies differentiation was mainly assessed by MHC levels and fusion 
capacity, thereby towards the end of myogenesis, where the key early differentiation marker, 
Myogenin, cannot be assessed (Connolly and Fearnhead 2016) (Larsen, Rampalli et al. 2010). 
However, the report of Fernando et al. showed Myogenin expression in the absence of 
caspase 3 activity, in condition of compromised fusion of myogenic cells (Fernando, Kelly et 
al. 2002). This result shows that caspase 3-dependent DNA fragmentation that promotes 
histone H2AX phosphorylation and DNA-PKcs response does not affect Myogenin 
expression, and therefore does not block differentiation at the earliest step. Caspase3-induced 
block of myogenesis seems therefore acting on successive MHC and fusion phases, 
depending on the gH2AX signal.  
 Conversely, in our case (results in Chapter I) show that DNAPKi treatment blocks 
Myogenin expression, therefore upstream of the intervention of caspase 3 activity (Fernando, 
Kelly et al. 2002).  This result uncouples the notion of DNA-PKcs activating differentiation in 
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a caspase-dependent manner (Connolly and Fearnhead 2016). Additionally, it should be noted 
that analysis of the DSB marker gH2AX alone, as it has been done in the abovementioned 
studies, is not sufficient to exclusively demonstrate endogenous DNA damage, since the 
histone H2AX is phosphorylated also in response to other events than DSBs, namely as 
mitotic progression, UV stress, cellular senescence, serum starvation (Tu, Li et al. 2013) 
(Turinetto and Giachino 2015) (Gagou, Zuazua-Villar et al. 2010) (McManus and Hendzel 
2005). 
Finally, in most of these studies myogenic differentiation has been performed in 
serum-starved differentiation medium, a stress-related condition that could be responsible for 
increased gH2AX signal, due to bona fide DNA damage, rather than myogenic 
differentiation. Indeed, it has been shown that serum starvation induces p38-dependent H2AX 
phosphorylation (Lu, Shi et al. 2008). We thus believe DNA-PKcs activation of caspase 3 
plays only a minor role in myogenesis. 
Delayed but not arrested myogenesis in SCID mice 
It has been previously shown that the regeneration capacity of SCs derived from mice 
with different genetic backgrounds may vary depending on the genetic background (Fukada, 
Morikawa et al. 2010). To correctly assess the regeneration capacity of SCID mice without 
reasonable interferences from the genetic background, we used corresponding WT mice with 
the Balb/c background as controls for experiments with SCID mice. For comparison, 
experiments in the presence of DNAPKi or upon DNA-PK-cs silencing were performed in 
SCs isolated from the B6D2 background or with the C2C7 cell line.  
Although inhibition and silencing of DNAPK-cs activity severely affected myogenesis 
in WT SCs, naturally mutated DNAPK-deficient (SCID) mice yet do develop muscles. Our in 
vitro analysis shows slight but significant defects in differentiation of SCID-derived SCs, 
namely delayed delayed myotube formation and reduced number of MHC+ cells by ≈10%. 
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Defects were also observed in vivo, where regeneration of injured TA muscle resulted in 
altered surface size and fiber number (see below) but also a higher number of renewing SCs, 
as well as MHC+ and Myogenin+ cells compared to the respective WT, five days post-injury. 
Increased number of myogenic and differentiated cells in regenerating TA may result 
from hyperactivity or, alternatively, delayed regeneration in SCID in agreement with in vitro 
data. A higher number of renewing SCs, MHC+ and Myogenin+ cells at 5dpi in SCID is 
compatible with some regeneration delay, based on an established scheme of the kinetics of 
myogenic markers during regeneration marker (Murphy, Keefe et al. 2014) (Fig. 36a).  
 
Figure 36. Schematic representation of regeneration kinetics and muscle structure of injured WT 
and SCID TA muscle. a) Representation of the kinetics of regeneration markers from day 1 until 28 
days post injur, based on an established representation of WT muscle (modified from Murphy et al. 
2014 (Murphy, Keefe et al. 2014)). Regeneration in SCID is added from the present study. Green 
curves stand for Pax7+ SCs, black curves stand for Myogenin+ differentiating cells, and red curves 
stands for eMHC+ multinucleated regenerating fibers. Straight lines, referring to WT mice, show that 
all markers peak between 4-5 days post injury and start to decline by the 5th day. Dotted lines, 
referring to SCID mice, indicate that this profile shifts to the right, since all myogenic markers at 5 
dpi are higher than the corresponding ones in the WT. b) Scheme of cross-sectional area of uninjured 
and injured TA muscle from WT and SCID mice. Orange circles represent individual fibers. The 
scheme aims to summarize the differences in fiber number and size in all conditions, and is not at 
scale. 
Indeed, uninjured SCID TA contains a lower number of fibers but of larger surface 
area compared to WT TA (Fig. 36b), despite the two TAs having similar sizes (not shown). 
Five days post injury the size of fibers decreased and their number increased in all cases, as a 
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result of the ongoing regeneration process. However, despite having the a similar size (not 
shown) regenerating SCID TA contains a larger number of fibers, which are also smaller in 
size, than the WT revealing different dynamics of regeneration at the macroscopic level in the 
SCID muscle (for a summary, see Fig. 36b). 
The TA muscle of SCID mice at 29dpi contains more fibers, and of slightly larger 
surface than WT TA (with similar TA cross-sectional surface in both muscles), indicating that 
the defective TA structure observed during early regeneration was maintained.  
We also challenged the regenerative capacity of SCID mice with multiple injury 
events. Analysis of TA parameters after a single, or 2, or 3 successive injuries (at an interval 
of 29 days form each other to allow each time full muscle regeneration), revealed that SCID 
mice have different regeneration dynamics and end-products compared to WT.  Indeed, while 
the WT TA increased in size after the 2nd injury, and maintained larger size after the 3rd 
injury, the size of SCID TA remained essentially unchanged after 3 injuries, finally resulting 
in larger TA in the WT (than SCID) at the end of the triple regeneration experiment. 
 
Figure 37. Changes observed upon repetitive injury in WT and SCID TA muscle. a) Summary of 
changes observed upon repetitive injury in WT and SCID TA muscle (measured per mm2) and b) 
Scheme of cross-sectional area of 1 time injured and 3 times injured TA muscle from WT and SCID 
mice. Orange circles represent individual fibers. The scheme aims to summarize the difference in fiber 
number and size in all conditions, and is not at scale. 
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After three muscle injuries, WT TA maintained the same number and size of 
fiber/mm2 in all conditions (Fig. 37). Conversely, SCID TA contained a higher number of 
fibers, and of smaller size than after the 1st injury. Interestingly, also the number of Pax7+ SCs 
kept increasing in SCID after repetitive injury, whereas it did not change in the WT. 
Altogether these data show that initial alterations were maintained and exacerbated upon 
repetitive injury in SCID muscle.  
Thus, delay in muscle regeneration of SCID was exacerbated after repetitive injury.  
Two main scenarios can be deduced from these results. Either repetitive injury leads to SC 
exhaustion in SCID mice, and these cells fail differentiating while increasing in number, or 
DNAPK-cs deficiency promotes SC self-renewal. Relevant to our findings, another study has 
shown that after repetitive injury, Notch3 deficient mice display accumulation of Pax7+ SCs, 
as SCID mice did after regeneration in our experiments, although in the other study this 
accumulation occurred in the context of muscle hyperplasia (Kitamoto and Hanaoka 2010), 
which was not the case in our experiments, as we have detailed above. It is thus possible that 
in addition to regulating Akt2 during differentiation, DNA-PKcs is also involved in the Notch 
signaling pathway, which plays a crucial role during cell activation and cell fate choice 
(Mourikis and Tajbakhsh 2014). In this context, in neural stem cells, inhibition of DNA-PKcs 
upregulates the expression Notch-targeted genes that change stem cell fate during brain 
development (Hunt, Fabb et al. 2013). 
Finally, to understand whether these macroscopic alterations of TA composition in 
SCID mice physiologically affect the muscle, further investigations should be done such as 
measuring the physical strength of the regenerated muscle. Additionally, mechanistic 
information could be provided by in vitro proliferation and differentiation analysis of SCs 
isolated after repetitive injuries, as well as isolated myofibers in culture, to assess the 
proliferation and self-renewal capacity of SCs.  
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Despite small regeneration defects in SCID mice, demonstrated above, may on the 
long-term affect muscle function, SCID mice successfully regenerate the muscle despite the 
DNA-PKcs deficiency. These results suggest that DNAPK-deficient mice rely on an 
alternative mechanism, which compensates the role of DNAPK-cs in the regulation of Akt 
kinases in myogenic differentiation, and technically in promoting the expression of 
Myogenin. Members of the PI3K family are good candidates since insulin, that activates 
PI3K, partially rescues Myogenin expression in DNA-PKcs-inhibited cells. Moreover, we 
showed that PI3Ki (ZST474) to some extent reduces Akt2 phosphorylation and myogenic 
levels. However, despite ZST474 differently from other PI3K inhibitors is poorly active on 
DNA-PKcs, we cannot fully exclude at this stage that the effect observed in cells treated with 
ZST474 is due to DNA-PKcs inhibition (Kong, Yaguchi et al. 2009).  
It is also possible that defective myogenesis observed upon DNA-PKcs-inhibition and 
silencing in WT cells differs from SCID myogenesis due to the type of mutation in these mice 
(Bosma, Custer et al. 1983). Indeed, DNAPK deficiency in SCID mice is due to a point 
mutation (Tyr-4046) that generates an early termination codon, and thereby a truncated 
protein at the extreme C-terminus, leaving the PI3K domain intact but abolishing the kinase 
activity (Beamish, Jessberger et al. 2000). The missing domain is suggested to responsible for 
the stability and/or the folding of the protein. Indeed, the transcript levels of DNAPKcs 
(PRKDC) are similar in WT and SCID mice, but the protein levels are negligible in SCID 
mice (Araki, Fujimori et al. 1997) (Blunt, Gell et al. 1996), suggesting rapid and efficient 
protein degradation in the mutant. It has been also suggested that the phenotype is leaky since 
some young adults and almost all aged SCID mice recover from immunodeficiency (Bosma 
and Carroll 1991).  Thus, although DNAPK-cs is not detected in SCID mice, likely for the 
large instability of the protein (Blunt, Gell et al. 1996), it is possible that DNAPK-cs is 
translated and manages to some extent regulating Akt2 or other downstream effectors during 
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myogenesis (through kinase-independent activities), within the short time frame before its 
degradation.  
SCID mice are a common model for the muscle dystrophy and transplantation studies. 
For example, SCID/mdx mice are both immunodeficient due to DNA-PKcs deficiency and are 
also a model of muscular dystrophy due to mutation in the dystrophin gene (DMD, Duchenne 
muscular dystrophy). The immunodeficiency of these mice allow them to be a good reciepent 
for the transplantation experiments, thereafter most studies are concentrated on the effects of 
immunodeficiency over muscle regeneration, either by assessing the transplanted cells 
derived from WT mice or human (Pisciotta, Riccio et al. 2015), or focusing on inflammation 
(Grabowska, Mazur et al. 2015) or fibrosis during regeneration of the injured muscle (Farini, 
Meregalli et al. 2007). Although SCID mice remain a good model for many studies, I have 
shown here that not only immunodeficiency, but also other defects due to impairment of 
DNA-PKcs should be considered in the final readout, in particular when assessing muscle 
regeneration. Indeed, the role of DNA-PKcs directly in myogenesis should be also taken into 
account in such scenarios. 
Radiation-induced DSB repair in myogenic cells 
As expected, viability of irradiated SCs and C2C7 cells and their capacity to repair 
radiation-induced DSBs were strongly ablated upon impaired DNAPK-cs activity, as shown 
by clonogenic assay and DSB repair markers, respectively. DNA-PKcs-dependent DSB repair 
(NHEJ) in myogenic cells was confirmed in SCs isolated from DNA-PKcs-deficient (SCID) 
mice. At the time of treatment/irradiation, SCs cells were not cycling, whereas C2C7 cells 
were highly proliferative, and the prevalent DSB repair mechanism operating in cycling cells, 
homologous recombination, did not seem to play a relevant role here, despite it is involved in 
the repair of some radiation-induced DSBs (Jeggo, Geuting et al. 2011). These findings 
confirm a previous study in the laboratory (Vahidi Ferdousi, Rocheteau et al. 2014).  
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A striking response to DNA damage was the essential lack of decrease of 53BP1 foci 
in SCs until 24h post-IR, compared to the decline of gH2AX foci in the same time period. 
This was not the case for C2C7 cells that showed decline of both markers with time post-IR, 
demonstrating ongoing DSB repair. Accordingly, in the presence of DNAPKi the decline in 
gH2AX foci number was dramatically slowed down in all cells, whereas the number of 
53BP1 foci was reduced only in C2C7 cells. These data suggest that DSBs labeled by 53BP1 
persist for long-time post-IR in SCs, and even increase 6h post-IR. These results are 
consistent with reported “slow” repair for a subset of DSBs after irradiation, that may include 
those with blocked ends requiring processing, and those located in heterochromatic regions. 
These “slow” DSBs are repaired by NHEJ and require 53BP1 and the upstream ATM kinase.  
Experiments performed on SCs isolated from Atm+/+, Atm+/- and Atm-/- mice partially 
showed the expected link between 53BP1 foci and ATM, since  “slow” 53BP1 foci appear at 
a later time point in cells where ATM is impaired (at 6h in in ATM-proficient and at 24h in 
ATM-deficient cells). In this experimental paradigm 53BP1 foci persisted until 2 days post-IR 
and were finally resolved at 5 days post-IR, when ATM is present. We consider these 53BP1 
foci to be ATM-dependent and likely correspond to “slow” DSBs already described (Rappold, 
Iwabuchi et al. 2001, Riballo, Kuhne et al. 2004). 
 However, in Atm-/- SCs the number of 53BP1 foci kept increasing until 2 days post-
IR, and are dramatically reduced by 5 days post-IR, indicating a second subpopulation of 
“very-slow” DSBs that do not require ATM and are nevertheless resolved at the same time as 
the ATM-dependent events.  
Importantly, 53BP1 foci corresponding to “slow” and “very slow” DSBs are present in 
non-activated SCs (not cycling at the time of treatment). Whereas cycling C2C7 display a 
large number of 53BP1 foci 1h post-IR (“fast” repair), in agreement with the literature 
(Croke, Neumann et al. 2013), irradiated SCs and post-mitotic myonuclei in the muscle fiber 
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do not, suggesting that late 53BP1 foci are specific of non-cycling cells. In line with this 
concept, ATM-dependent (“slow”) and ATM-independent (“very-slow”) 53BP1 DSBs start 
be resolved at 48h, compatibly with the first division of isolated SCs in vitro (≈ 30h post-
seeding in the absence of irradiation, likely later upon irradiation).  
It should be noted that only “slow” DSBs require ATM, whereas the majority of IR-
induced DSBs (“fast”, ≈ 80%, normally repaired in less than 2h) does (Beucher, Birraux et al. 
2009). ATM-dependent “slow” DSBs are then repaired by NHEJ for cells in G1 or by HR for 
cells in G2. Our data point to a novel scenario, where “very-slow” 53BP1 DSBs are repaired 
by an ATM-independent mechanism in SCs. Normally 53BP1 is not recruited in growth 
arrested cells upon irradiation (Croke, Neumann et al. 2013), which also correlates with SCs 
activation and 53BP1 recruitment at later stages post irradiation. 
In SCs at 24h 53BP1 foci co-localize with Rad50 (member of MRN complex) that 
recruits ATM to DNA lesions and activates its kinase activity once there (Lee, Goodarzi et al. 
2010). Since a subpopulation of 53BP1-DSBs (“very-slow”) is ATM-independent, it is 
possible that another kinase is recruited by MRN at these DSBs, or that no such kinase is 
required. Alternatively, 53BP1 would locate at DSBs to inhibit the resection activity of Mre11 
(another member of MRN complex), and thereby inhibit HR repair. In this context, 53BP1 
also competes with BRCA1 that stimulates CtIP, and thereby HR (Escribano-Diaz, Orthwein 
et al. 2013). HR would be activated by cell cycle progression, after 24h, and 53BP1 would 
promote NHEJ instead. It is thus conceivable that in SCs 53BP1 has an ATM-independent 
role in maintaining unrepaired broken DNA ends in stand-by and protecting them from 
translocation (Rybanska-Spaeder, Reynolds et al. 2013), in the mean time ensuring NHEJ 
once cells cycle again. 
Finally, I showed that DSB repair efficiency in SCs declines with the loss of stemness, 
being the highest in Pax7high cells and the lowest in Pax7low cells, according to disappearance 
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of DSB repair markers. Although the repair profile appears similar in all SC sub-populations 
at critical points like 6h and 28h post-IR Pax7high SCs display less gH2AX and 53BP1 foci 
than the other populations, indicating more efficient DSB repair. Although we cannot exclude 
with this experiment that Pax7high SCs are instead more resistant to radiation-induced DSBs, a 
previous study in the lab showed similar exposure to DSBs for SC and SC-derived cells in 
vitro and in vivo (Vahidi Ferdousi, Rocheteau et al. 2014).  
I would also like to speculate that higher repair efficiency in the Pax7high population 
originates, at least in part, from the epigenetic conformation of these cells, that may result 
from non-random, asymmetric, chromosome segregation, an event that is quite frequent in the 
Pax7high population upon activation or self-renewal (Rocheteau, Gayraud-Morel et al. 2012) 
(Yennek, Burute et al. 2014). A more structured and protective DNA packaging, resulting 
from epigenetic asymmetry, has been indeed demonstrated in asymmetrically dividing 
Drosophila male germline stem cells (Xie, Wooten et al. 2017). 
Studing the DNA damage repair mechanism of SCs, not only helped better 
understanding how DSBs are processed in these cells compared to other myogenic/muscle 
cells, but also revealed a novel scenario in DNA damage repair that could also occur, and be 
relevant, in other (perhaps stem) cell types. Therefore these findings could also impact on 
future studies aiming to improve DNA damage repair targeted cancer therapies. 
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Conclusions and Perspectives 
These studies primarily reveal that DNA-PKcs, an essential protein in the DSB repair 
process non-homologous end-joining (NHEJ), affects myogenesis independently of its role in 
DNA repair. Following myogenesis from muscle stem cells (satellite cells) to differentiated 
muscle structures, I discovered that DNA-PKcs affects myogenic differentiation by activating 
the protein kinase Akt2. I also demonstrated that DNA-PKcs-deficient SCID mice complete 
regeneration of the injured muscle in a delayed and altered manner compared to wild type 
mice. I also dissected the dynamics and long-term consequences of these alterations on 
muscle fibers upon multiple successive regeneration events in vivo. This study also revealed 
that SCID mice rely on alternative mechanisms to activate the Akt pathway during muscle 
regeneration, likely through other PI3 kinases, a family of proteins associated to DNA-PKcs. 
The proposed role of DNA-PKcs during myogenesis through regulation of Akt 
kinases, in particular phosphorylation of Akt2, needs to be validated by showing direct 
interaction with the partner proteins. Alternatively, DNA-PKcs could activate Akt, and in 
particular Akt2, via other kinases such as mTORC2, as it was shown in renal cell carcinoma 
(Zheng, Mao et al. 2016). For this validation, immunoprecipitation experiments with DNA-
PKcs are required. Depending on the tested partners in these immunoprecipitation 
experiments, this approach may identify alternative or additional partners of DNA-PKcs than 
Akt kinase regulation. Additionally, the differentiation potential of the muscle stem cells 
could be assessed with constitutively active Akt kinases in the presence of DNAPKi. 
Moreover, to understand how the expression of Myogenin is regulated by DNA-PKcs, 
chromatin immunoprecipitation experiments targeting the Myogenin promoter should be 
performed to assess the presence of DNA-PKcs itself, or assess the levels of established 
interactors like MyoD and p300 (Simonatto, Marullo et al. 2013) upon DNA-PKcs inhibition. 
An important question that should be assessed is whether DNA-PKcs activation of myogenic 
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differentiation relies, at least in part, on endogenous DNA damage, or is essentially 
independent of DNA damage. A precise assessment of the extent of endogenous DNA 
damage before Myogenin expression, and perhaps at the level of the Myogenin locus itself 
should be performed. In this context, and also to uncouple the role of DNA-PKcs in DSB 
repair and myogenesis, other DNA repair factors such as Ligase 4 that is essential to NHEJ 
should be impaired (with functional DNA-PKcs), in the absence of irradiation.  DNA repair of 
endogenous DNA damage would be affected but not myogenesis, allowing to evaluate 
whether DNA damage repaired by DNA-PKcs is essential for muscle stem cell fate. We can 
not exclude, however, that this/these other factor(s) may also play a role in myogenesis, 
independently of DNA repair.   Several of these experiments are ongoing or planned. 
In another set of experiments I demonstrated that repair factors that signal DSB or 
initiate the cellular response to DSBs, namely the ATM kinase and the chromatin remodelers 
PARPs, also affect myogenesis independently of their role in the DNA repair process. These 
factors have distinct effect on myogenic cells proliferation and/or differentiation. These 
results gave the cue to prepare a review work on multiple functions of several DNA repair 
factors, beyond the repair process itself. 
In addition to its role in DSB repair the ATM kinases is also implicated in the 
response to oxidative stress (Zhang, Lee et al. 2018). On the contrary, PARP activity leads to 
NAD+ consumption, which has a negative effect on oxidative stress responses (Pirinen, Canto 
et al. 2014) (Olah, Szczesny et al. 2015). Therefore the impact of ATM or PARPs on 
myogenesis (as well as in other processes of interest) should be considered not only in the 
context of radiation-induced DSB repair but taking into account the other established roles of 
these factors. In particular, these additional functions may interfere with the fate of muscle 
stem cells during myogenesis. 
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Finally, to address the mechanism by which satellite cells (SCs) efficiently repair 
radiation-induced DSBs, I report that these cells repair persistent DSBs relying, at least in 
part, on an apparently novel mechanism that implies the presence of the repair factor 53BP1 
at sites of damage, without intervention of its classical activator ATM. Additionally I 
observed that the efficiency of the DSB repair directly correlates with SCs “stemness of 
distinct SC populations, with Pax7high SCs displaying the highest efficiency. 
To dissect the DSB repair mechanism of satellite cells, other DNA damage repair 
factors should also be analysed during different phases of repair, in particular during “very 
slow” repair. In this context, the ATM-independent role of 53BP1 during “very slow” DSB 
repair should be studied in more depth for instance by assessing the phase of the cell cycle in 
which 53BP1 is recruited to the DNA damage site, and also systematically evaluate the 
presence of NHEJ factors in these repair events. Furthermore, considering that 53BP1 also 
plays a role in chromatin modification, and that satellite cells display a distinct chromatin 
conformation compared to committeed cells (previous experiments in the lab, not shown, and 
epigenetic histone modifications reported at the different states of myogenesis (Segales, 
Perdiguero et al. 2015) the chromatin conformation should also be verified during fast, slow, 
and very slow DSB repair in SCs. 
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Satellite cell heterogeneity
Muscle growth during embryogenesis , and muscle 
homeostasis and replacement upon injury in the adult 
rely on muscle stem cells, referred to as satellite cells. 
Satellite cells are quiescent and become activated following 
injury. Activation results in extensive cell proliferation 
(proliferating satellite cells are called myoblasts), followed 
by myogenic differentiation and fusion of differentiated 
cells into myotubes and then myofibers that repair the 
muscle. During myotube formation, a small fraction of 
satellite cells self-renews and returns to the quiescent state, 
thereby providing a reservoir for future muscle repair. 
A single muscle myofiber contains multiple nuclei (up 
to several hundred in mice), which result from fusion of 
differentiated myogenic cells and they are post-mitotic. 
Adult myogenesis involves all phases of the cell cycle, and 
also a reversible (satellite cells) and irreversible (post-mitotic 
myogenic cells) cell cycle exit (Figure 1). In the embryo, 
where stem cells continually yield differentiating cells to 
ensure tissue genesis, muscle stem cells proliferate and 
they enter quiescence during the perinatal period in the 
mouse (1), therefore, these cells essentially explore cell cycle 
progression.
Muscle stem cells are defined by transcriptional programs 
that rely on both Pax3 and Pax7 transcription factors, the 
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former with a prevalent role in the embryo, and the latter 
from mid-embryogenesis onwards [for a review, see (1)]. 
Myogenic regulatory factors (MRFs) Myod, Myf5, Mrf4, 
and later Myogenin act sequentially to promote satellite 
cells commitment and differentiation. Although muscle 
stem cells are well characterized by the abovementioned 
transcription factors, heterogeneity of both embryonic 
and adult stem cells has been reported extensively [for 
reviews, see (2,3)]. In the embryo, the ancestors of satellite 
cells display heterogeneity in behavior including different 
proliferative rates (4), requirement for upstream specific 
transcription factors [e.g., Pax3 is not required for head 
muscle progenitors (5); extraocular and pharyngeal arch 
muscle progenitors rely on distinct regulatory factors (6)], 
commitment transcription factors [Myf5 and Myod (7); 
see also (1)]. Muscle stem cell heterogeneity persists in the 
adult where satellite cell heterogeneity has been reported 
for transcription factors and surface markers [for a review, 
see (2)], type of muscle (8), transplantation efficiency (9) 
metabolism (10), and age-dependent loss of quiescence and 
self-renewing capacity (11). 
Moreover, subpopulations of satellite cells in adult mice 
(all express Pax7) have been identified. For example, during 
homeostasis and regeneration Pax7Hi cells display more 
“stemness” properties, with higher capacity for asymmetric 
division and self-renewal during the regeneration 
process (10). A subpopulation of “dormant” Pax7+ cells has 
been also reported with capacity to survive and maintain 
full regenerative capacity in necrotic tissues after death 
in mice and humans (12). It remains unclear to what 
extent the expression levels of Pax7 correlate with post-
mortem “dormant” satellite cell populations. Pax7Hi cells 
from homeostatic muscle and those isolated from post-
mortem tissue share several properties including reduced 
mitochondrial and metabolic activity. Heterogeneity is also 
evidenced in the decline of regenerative capacity as most 
satellite cells in old mice (20–24 months of age) undergo 
permanent cell cycle withdrawal via senescence that blocks 
their proliferation capacity (13). This capacity is however 
restored in a subset of cells in the presence of rejuvenation 
factors (14), whereas this is not the case in geriatric mice 
(28–32 months of age). Nevertheless, in geriatric mice a 
subpopulation of cells re-enter the cell cycle via induction 
of autophagy (15). Thus, in adult mice, satellite cells are 
heterogeneous also in the context of quiescence and cell-
cycle exit [see also (16)].
The origins and the function of this heterogeneity 
are not clear, but it is believed that it endows satellite 
cells with a level of plasticity that is necessary to adapt to 
different needs of skeletal muscle growth, homeostasis, 
regeneration (3), and resistance to unfavorable conditions. 
More generally, stem cell heterogeneity is expected to 
maintain a range of functional capacities to face changing 
conditions and be operational under a variety of types of 
stress. It is thus counterintuitive that, at least under some 
conditions, muscle growth and regeneration would rely 
on the loss of satellite cell diversity and accentuate the 
proliferation of single satellite cells. Since heterogeneity as 
well as its loss are linked to the switch between quiescence/
re-entry in the cell cycle and proliferation/differentiation, 
Figure 1 The cell cycle and myogenesis. Cell cycle: the G1 phase 
commits cells to enter the cell cycle and prepare them to duplicate 
their DNA during the S phase. After DNA duplication, cells enter 
G2 phase that prepares for mitosis (M phase), where chromatids 
and daughter cells separate. After M phase cells can enter G1 or 
G0, the latter being non-proliferating and metabolically quiescent 
phase. In satellite cells upon exit from G0/G1, the duration of 
the first cell cycle in mice is much longer than in cycling cells. 
The length of the first cell cycle is longer in the satellite cell 
subpopulation with higher stemness, dormant properties (Pax7Hi). 
Fused nuclei that constitute the differentiated muscle cell have 
irreversibly exited the cell cycle. In the muscle fiber, a few satellite 
cells are maintained in G0 (two cells are represented in green in 
the myotube), ready to re-enter the cell cycle upon injury. In a 
variety of cells and organisms, DNA damage or adverse survival 
conditions (see text) may induce arrest at other phases of the cell 
cycle than in G0, namely in G1 or G2 (also indicated as G1/S or 
G2/M transition, respectively). This is the case for embryonic 
myogenesis in zebrafish that halts stem cells in G2 (see text). SC, 
stem cell.
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this condition is essential for understanding stem cell 
properties as well as their regenerative potential. 
The clonal drift
The “clonal drift” model implies expansion of clonally 
related stem cells and has been originally reported for 
tissue replacement by intestinal stem cells in the adult 
and later in other tissues and organisms. Unlike other 
mammalian tissues, the stem cells of the intestine are 
strictly compartmentalized in crypts, and the cellular 
progeny remain associated with the stem cell compartment 
of origin. Crypts then drift toward clonality. According 
to the prevalent model, adult intestinal stem cells (Lgr5hi) 
divide symmetrically, and stochastically one of them 
adopts a stem cell fate (the other proliferates/differentiates 
following transit amplification) (17). This process results in 
the stochastic loss of stem cell properties in one case, and 
expansion of the progeny in the other, eventually leading to 
a pool of clonally related stem cells that replenish the entire 
stem cell population. At the population level, clones expand 
and contract at random until they either take over the crypt 
or are lost, and finally stem cell loss is compensated by 
proliferation of the neighbor, with a concomitant increase 
of clonality (18). This mechanism is retained also for 
homeostasis of the fish intestine (but not in other tissues), 
suggesting that the mode of stem cell division is not 
species-specific but is instead characteristic for the stem cell 
type (19). In an experimental paradigm in the mouse, it has 
been shown that when competition involves wild type versus 
mutant cells with an accelerated division rate (dependent on 
the oncogene K-ras), this process results in clonal expansion 
of crypts carrying the oncogenic mutation, with potential 
implications for cancer development (20). 
Stem cell loss and replacement, apparently at random, 
has been also shown as a mechanism for niche occupancy of 
epithelial follicle stem cells (FSCs) in the Drosophila ovary 
during normal homeostasis (21). In this case, establishment 
of cell polarity is an important early differentiation 
event and FSCs that maintain immature polarity have 
an advantage in occupying the niche. Reduced clonal 
complexity leading to clonal drift in muscle stem cells has 
been recently reported only following successive injuries 
and tissue repair events in adult mice, but not during 
ageing (22). This impoverishment of stem cell diversity, 
however, did not lead to an apparent reduced regeneration 
capacity, at least in young mice. In other contexts, reduction 
of the clonal diversity has been associated with non-
beneficial outcomes. For instance, somatic mutations 
drive clonal expansion of cells in tumors. However, the 
size of clonal expansion does not necessarily correlate 
with the capacity of inducing malignant transformation in 
skin (23), and somatic mutations leading to clonal 
outgrowth in hematopoietic cells are frequent in the general 
population, the majority of which does not develop blood 
cancers (24). 
Clonal drift has been poorly investigated during 
embryogenesis. This condition is of particular interest 
because during organ growth there is a continuous need for 
cellular differentiation and repopulation of active stem cells. 
Some studies suggest that clonal dominance is a recurring 
mechanistic strategy to help shape vertebrate organs. 
In zebrafish, it was reported that about eight dominant 
cardiomyocytes in the embryonic ventricle contribute to 
building the adult cortical myocardium (25), and more 
generally a few lineages contribute to the formation of 
most adult organs (26). A recent study by Nguyen et al. (27) 
directly addresses this topic, and also provides a mechanism 
that drives clonal drift in the developing muscle in zebrafish. 
Using a muscle-specific fluorophore maturation assay 
that relies on two fluorophores with different maturation 
rates, they identify fiber ages during growth, and combine 
this analysis with morphometric measurements. They 
show that muscle stem cells undergo clonal drift, and the 
majority of muscle fibers in the adult are generated from 
a limited number of stem cells. Thus, initially multiple, 
independent stem cells contribute to fiber generation, 
whereas after successive self-renewal events, a single stem 
cell clone dominates growth in individual myotomes. As 
in the cases of homeostasis in the adult described above, 
also homeostasis during muscle growth appears to occur 
randomly. Importantly, Nguyen et al. showed that the 
clonal drift is controlled by the homeobox protein Meox1 
that inhibits the cell cycle checkpoint gene ccnb1 halting 
stem cells in G2 phase, whereas the other cells undergo 
proliferation and differentiation (Figure 2). 
Meox1 is a homeobox transcription factor that together 
with Meox2 regulates the development of somites that give 
rise to the sclerotome, dermomyotome and myotome (28). 
Meox1 impairment alone affects the sclerotome. Meox1 
also plays a role in the commitment of the skeletal muscle 
lineage (29). Interestingly, in endothelial cells Meox1 and 
Meox 2 arrest the cell cycle at the G1/S transition through 
activation of the cycline-dependent kinase inhibitors 
p21CIP/WAF1 and p16INK4 (30), where overexpression of these 
proteins is a known factor leading to cellular senescence (31). 
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Figure 2 Myogenesis and clonal drift in the zebrafish embryo. (A) Muscle stem cells blocked in G2 by Meox1 maintain the capacity of self-renewal 
and when the cell cycle blockage is lifted they re-enter the cell cycle (activated) and, after mitosis, the daughter cells have either a differentiated fate 
(purple arrows), or a stem cell fate (green arrows). In the first case, cells enter the cell cycle, proliferate, differentiate and generate muscle fibers. 
In the second case cells blocked in G2 become quiescent thereby, maintaining stemness and the capacity of self-renewal upon re-entering the cell 
cycle. They can undergo multiple rounds of this process (two cycles, N and N+1 are represented here). This process takes place in muscle stem cells 
that express Meox1 (represented in the scheme). Muscle stem cells that do not express Meox1 primarily undergo proliferation and differentiation 
but have reduced or lost capacity of self-renew; (B) stem cells heterogeneity in the early phases and, as a consequence, over successive self-renewal 
events (N, N+1, … N + x), the dominance of a single stem cell clone in the growth of individual myotomes (clonal drift).
A
B
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Two notable points emerge from the Meox1-dependent 
clonal drift study in the zebrafish myotome. First, the 
determination of cell fate by direct cell cycle arrest rather 
than induction of cell cycle exit by exogenous factors. As 
examples of exogenous factors: non-acquisition of polarity 
in one of the daughter cells determines the stem cell fate in 
FSCs; or positional or niche-dependent factors are assumed 
to be determinant in much of the random events described 
above. Direct regulation by a single transcription factor has 
the advantage of effecting a direct response by regulation 
of a specific target gene. However, one cannot exclude 
that exogenous factors contribute to the cell fate decision 
in the zebrafish myotome, since loss of segmentation and 
abnormal skeletal organization may contribute to the loss 
of the clonal drift in meox1 mutants. Second, the transient 
cell cycle arrest in the G2 phase, which contrasts with a 
transient arrest in G0 that is frequently observed during 
quiescence (32). Quiescence is a non-proliferative, 
metabolically resting phase displayed by many adult 
stem cells and by some organisms in response to nutrient 
limitations or adverse survival conditions. Quiescence in 
G0 occurs in cells whose genome has not yet replicated, 
whereas muscle stem cell quiescence in the zebrafish 
embryo, which is correlated with the maintenance of 
stemness, occurs in G2 and therefore in 4n cells. 
G2 pausing has been associated with efficient adult stem 
cell regeneration in a variety of organisms. For instance, 
adult stem cells of Hydra, a freshwater invertebrate with 
high regenerative potential, display a robust pause in G2, 
which can be maintained over weeks of starvation, and this 
is correlated with vigorous regeneration (33). Similarly, 
regeneration of amputated limbs in the Mexican salamander 
(Axolotl) depends on upregulation of Evi5, a centrosomal 
protein that regulates the G2 arrest by preventing mitosis. 
This last mechanism is shared with skin regeneration (ear 
hole punches) in super-healing MRL mice (34), which also 
display downregulation of p21 (a key trigger of senescence). 
In differentiated cells, G2 arrest has been generally 
associated with the response to DNA damage to allow time 
for DNA repair. Since the DNA is fully duplicated in this 
phase, repair of DNA double strand breaks (DSBs) that 
might result from the replication process itself can rely 
on the presence of the sister chromatid and therefore on 
homologous recombination. In these cases, the cell cycle 
resumes upon repair of the DNA damage. However, if 
DNA damage is too extensive, or repair is inefficient, DNA 
damage accumulates and prolonged G2 arrest may become 
incompatible with the proliferation requirements of the 
cell, leading to cell death. Alternatively, the cell cycle arrest 
becomes irreversible leading to cell senescence. Overcoming 
the G2 blockage in the presence of DNA damage may drive 
the cell to apoptosis or enhance proliferation of a cancer 
cell (35). 
The role of the G2 arrest in stem cell quiescence appears 
functionally and mechanistically different from G2 arrest 
in differentiated cells. Whether the G2 arrest takes place 
in embryonic stem cells (as in muscle zebrafish) or in adult 
stem cells (as in the abovementioned cases), it is associated 
with robust regeneration capacity. Moreover, in all of 
these cases, the G2 arrest is reversible and released when 
regeneration must be activated. Does G2 arrest provide 
advantages that ultimately promote robust regeneration? 
And if this is the case, which regulatory factors are 
implicated? The genome of cells in G2 is replicated and 
these cells are poised to undergo mitosis when the proper 
signal is provided. Perhaps having already undergone the 
sensitive phases of DNA replication and correction of DNA 
damage positions stem cells in a favorable condition for 
efficient proliferation and self-renewal when the embargo is 
lifted. Perhaps re-entry into the cell cycle is easier, since the 
G2/M checkpoint is not as robust as the G1/S checkpoint, 
at least in the context of DNA damage (36). Alternatively, 
cells in G2 may have characteristics that are relevant to the 
next steps; as an example, cells arrested in mitosis tend to 
adhere less well to the neighboring cells than cells in other 
phases of the cell cycle. It is also possible that G2 arrest is 
advantageous for short periods that are followed by rapid 
and numerous cycles of proliferation and self-renewal. 
This situation contrasts with satellite cells that display long 
periods of quiescence. 
Conclusions
The reasons of clonal drift and progressive loss of stem 
cell heterogeneity in adult and embryonic organ growth 
remain to be elucidated. This process appears to be 
dependent on the type of stem cell, rather than the type 
of organism, at least with the limited examples available 
to date. Heterogeneity is perhaps a requirement for stem 
cells that undergo extensive periods of quiescence, in 
order to maintain specialized subpopulations to face a 
variety of conditions when regeneration is activated. The 
establishment of stem cell diversity, perhaps favored by 
asymmetric division that generates different daughter cells 
(10,37), its possible refinement during inactive phases, as 
well as the maintenance of this diversity during time appear 
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to be necessary conditions for this type of regeneration. 
Conversely during clonal drift, the success of expansion 
(although of a few stem cells) prevails over the maintenance 
of diverse stem cell pools, and this suggests a process 
where stem cell heterogeneity is perhaps not functional to 
the regeneration process. Loss of stem cell heterogeneity 
seems to favor conditions of almost continuous expansion 
interspaced by relatively short periods of quiescence 
(embryonic growth, repetitive muscle injury) and also 
stem cells localized in restricted structures (e.g., intestinal 
stem cells). In these conditions, cells normally undergo 
symmetric divisions, and the original stem cell diversity lost 
by apparently random events. These salient features of this 
randomness are beginning to be identified, like the Meox1 
protein in the zebrafish myotome, although we cannot 
presently exclude the possibility that determinant factors 
might concomitantly direct stem cell fates.
Muscle stem cells in the zebrafish embryo are maintained 
as such by blockage in the G2 phase of the cell cycle, 
a condition that has been reported in other cases, and 
this event appears to be linked to robust regeneration 
potential. Conversely, arrest in G2 phase in differentiated 
cells is essentially linked to ensure genome stability and its 
outcome is at the crossroad of cell proliferation, apoptosis, 
cellular senescence, and clonal expansion of cancer cells. 
The salient properties of stem cells, namely self-renewal and 
differentiation, may help us to understanding in more detail 
the impact of G2 arrest in cells with a highly proliferative 
potential.
Acknowledgements
M Ricchetti thanks Japan Aerospace Exploration Agency 
(JAXA) "Living in Space" program for support and Dr. 
Atsuko Sehara, Kyoto University, Japan, for helpful 
discussion.
This work was supported by Association Française contre 
les Myopathies (AFM, PhD grant to HH Sutcu).
Footnote
Conflicts of Interest: The authors have no conflicts of interest 
to declare.  
References
1. Tajbakhsh S. Skeletal muscle stem cells in developmental 
versus regenerative myogenesis. J Intern Med 
2009;266:372-89.
2. Motohashi N, Asakura A. Muscle satellite cell 
heterogeneity and self-renewal. Front Cell Dev Biol 
2014;2:1.
3. Tierney MT, Sacco A. Satellite Cell Heterogeneity 
in Skeletal Muscle Homeostasis. Trends Cell Biol 
2016;26:434-44.
4. Picard CA, Marcelle C. Two distinct muscle progenitor 
populations coexist throughout amniote development. Dev 
Biol 2013;373:141-8.
5. Harel I, Nathan E, Tirosh-Finkel L, et al. Distinct origins 
and genetic programs of head muscle satellite cells. Dev 
Cell 2009;16:822-32.
6. Sambasivan R, Gayraud-Morel B, Dumas G, et al. 
Distinct regulatory cascades govern extraocular and 
pharyngeal arch muscle progenitor cell fates. Dev Cell 
2009;16:810-21.
7. Kassar-Duchossoy L, Giacone E, Gayraud-Morel B, et al. 
Pax3/Pax7 mark a novel population of primitive myogenic 
cells during development. Genes Dev 2005;19:1426-31.
8. Ono Y, Boldrin L, Knopp P, et al. Muscle satellite cells 
are a functionally heterogeneous population in both 
somite-derived and branchiomeric muscles. Dev Biol 
2010;337:29-41.
9. Collins CA, Partridge TA. Self-renewal of the adult 
skeletal muscle satellite cell. Cell Cycle 2005;4:1338-41.
10. Rocheteau P, Gayraud-Morel B, Siegl-Cachedenier I, et 
al. A subpopulation of adult skeletal muscle stem cells 
retains all template DNA strands after cell division. Cell 
2012;148:112-25.
11. Chakkalakal JV, Jones KM, Basson MA, et al. The aged 
niche disrupts muscle stem cell quiescence. Nature 
2012;490:355-60.
12. Latil M, Rocheteau P, Chatre L, et al. Skeletal muscle stem 
cells adopt a dormant cell state post mortem and retain 
regenerative capacity. Nat Commun 2012;3:903.
13. Sousa-Victor P, Gutarra S, Garcia-Prat L, et al. Geriatric 
muscle stem cells switch reversible quiescence into 
senescence. Nature 2014;506:316-21.
14. Conboy IM, Conboy MJ, Wagers AJ, et al. Rejuvenation 
of aged progenitor cells by exposure to a young systemic 
environment. Nature 2005;433:760-4.
15. Garcia-Prat L, Martinez-Vicente M, Perdiguero E, et al. 
Autophagy maintains stemness by preventing senescence. 
Nature 2016;529:37-42.
16. Ricchetti M. How stem cells manage to escape senescence 
and ageing - while they can: A recent study reveals that 
autophagy is responsible for senescence-dependent loss of 
Stem Cell Investigation, 2018
© Stem Cell Investigation. All rights reserved. Stem Cell Investig 2018;5:9sci.amegroups.com
Page 7 of 7
regenerative potential of muscle stem cells during ageing. 
Bioessays 2016;38:857-62.
17. Snippert HJ, van der Flier LG, Sato T, et al. Intestinal 
crypt homeostasis results from neutral competition 
between symmetrically dividing Lgr5 stem cells. Cell 
2010;143:134-44.
18. Lopez-Garcia C, Klein AM, Simons BD, et al. Intestinal 
stem cell replacement follows a pattern of neutral drift. 
Science 2010;330:822-5.
19. Aghaallaei N, Gruhl F, Schaefer CQ, et al. Identification, 
visualization and clonal analysis of intestinal stem cells in 
fish. Development 2016;143:3470-80.
20. Snippert HJ, Schepers AG, van Es JH, et al. Biased 
competition between Lgr5 intestinal stem cells driven by 
oncogenic mutation induces clonal expansion. EMBO Rep 
2014;15:62-9.
21. Kronen MR, Schoenfelder KP, Klein AM, et al. Basolateral 
junction proteins regulate competition for the follicle 
stem cell niche in the Drosophila ovary. PLoS One 
2014;9:e101085.
22. Tierney MT, Stec MJ, Rulands S, et al. Muscle Stem 
Cells Exhibit Distinct Clonal Dynamics in Response to 
Tissue Repair and Homeostatic Aging. Cell Stem Cell 
2018;22:119-27.e3. 
23. Martincorena I, Roshan A, Gerstung M, et al. Tumor 
evolution. High burden and pervasive positive selection 
of somatic mutations in normal human skin. Science 
2015;348:880-6.
24. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related 
clonal hematopoiesis associated with adverse outcomes. N 
Engl J Med 2014;371:2488-98.
25. Gupta V, Poss KD. Clonally dominant cardiomyocytes 
direct heart morphogenesis. Nature 2012;484:479-84.
26. McKenna A, Findlay GM, Gagnon JA, et al. Whole-
organism lineage tracing by combinatorial and cumulative 
genome editing. Science 2016;353:aaf7907.
27. Nguyen PD, Gurevich DB, Sonntag C, et al. Muscle 
Stem Cells Undergo Extensive Clonal Drift during Tissue 
Growth via Meox1-Mediated Induction of G2 Cell-Cycle 
Arrest. Cell Stem Cell 2017;21:107-19.e6. 
28. Mankoo BS, Skuntz S, Harrigan I, et al. The concerted 
action of Meox homeobox genes is required upstream 
of genetic pathways essential for the formation, 
patterning and differentiation of somites. Development 
2003;130:4655-64.
29. Petropoulos H, Gianakopoulos PJ, Ridgeway AG, et 
al. Disruption of Meox or Gli activity ablates skeletal 
myogenesis in P19 cells. J Biol Chem 2004;279:23874-81.
30. Douville JM, Cheung DY, Herbert KL, et al. Mechanisms 
of MEOX1 and MEOX2 regulation of the cyclin 
dependent kinase inhibitors p21 and p16 in vascular 
endothelial cells. PLoS One 2011;6:e29099.
31. Munoz-Espin D, Serrano M. Cellular senescence: 
from physiology to pathology. Nat Rev Mol Cell Biol 
2014;15:482-96.
32. Rumman M, Dhawan J, Kassem M. Concise Review: 
Quiescence in Adult Stem Cells: Biological Significance 
and Relevance to Tissue Regeneration. Stem Cells 
2015;33:2903-12.
33. Buzgariu W, Crescenzi M, Galliot B. Robust G2 
pausing of adult stem cells in Hydra. Differentiation 
2014;87:83-99.
34. Heber-Katz E, Zhang Y, Bedelbaeva K, et al. Cell cycle 
regulation and regeneration. Curr Top Microbiol Immunol 
2013;367:253-76.
35. Sperka T, Wang J, Rudolph KL. DNA damage checkpoints 
in stem cells, ageing and cancer. Nat Rev Mol Cell Biol 
2012;13:579-90.
36. Lobrich M, Jeggo PA. The impact of a negligent G2/M 
checkpoint on genomic instability and cancer induction. 
Nat Rev Cancer 2007;7:861-9.
37. Yennek S, Burute M, Thery M, et al. Cell adhesion 
geometry regulates non-random DNA segregation and 
asymmetric cell fates in mouse skeletal muscle stem cells. 
Cell Rep 2014;7:961-70.
doi: 10.21037/sci.2018.03.02
Cite this article as:  Sutcu HH, Ricchetti M. Loss of 
heterogeneity, quiescence, and differentiation in muscle stem 
cells. Stem Cell Investig 2018;5:9. 
 175 
Annex 2: AKT-dependent DNA-PKcs activation of myogenesis in the absence of 
induced DNA damage 
 
Manuscript in preparation 
 
AKT-dependent DNA-PKcs activation of myogenesis in the absence of 
induced DNA damage 
 
Haser Hasan Sutcu1,2,3 and Miria Ricchetti1,2 
 
1Institut Pasteur, Team “Stability of Nuclear and Mitochondrial DNA”, Stem Cells and 
Development, 2CNRS UMR3738, 3University Pierre and Marie Curie (Sorbonne Universities, 
ED515) 
 
Corresponding author: MR 
 
 
Running title : DNA-PKcs regulates myogenin during regeneration  
 
 
 
Keywords: Satellite cells, DNA double-strand-breaks, SCID, DNA-PKcs, muscle, Akt, DNA 
repair, myogenin 
 
 Summary 
DNA double-strand breaks (DSBs) are dangerous DNA damages and a risk factor for genome 
stability. The maintenance of genome integrity is crucial for adult stem cells that are responsible 
for regeneration of damaged tissues and tissue homeostasis throughout life. Muscle regeneration 
in the adult relies on muscle stem cells (satellite cells, SCs) that have a remarkable DSB repair 
activity, but the underlying mechanism is not known. The aims of the present PhD project were 
to investigate how muscle differentiation is affected when DSB repair is impaired, and which 
are the mechanism(s) and the consequences on muscle regeneration. During this study, a novel 
possibility has arisen, namely that DSB repair factors affects myogenesis independently of their 
DNA repair activity, suggesting a novel function, not previously anticipated, of these factors. 
The present study has addressed the role of DNA-dependent protein kinase (DNA-PK), a crucial 
factor in non-homologous end-joining (NHEJ) repair of DSBs, in muscle differentiation in the 
mouse. Studies have targeted SC activation and muscle regeneration in vitro and in vivo and 
also addressed the regulation of this kinase. In parallel the more “canonical” role of DNA-PK, 
and thereby of NHEJ, has been investigated in SCs via radiation-induced DNA damage. The 
role of ATM, a kinase that orchestrates cellular responses to DSBs in muscle regeneration has 
also been addressed. These results support the emerging notion of multifunctional repair 
proteins in a variety of physiological processes beyond the repair process itself, on which I have 
conducted a bibliographical study. This work i) identifies novel regulators of myogenesis, and 
ii) helps understanding the resistance of muscle stem cells to genotoxic stress. It has potential 
implications for improving cellular therapies for muscle dysfunction by acting on the newly 
discovered regulators. 
 
Résumé 
Les cassures double-brin (DSB) sont des dommages dangereux de l’ADN et représentent un 
facteur de risque pour la stabilité du génome. Le maintien de l'intégrité du génome est essentiel 
pour les cellules souches adultes, qui sont responsables de la régénération des tissus 
endommagés et de l'homéostasie tissulaire tout au long de la vie. La régénération musculaire 
chez l'adulte repose sur les cellules souches musculaires (cellules satellites, SCs) qui possèdent 
une remarquable capacité de réparation des DSB, mais dont le mécanisme sous-jacent reste 
inconnu. Ce projet de thèse consistait à étudier comment la différenciation musculaire est 
affectée lorsque la réparation des DSB est altérée, et quels sont le(s) mécanisme(s) et les 
conséquences de ce défaut de réparation sur la régénération musculaire. Au cours de cette étude, 
il est apparu de façon originale que les facteurs de réparation des DSB peuvent affecter la 
myogenèse, indépendamment de leur fonction dans la réparation de l'ADN. La présente étude a 
porté sur le rôle de la protéine kinase dépendante de l'ADN (DNA-PK), un facteur crucial pour 
la réparation non-homologue des DSBs (NHEJ), au cours de la différenciation musculaire chez 
la souris. L’étude a ciblé l'activation des SCs et la régénération musculaire in vitro et in vivo et a 
également abordé la régulation de cette kinase. Le rôle "canonique" de la DNA-PK, et donc du 
NHEJ, dans les SCs a également été étudié en présence de lésions de l'ADN radio-induites. Le 
rôle d’ATM, une kinase qui orchestre les réponses cellulaires aux DSB, a également été abordé 
dans le contexte de la régénération musculaire. Ces résultats confirment la notion émergente du 
rôle multifonctionnel des protéines de réparation de l’ADN dans d’autres processus 
physiologiques que la réparation elle-même, ce qui m’a également permis de réaliser une étude 
bibliographique. Ce travail i) identifie de nouveaux régulateurs de la myogenèse et ii) contribue 
à la compréhension de la résistance des cellules souches musculaires au stress génotoxique. Ces 
résultats pourraient avoir des implications dans l'amélioration des thérapies cellulaires de la 
dysfonction musculaire en agissant sur les régulateurs nouvellement découverts. 
